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Spondyloarthritis (SpA) is a chronic inflammatory rheumatic disease. Until the 1960s, it was 
not identified as a separate disease entity but considered to be a subtype of seronegative 
arthritis. Fortunately, major advances have been made since then.
First, ankylosing spondylitis (AS) was recognized as a distinct disease entity with well-
defined clinical and structural manifestations. Somewhat later in 1974, Moll et al. proposed 
for the first time to emphasize the interrelatedness of ankylosing spondylitis (AS) and several 
other conditions that had previously been described separately.1 The umbrella term SpA was 
introduced and encompasses a group of clinically and genetically interrelated inflammatory 
rheumatic disorders, amongst others: AS, psoriatic arthritis (PsA) and arthritis associated 
with inflammatory bowel diseases (IBD). Patients with SpA features that do not fulfil criteria 
for one of the subgroups, were formerly known as undifferentiated SpA. The reason for this 
differentiation was both historical and practical, but all the subtypes share similar axial or 
peripheral articular manifestations and therefore each category does not represent a discrete 
disease entity.
Recent advances in the field accomplished that patients are nowadays distinguished 
according to their clinical presentation and distribution of joint involvement, in predominantly 
axial or peripheral disease.2 Inflammation of the axial skeleton including the spine and 
sacroiliac (SI) joints is prominent in axial spondyloarthritis (axSpA) which is the main subject 
of this thesis. In peripheral spondyloarthritis (pSpA), inflammation is mainly located in 
peripheral joints. The advantages of this approach to describe patients with SpA are: a better 
characterization of the presenting disease and improved administration of treatment (since 
therapeutic approaches are different).
The estimated prevalence of SpA in the general population is 1-1.4%.3,4 Although figures on 
the incidence and prevalence vary and are highly dependent on methodological differences 
between studies, the case definition used to define disease, HLA-B27 prevalence etcetera. 
SpA is associated with a significant burden of disease and young patients are affected. 
Around 80% of the patients develop first symptoms below 30 years of age (less than 5% of 
patients beyond 45 years of age).5 The outcome of disease in terms of debilitating symptoms, 
decreased mobility, work-productivity and health-related quality of life (HR-QoL) has a major 
impact on patients in important stages in life.6-9 
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Early recognition of SpA is highly relevant. It is important to identify patients timely in 
order to treat early and possibly alter the disease course. Whereas adequate treatment 
was not available only years ago, the therapeutic arsenal has rapidly expanded since 
then. Non-steroidal anti-inflammatory drugs (NSAIDs) are still the recommended first-line 
drug treatment for patients with axSpA with pain and stiffness.10-13 But the biologic era has 
revolutionized treatment options for patients refractory to first line treatment with impressive 
improvements.14-19
Unfortunately, the timely identification of patients is difficult and diagnostic delay is a major 
challenge in axSpA. The extended interval between symptom onset and diagnosis is 
reported to be 8-10 years (Figure 1).20 AxSpA remains a relatively uncommon cause of a very 
common first symptom: 60-80% of the general population report back pain at some point in 
their lives. Also other factors play a role, which will be pointed out below. In general, the urge 
for an early recognition of axSpA provides the main rationale behind the different chapters 
described in this thesis.
The average age at disease onset among men and
women did not differ significantly, as shown in Table 1,
but there was a significantly longer delay in disease
diagnosis among women, although the observed differ-
ence in the delay of diagnosis is much less than that
reported in 1984 by van der Linden et al. [18,19]. In
Figure 4, the cumulative distribution of the diagnosis
delay is shown for different subgroups. Each curve
represents a subgroup containing patients with disease
onset within the same 5 calendar years. For instance, of
the 87 patients with disease onset between 1955 and
1959, only 45 received their diagnosis within the first 15
years after disease onset. The 1975-to-1979 subgroup
was the first in which more than 5% of the patients had
entered the same age for the disease onset and for the
diagnosis (ie, diagnosis delay <1 year). This subgroup is
also the last one for which the completely represented
diagnosis-delay-years (black symbols in Fig. 4) indicate an
approach to saturation, suggesting that the disease has
already been diagnosed in most of the patients from
these disease-onset years in whom it can be diagnosed
with present diagnostics. The data demonstrate that the
subgroup with disease onset between 1955 and 1959
experienced a longer average delay in diagnosis than the
subgroup with disease onsets in 1975 to 1979.
In order to make a relatively reliable comparison of the
average delay in diagnosis for the different years of disease
onset, it was assumed that almost no additional diagnoses
will be made in patient subgroups with a disease onset
before 1975, and that patients with a disease onset after
1979 (including those whose disease was not yet diag-
nosed but would be diagnosable according to present stan-
dards) have a similar frequency to those with a disease
onset between 1975 and 1979. In Figure 5, each subgroup
of Figure 4 has been adjusted to a percentile scale with
the above-mentioned assumptions.
The increasing slopes in Figure 5 indicate a decreasing
average delay in diagnosis in the decades analyzed. This
is the first time that it has been quantitatively demon-
strated that the average diagnosis delay for spondy-
loarthritis patients could indeed be getting shorter in
recent decades, at least in Germany. Whereas the
average diagnosis delay was 15 years for patients with
disease onset in the 1950s, it was about 7.5 years for
patients with disease onset between 1975 and 1979. An
average delay in diagnosis of less than 7.5 years for
patients with a disease onset later than 1979 is not
expected on the basis of current data.
The relatively smaller number of female spondyloarthri-
tis patients in whom the disease was diagnosed in
former decades (Fig. 2), as well as the longer average
delay in diagnosis in female patients (Figs. 3 and 5), may
have resulted primarily from the facts that in the past
ankylosing spondylitis was wrongly assumed to be rare
among women, and there was a relative lack of adequate
knowledge about ankylosing spondylitis on the part of
physicians. Moreover, the newer imaging modalities for
Scientific contributions of ankylosing spondylitis patient advocacy groups Feldtkeller et al. 243
Large steps in the distribution of the age
at onset at round numbers (20, 25, 30
years, etc.) result from the fact that these
numbers are preferably entered in case of
uncertainty. Distributions published by van
der Linden et al. [18,19] in 1984 are
shown for comparison.
Age at diagnosis
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Figure 3. Cumulative distribution of the age at disease onset (occurrence of the first spondylitic symptoms) and of the age at
diagnosis for 920 male and 476 female spondyloarthritis patients who responded to these questions
Figure 1: Cumulative distribution in age at symptom onset and diagnosis of SpA
Feldtkeller E, Bruckel J, Khan MA. Curr Opin Rheumatol 2000;12: 239-247.
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EARLY RECOGNITION AND CLASSIFICATION CRITERIA
The exact aetiology of axSpA remains unknown and there is no single pathognomonic 
feature that distinguishes the disease from other conditions with similar symptoms. This is 
in contrast with other for example malignancies and infectious diseases where respectively 
histopathology findings and positive blood cultures are key findings in the diagnostic process.
The major clinical features which discriminate SpA from other forms of arthritis are the 
distribution and character of musculoskeletal manifestations and the co-existence of 
certain extra-articular manifestations. The most typical first presenting symptom of patients 
with axSpA is chronic back pain (CBP).21,22 A combination of features is suggestive for an 
inflammatory aetiology: an insidious onset, onset of CBP before 40 years of age, improvement 
with exercise but not with rest and pain at night (with improvement at getting up). If four 
out of these five features are present CBP can be defined as inflammatory back pain (IBP) 
according to the Assessment of SpondyloArthritis international Society (ASAS) criteria.23 IBP 
is present in 70-80% of patients with axSpA, but can also be seen in non-SpA patients, and 
therefore sensitivity and specificity are suboptimal.24,25 Another characteristic of CBP in some 
axSpA patients is a good response to treatment with non- steroidal anti-inflammatory drugs 
(NSAIDs). Patients with back pain of other origin (e.g. overuse or degenerative changes, 
prevalence of degenerative changes was high in the SPACE cohort26 may also experience 
alleviation of symptoms with NSAIDs, but marked improvement of pain within 24-48 hours 
after a full dose is relatively typical for SpA.27 The natural history of axSpA is associated with 
a progressive impairment in spinal mobility over time. A restricted range of motion can be 
assessed by eleven tests during physical examination.28-30 However, these tests are not very 
sensitive in the early detection of axSpA and subject to too large variation in normal subjects 
to be of diagnostic utility.31
When peripheral arthritis occurs in SpA it affects mainly (though not exclusively) the lower 
limbs (knees, ankles) typically in an asymmetrical pattern and is mostly mono-articular 
or oligo-articular of origin.32,33 Enthesitis is a relatively specific SpA feature and refers to 
inflammation around the entheses: the site of insertion of ligaments, tendons, joint capsule 
or fascia to bone.34 Typical locations are the insertion sites of the achilles tendon and plantar 
fascia ligament into the calcaneus, the ligamentous structures of the synchondrosis at the 
costovertebral joints and flexor and extensor tendon insertions at the humeral epicondyles.32 
These sites can be painful on palpation. Another characteristic feature of SpA is dactylitis, 
where in contrast to synovitis a diffuse inflammation and swelling of one digit (either foot or 
hand), also called a ‘sausage finger’ is present.
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Next to musculoskeletal related symptoms, some extra-articular manifestations can be 
seen in patients with SpA: acute anterior uveitis, psoriasis and IBD. Acute anterior uveitis 
is characterized by abrupt, unilateral attacks of pain, photophobia, visual impairment and 
circumlimbial hyperaemia around the iris.35,36 Around 50% of patients with acute recurrent 
unilateral anterior uveitis have SpA and in patients with AS there is a lifetime prevalence of 
uveitis of 30-40%.36 Episodes of uveitis do not necessarily parallel the course of arthritis. The 
pooled prevalence of IBD among patients with AS was 6.8%, ulcerative colitis (UC) more 
common than Crohn’s disease.37 The dermatologic disorder psoriasis is present in up to 10% 
of patients with AS and it is more associated with peripheral joint involvement.37,38
Laboratory findings are useful in the diagnostic work-up of SpA, though there are no findings 
that are absolutely specific. Acute phase reactants including erythrocyte sedimentation 
rate (ESR) and levels of C-reactive protein (CRP) are increased in 35-50% of the axSpA 
patients.5,39 Studies have shown that AS is associated with Human Leukocyte Antigen 
(HLA) B27 positivity and first-, second-, and third-degree relatives of patients with AS have 
markedly increased risk of developing disease.40 The mode of inheritance is polygenic with 
multiplicative interaction among loci. More information on the association with HLA-B27 and 
other genetic risk factors can be found below.
No formal diagnostic criteria are available for SpA. Instead, the expert opinion of the 
rheumatologist is leading. Diagnosis is generally based on a combination of the described 
SpA features in Table 1: symptoms obtained from medical history, physical examination and 
laboratory investigation, in addition to imaging findings (which will be addressed in the next 
part).27 All these different characteristic features of the disease determine the likelihood of the 
Table 1: Overview of several axial SpA manifestations with accompanying test characteristics
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M
aking a diagnosis of ankylosing spondylitis in
patients with chronic back pain can be difficult at
an early stage—that is, before radiographic sacroiliitis
is definitely pres nt (also referred to as axial spondyloar-
thritis (SpA) at the preradiographic state). We recently
proposed to diagnose patients at this early tage by
probability estimations1 based on a pretest probability (ppre)
of 5% in pati nts with chr nic back pain.2 To facilitate the
probability calculation in each patient, we subsequently3
proposed the use of likelihoo ratios (LR).4 W suggested
that the diagnosis could be considered definite if the post-
test probability (ppost) is >90% (LR product >171), probable
if the post-test probability is 80–90% (LR product 76–171)
and unlikely if the post-test probability is (10–20% (LR
product ,2–4).1 3
Mainly because of the complicated mathematics, we
previously3 concentra d on the use of positive likelihood
ratios—that is, in case the parameter is present. However,
wh n making a diagnosis in daily practice, a negative test
result (absence of a certain parameter) sometimes helps to
rule out a diagnosis. In axial SpA, a few parameters, if absent,
clearly render the diagnosis less likely. These include
negativity for human leucocyte antigen-B27, a negative
magnetic resonance image (showing no signs of inflamma-
tion), the absence of the inflammatory type of back pain, a
normal C reactive protein level or erythrocyte sedimentation
rate, no good response to non-steroidal anti-inflammatory
drugs and, probably, a negative family history (discussed
already by Rudwaleit et al1). On the other hand, other mostly
clinical parameters should not be considered to be definitely
absent if not present at disease onset, as these may occur
later in the disease course a d therefore are rather a f nction
of disease duration. These include peripheral arthritis,
en hesit s, dactylitis, acute anterior uveitis, psoriasis and
inflammatory bowel disease. These parameters are helpful in
increa ing the dise se probability if present, but should b
ignored if absent at an early disease stage.
Table 1 shows the list of LR+ values for positive test results
supplemented by LR2 values for negative test results. The
likelihood ratio product is calculated by multiplying the
relevant LR+ and LR2 values as derived from table 1,
according to the presence or absence of particular features as
appropriate. The final post-test probability can be read from
fig 1, which presents a probability curve showing the
dependency of the post-test probability on the LR product,
again based on a pretest probability of 5%. The curve in fig 1
has been calculated using the formula
where ppost is the post-test probability, PLR the product of
likeli ood ratios and ppre the pretest probability.
Thus, taking into account all positive and negative
diagnostic test results as appropriate, the disease probability
of axial SpA at the preradiographic stage in a patient with
chronic back pain can now be easily assessed at the bedside
with the help of table 1 and fig 1.
Table 1 Representative values of sensitivity and specificity for several tests relevant for axial spondyloarthritis as evaluated






Inflammatory type of back pain5 6 75 76 3.1 0.33
Heel pain (enthesitis) 37 89 3.4 (0.71)�
Peripheral arthritis 40 90 4.0 (0.67)�
Dactylitis 18 96 4.5 (0.85)�
Iritis or anterior uveitis 22 97 7.3 (0.80)�
Psoriasis 10 96 2.5 (0.94)�
IBD 4 99 4.0 (0.97)�
Positive family history for axial SpA, reactive arthritis, psoriasis,
IBD or anterior uveitis
32 95 6.4 0.72
Good response to NSAIDs 77 85 5.1 0.27
Raised acute-phase reactants (CRP/ESR) 50 80 2.5 0.63
HLA-B27` 90 90 9.0 0.11
Sacroiliitis shown by magnetic resonance imaging 90 90 9.0 0.11
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HLA, human leucocyte antigen; IBD, inflammatory bowel disease; LR+, positive likelihood ratio; LR2,
negative likelihood ratio; NSAID, non-steroidal anti-inflammatory drugs; SpA, spondyloarthritis.
*LR+= sensitivity/(1 – specificity); LR2 = (1 – sensitivity)/specificity.
�As enthesitis, dactylitis, uveitis, peripheral arthritis, psoriasis and IBD may not be present at disease onset but may develop later, it is recommended to ignore a
negative test result of these tests in an early state of possible axial SpA. The LR2 of parameters, which should be ignored, are shown in brackets.
`The figures for sensitivity and specificity of HLA-B27 refer to a European Caucasian population. In European Caucasian patients with psoriasis or IBD, a sensitivity
of 50%, a specificity of 90%, an LR+ of 5.0 and an LR2 of 0.56 for HLA-B27 should be applied. In other ethnic populations, sensitivity and specificity of HLA-B27
may be different, resulting in different LR+ and LR2 (also discussed by Rudwaleit et al1).
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an early stage—that is, before radiographic sacroiliitis
is definitely present (also referred to as axial spondyloar-
thritis (SpA) at the preradiographic state). We recently
proposed to diagnose patients at this early stage by
probability estimations1 based on a pretest probability (ppre)
of 5% in patients with chronic back pain.2 To facilitate the
probability calculation in each patient, we subsequently3
proposed the use of likelihood ratios (LR).4 We suggested
that the diagnosis could be considered definite if the post-
test probability (ppost) is >90% (LR product >171), probable
if the post-test probability is 80–90% (LR product 76–171)
and unlikely if the post-test probability is (10–20% (LR
product ,2–4).1 3
Mainly because of the complicated mathematics, we
previously3 concentrated on the use of positive likelihood
ratios—that is, in case the parameter is present. However,
when making a diagnosis in daily practice, a negative test
result (absence of a certain parameter) sometimes helps to
rule out a diagnosis. In axial SpA, a few parameters, if absent,
clearly render the diagnosis less likely. These include
negativity for human leucocyte antigen-B27, a negative
magnetic resonance image (showing no signs of inflamma-
tion), the absence of the inflammatory type of back pain, a
normal C reactive protein level or erythrocyte sedimentation
rate, no good response to non-steroidal anti-inflammatory
drugs and, probably, a negative family history (discussed
already by Rudwaleit et al1). On the other hand, other mostly
clinical parameters should not be considered to be definitely
absent if not present at disease onset, as these may occur
later in the disease course and therefore are rather a function
of disease duration. These include peripheral arthritis,
enthesitis, dactylitis, acute anterior uveitis, psoriasis and
inflammatory bowel disease. These parameters are helpful in
increasing the disease probability if present, but should be
ignored if absent at an early disease stage.
Table 1 shows the list of LR+ values for positive test results
supplemented by LR2 values for negative test results. The
likelihood ratio product is calculated by multiplying the
relevant LR+ and LR2 values as derived from table 1,
according to the presence or absence of particular features as
appropriate. The final post-test probability can be read from
fig 1, which prese ts a probability curve showing the
dependency of the post-test probability on the LR product,
again based on a pretest probability of 5%. The curve in fig 1
has been calculated using the formula
where ppost is the post-test probability, PLR the product of
likelihood ratios and ppre the pretest probability.
Thus, taking into account all positive and negative
diagnostic test results as appropriate, the disease probability
of axial SpA at the preradiographic stage in a patient with
chronic back pain can now be easily assessed at the bedside
with the help of table 1 and fig 1.
Table 1 Representative values of sensitivity and specificity for several tests relevant for axial spondyloarthritis as evaluated
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diagnosis SpA or axSpA; some are weighted more heavily than others (Table 1). The more 
features are present, the higher the probability of an axSpA diagnosis.
It is easy to understand that the diagnostic process for axSpA as described above will 
result in a heterogeneous group of patients. However, for research purposes (like cohort 
studies and clinical trials) the goal is to apply findings on a group-level. Therefore, more 
homogeneous groups of patients are warranted and this formed the basis of the development 
of classification criteria. Over time, several classification criteria sets have been developed. 
Most widely known are the, in 1984 developed, modified New York (mNY) criteria.41 These 
are used for the classification of AS which is the most typical expression of axSpA. This 
criteria set combines the presence of clinical symptoms with radiographic sacroiliitis visible 
on conventional radiographs of the pelvis (sacroiliac joints). Radiographic sacroiliitis for the 
radiographic criterion of the mNY is defined as at least grade 2 bilateral sacroiliitis or grade 3 
or 4 sacroiliitis unilaterally. A patient is classified as definite AS when in addition to fulfilment 
of the radiographic criterion, one of the following clinical criteria is met: low back pain and 
stiffness for more than three months with improvement during exercise but not during rest 
(1), limited motion of the lumbar spine in sagittal as well as frontal planes (2) or limited chest 
expansion compared to age- and sex-related normal values (3).
The mNY criteria are limited to axial features of the disease. Also important is the fact that 
radiographs are mainly useful in the assessment of advanced disease (which will be more 
extensively discussed below) and that not all patients will develop radiographic sacroiliitis. 
Overall, limitations of the mNY criteria initiated the development of the Amor criteria and 
ESSG criteria in the early 1990s.32,42 These two criteria sets cover the whole spectrum of SpA 
and a broader range of manifestations of SpA are included, in comparison with the mNY 
criteria.
The Amor criteria consist of a list of symptoms, none of which is required to classify a patient 
as SpA. Points (between 1 and 3) are assigned to the different symptoms and in total at 
least 6 points are necessary for classification.42 In contrast to the Amor criteria, the ESSG 
criteria uses entry criteria by means of a mandatory presence of inflammatory back pain 
(IBP) or peripheral arthritis.32 According to the ESSG criteria, patients with at least one of the 
entry criteria in combination with one minor criterion are classified as having SpA. The Amor 
and ESSG criteria cover the whole spectrum of SpA, but they are not able to differentiate 
axial from peripheral disease, which is important as stated earlier. There are also drawbacks 
with respect to sensitivity; Magnetic Resonance (MR) imaging is a more sensitive tool than 
conventional radiographs to detect early sacroiliitis, changes are visible even years before 
the development of radiographic sacroiliitis (which will be further explained in Part 2). In 
2009, a group of experts in the ASAS proposed two new classification criteria sets for SpA 
1
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(Figure 2): one for axSpA39, one for peripheral SpA.33 
According to the ASAS classification criteria for axSpA (ASAS axSpA) application of the 
criteria can take place when a patient suffers from chronic back pain for minimal three months 
with age at onset before 45 years (entry criterion). A patient can be classified as axSpA when 
fulfilment is met via (minimally) one of the two arms: the imaging and/or clinical arm. 
In the imaging arm, patients can be classified as axSpA if one SpA feature is present in 
addition to either radiographic sacroiliitis (mNY criteria) or active inflammation detected 
by MRI highly suggestive of sacroiliitis.39 To fulfil the clinical criteria, the patient should be 
HLA-B27 positive and have at least two other SpA-associated features.
The classification criteria for peripheral SpA can be applied in patients with currently 
peripheral manifestations only. To fulfil these criteria, a patient must have arthritis, dactylitis 
or enthesitis in combination with either at least one other SpA feature (Table 1, Figure 2).33 
All three different criteria sets described above have shared SpA features and this overlap 
is visualized in Figure 3.
The ASAS criteria have been implemented worldwide. Validation was performed in different 
cohorts. When tested against the expert’s diagnosis (‘gold’ standard) the criteria set 
performed well. In the original validation study, the following test characteristics were seen: 
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a diagnosis of axial SpA can be made. Also, the intro‑
duction of TNF inhibitors has dramatically improved 
treatment for all the clinical features of SpA, in luding 
peripheral manifestations.
Incidence and prevalence of SpA
Global prevalence values for SpA calculated before the 
introduction of the ASAS criteria were reported to be 
~1%,36,37 but range substantially, from 0.01% in Japan38 
to 2.5% in Northern Arctic natives.39,40 Also, the inci‑
dence of SpA ranges broadly, from 0.48 cases per 100,000 
person years in Japan38 to 62.5 per 100,000 person years 
in Spain.41 Important contributors to these differences 
are heterogeneity in the populations analysed, variation 
in the criteria used for case definition, and the number 
of participants approached and included in each study 
(Box 3). Classification criteria are often developed 
for conducting clinical trials, and are not always feasi‑
bl  for epidemiological studies in the field. Population‑
derived data from other sources, such as data from 
insurance companies or physician reports from clinics, 
should b  regarded with caution as selection bias might 
have occurred. Furthermore, the incidence and preva‑
lence of SpA vary widely in different populations and 
ethnic groups, which can, at least partly, be explained by 
differences in the prevalence of HLA‑B27. The preva‑
lence of HLA‑B27 is the highest in the Pawaia tribe in 
Papua New Guinea (53%),42 the Haida indigenous people 
in western Canada (50%)43 and the Chukotka natives in 
eastern Russia (40%).44 In northern Scandinavian coun‑
tries, the prevalence of HLA‑B27 is 15–25%,45–47 whereas 
in western European countries it varies from 4–13%.48 
HLA‑B27 is rare in Arab populations (2–5%)49 and Japan 
(1%),38 and is almost absent in indigenous people from 
South America and Australia and in black Africans.48
In only one study have the ASAS classification cri‑
teria been used to estimate the overall prevalence of 
SpA (including axial and peripheral SpA).50 In this large 
p opulation‑based cohort (the GAZEL cohort) consisting 
of 20,625 employees of the French national electricity 
and gas company, representative of the French popula‑
tion, the prevalence of SpA was estimated to be 0.43%; 
75% of these patients fulfilled the ASAS axial SpA criteria 
and 25% the peripheral SpA criteria.50
Axial SpA
Most literature on the incidence and prevalence of axial 
SpA relates to the AS subtype. Not taking into account the 
heterogeneity of the studies, estimates for the incidence 
of AS vary from 0.44 in Iceland51 to 7.3 cases per 100,000 
person years in the USA52 and northern Norway,53 and 
the prevalence varies from 0.01% in Japan38 to 1.8% in 
Norwegian Samis.47 Prevalence estimates of AS have 
also been reported for each continent: 0.24% for Europe; 
0.17% for Asia; 0.32% for North America; 0.10% for Latin 
America and 0.07% for Africa.54 These figures mostly 
match the geographical distribu i n of HLA‑B27.
Several attempts to provide prevalence estimates for 
the broader axial SpA population have been made. The 
2009–2010 National Health and Nutrition Examination 
Survey (NHANES) study assessed the prevalence of axial 
SpA in the USA using SpA features from the Amor and 
ESSG criteria.37 In this study, the prevalence of axial SpA 
was estimated at 0.9–1.4%.
Figure 2 | ASAS classification criteria for axial and peripheral SpA. The ASAS classification criteria distinguish axial from 
peripheral SpA according to the presence of different combinations of clinical and imaging entry criteria and the number of 
features of SpA. *Either active inflammation detected by MRI highly suggestive of sacroiliitis associated with SpA, or definite 
radiographic sacroiliitis according to the modified NY criteria. Abbreviations: ASAS, Assessment of SpondyloArthritis 
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Figure 2: ASAS classification criteria for axial and peripheral SpA
ASAS, Assessment of SpondyloArthritis international Society; CRP, C-reactive protein; NSAIDs, non-
steroidal anti-inflammatory drugs; HLA-B27-positive, human leukocyte antigen B27-positive; IBD, 
inflammatory bowel disease; SpA, spondyloarthritis.
Van Tubergen A. Nat Rev Rheumatol 2015;11: 110-118.
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a sensitivity of 82.9% and a specificity of 84.4% (overall); sensitivity of 66.2% and specificity 
of 97.3% (imaging arm alone) and a sensitivity of 56.6% (sensitivity) and 83.3% (specificity) 
for the clinical arm alone.39 The ASAS criteria reflect the current perception of what SpA looks 
like (so-called gestalt) better than the ESSG and Amor criteria.
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and with ≤1 feature of SpA, additional MRI testing to 
increase the probability of detecting the disease is recom‑
mended.16 This approach not only reduces the chance of 
finding abnormalities in healthy subjects, but costs less as 
fewer MRI tests are needed overall.
In the absence of imaging abnormalities of the sacro‑
iliac joint or of imaging facilities, axial SpA can be recog‑
nized on the basis of genetic predisposition (HLA‑B27 
positivity) and typical features of SpA, thereby ful‑
filling the clinical arm of the ASAS axial SpA criteria.3 
A common question is whether patients without abnor‑
malities of the sacroiliac joint, detected by imaging, truly 
have SpA. In the validation study of the ASAS axial SpA 
criteria, imaging alone had only 66% sensitivity; experts 
agreed that, clinically, one‑third of the patients had axial 
SpA despite normal imaging results.3 Independent studies 
have shown that patients fulfilling the clinical arm of the 
ASAS criteria do not substantially differ from those ful‑
filling the imaging arm with respect to clinical features 
(for example peripheral symptoms and extra‑articular 
manifestations), disease activity, functional impair‑
ment and quality of life, but those patients fulfilling the 
clinical arm are more likely to be female, be older and 
have lower serum C‑reactive protein (CRP) levels than 
patients fulfilling the imaging arm (Table 1).17,18 Of the 
patients fulfilling the clinical arm without active sacro‑
iliitis detected by imaging, a substantial proportion 
have other abnormalities detected by MRI, in particu‑
lar, spinal inflammation and structural damage in the 
sacroiliac joint or spine.18,19 However, these findings are 
not included in the criteria for active sacroiliitis by MRI 
according to the ASAS–OMERACT (Outcome Measures 
in Rheumatology) definition,20 which is a prerequisite to 
fulfill the ASAS criteria.3
Several other interesting observations have emerged 
from cohort studies comparing nonradiographic axial 
SpA with AS (Table 2).17,18,21–24 Unlike AS, which pre‑
dominately affects men, nonradiographic axial SpA has 
a more balanced sex distribution. Furthermore, patients 
with this disease are comparable to those with definite 
AS with respect to disease activity, pain and quality of 
life. Also, treatment with TNF inhibitors is effective for 
both subgroups.25 However, more radiographic damage 
of the spine, worse physical function (which is partly 
explained by radiographic damage26) and higher serum 
CRP levels have been reported in patients with AS than 
in patients with nonradiographic axial SpA.17,18,21–24
Studies of independent cohorts of patients specifi‑
cally fulfilling the ASAS criteria for peripheral SpA are 
lacking. Enthesitis (inflammation at the bone insertion 
site of ligaments and tendons) is frequently in the heel,27 
but all entheseal sites are considered for fulfillment 
of the ASAS peripheral SpA criteria.4 Also, a history of 
inflammatory back pain and the presence of sacroiliitis 
are included in the criteria for peripheral SpA, provided 
that back pain is not the most prominent symptom, in 
which case the criteria for axial SpA should be applied. 
Peripheral disease is more common in women, whereas 
the male sex is associ ated with axial disease, radiographic 
abnormalities and HLA‑B27.28 Small randomized con‑
trolled trials showed good efficacy of TNF inhibitors in 
treating peripheral SpA.29,30
Although SpA is associated with HLA‑B27, not all 
patients with SpA are HLA‑B27‑positive; ~75–90% 
of patients with AS are HLA‑B27‑positive,31 and similar 
proportions have been reported for patients with non‑
radiographic axial SpA.16,17,20–23 In undifferentiated and 
peripheral SpA, the proportion of patients reported to be 
HLA‑B27‑positive is 25–70%.31 All features of SpA can 
occur in HLA‑B27‑negative patients,12 but differences 
at the group level have been reported. In patients with 
axial SpA, HLA‑B27 is associated with younger age at 
onset of disease, with anterior uveitis, a lower frequency 
of psoriasis, more inflammation detected by MRI, and 
with radiographic damage of the sacroiliac joint.21,32–35
Overall, the introduction of the ASAS classification 
criteria have contributed to a broader understanding of, 
and clinical approach to, suspected SpA. Particularly, 
the use of MRI is a major step towards earlier diagnosis. 
Physicians are increasingly aware of the range of fea‑
tures of the disease that should be taken into account, 
in both men and women. Furthermore, in a subgroup 
of patients without abnormalities detected by imaging, 
Figure 1 | Venn diagram of features of the SpA criteria sets. The features are 
listed independently of being an entry criterion and independently of the number 
of features necessary for fulfillment of a particular criteria set. No distinction  
was made for features considered for the clinical versus the imaging arm of  
the ASAS axial classification criteria. Different definitions exist for inflammatory 
back pain in the different criteria sets. Abbreviations: ASAS, Assessment  
of SpondyloArthritis international Society; CRP, C-reactive protein; ESSG,  
European Spondyloarthropathy Study Group; IBD, inflammatory bowel disease; 
SpA, spondyloarthritis.
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Figure 3: Venn diagram showing overlap of features of the various SpA classification criteria sets
ASAS, Assessment of SpondyloArthritis international Society; axial SpA, axial spondyloarthritis; ES G, 
European Spondyloarthropathy Study Group; CRP, C-reactive protein; HLA-B27, human leukocyte 
antigen B27; NSAIDs, non-steroidal anti-inflammatory drugs; IBD, inflammatory bowel disease.
Van Tubergen A. Nat Rev Rheumatol 2015;11: 110-118.
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THE USE OF IMAGING (MRI) IN EARLY AXIAL 
SPONDYLOARTHRITIS
As mentioned before sacroiliitis is the hallmark of axSpA and therefore sacroiliac joint imaging 
plays a pivotal role in both the diagnostic work-up and the classification of axSpA. For many 
years, conventional radiographic imaging of the pelvis was the only imaging modality of 
choice.
Over time it became apparent that in early axSpA patients radiographic abnormalities can 
be absent. Structural changes might only become apparent several years after the onset 
of symptoms, which severely contributes to diagnostic delay. Moreover, it has been shown 
that it is very difficult to reliably detect and grade sacroiliitis on conventional radiographs. 
Substantial intra- and interobserver variability exists and this is not ameliorated by training.43,44
Since MRI shows high anatomic detail in addition to bone marrow changes, early 
inflammatory lesions in the sacroiliac (SI) joints can be identified.45,46 It has become evident 
that inflammatory lesions can be visible on MRI years before radiographic structural changes 
are detectable. Therefore, in the early disease course MRI may detect acute inflammatory 
lesions in the absence of radiographic sacroiliitis. A short screening protocol is introduced 
using two sequences: a coronal oblique T1-weighted (turbo spin echo) TSE sequence and 
short tau inversion recovery (STIR) sequence. Consequently, MRI has become an important 
additional instrument in the early detection of axSpA and was included in the modified Berlin 
Algorithm (a helpful tool in axSpA diagnosis.47  The term non-radiographic axSpA (nr-axSpA) 
was introduced to differentiate patients with AS (radiographic axSpA, r-axSpA). (Figure 4). 
It is important to emphasize that a substantial proportion of the patients with nr-axSpA will 
progress to r-axSpA, but not all nr-axSpA patients will develop r-axSpA. The speed of this 
shift is still unclear and only a few predisposing factors are identified yet.
In 2009, a group of ASAS experts in the field of axSpA set up specific criteria to define a 
so-called ‘positive MRI’.45 The presence of definite subchondral bone marrow edema (BME)/
osteitis highly suggestive of sacroiliitis is mandatory. On the other hand, the presence of 
synovitis, capsulitis, or enthesitis only, without subchondral BME/osteitis, is compatible with 
but not sufficient for defining a positive MRI. Furthermore, to mark an MRI-SI as positive, one 
inflammatory lesion should be visible on at least two consecutive coronal-oblique slices or 
more lesions should be present on a single slice.
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GENETIC ASPECTS IN EARLY AXIAL 
SPONDYLOARTHRITIS
The aetiology of SpA is largely unknown but both genetic and environmental factors play 
a role. Despite the above described heterogeneous character of clinical manifestations, 
genetic similarities among patients are seen.48 Family aggregation studies have shown that 
genetic risk factors contribute 80-90% of the susceptibility to AS; with high concordance 
rates in monozygotic (50-75%) and dizygotic twins (15%), which are markedly higher than 
the prevalence in the population at large.49,50 
The major genetic risk factor currently known is HLA-B27, a major histocompatibility (MHC) 
class I molecule. The association between HLA-B27 and AS was recognized 40 years 
ago and is by far the strongest association with the disease.51,52 The overall contribution of 
HLA-B27 to AS heritability is estimated at 23.3% and only 5-6% of HLA-B27 positive people 
in the general population will develop SpA.53 This led to the hypothesis that HLA-B27 by itself 
is not sufficient for development of the disease, suggesting the contribution of additional 
genes.
Figure 4: Unifying concept of axial SpA showing schematically the transition from early to late 
disease
Rudwaleit M, Khan MA, Sieper J. Arthritis Rheum 2005;52: 1000-1008.
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Different single nucleotide polymorphisms (SNPs) have been identified via candidate gene 
studies. More recently, due to technologic improvements large genome-wide association 
studies (GWAS) have been carried out, which has led to the identification of many new 
genetic risk factors. Currently, over 30 genetic loci have been described to be operative in 
AS susceptibility.54
DATABASES USED IN THIS THESIS
To accomplish the objectives of this thesis (presented below), data from three different 
cohort studies were used. A summary of these studies is provided below:
SPACE
SPondyloArthritis Caught Early (SPACE) is a multinational cohort study aiming at an early 
diagnosis of axSpA as well as identifying factors that are predictive for progression of the 
disease.55 Unlike the cohorts stated below this is an on-going cohort study founded in the 
Leiden University Medical Center (LUMC) in the Netherlands. But inclusion rapidly expanded 
to other countries (Norway, Italy, Sweden) and other participating centres in the Netherlands 
(Amsterdam, Gouda). Since the initiation of the cohort in 2009, more than 600 patients are 
included. Patients aged 16 years and older are included in case of chronic back pain for 
more than 3 months, but less than two years with an onset before the age of 45 years. 
Patients were not included if other painful conditions not related to SpA could interfere with 
the evaluation.
DESIR
Baseline data from the Devenir des Spondylarthropathies Indifférenciées Récentes (DESIR) 
cohort were also used. DESIR is a prospective, longitudinal cohort study in which patients 
aged 18-50 years with inflammatory back pain (IBP) suggestive of axSpA are included.56 
The presence of IBP according to the Calin or Berlin criteria57,58 and a back pain duration of 
more than three months and less than three years was required for inclusion. Besides the 
mandatory presence of IBP, a patient was only included if the rheumatologist responsible for 
the enrolment had a level of confidence about the diagnosis of SpA of at least 5 (0-10 scale; 
where 0 is not confident and 10 is very confident). All patients included in the cohort have the 
French nationality, but the study has a multi-centre character due to the fact that inclusion 
took place in 25 different centres across France. The cohort is aiming at a 10-year follow-up, 
though only baseline data were used for this thesis. In contrary to the SPACE-cohort which 
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has an on-going inclusion, DESIR is a closed cohort of 708 patients and inclusion stopped 
after the goal of 700 patients was reached (inclusion between January 2007-April 2010).
In general, the SPACE cohort has important similarities to DESIR, though an important 
difference is that in DESIR patients with IBP are included, whereas SPACE includes patients 
with chronic back pain not necessarily IBP. Furthermore, in DESIR the presence of an axSpA 
diagnosis is at least probable whereas this is not the case in SPACE.
COMOSPA
Under the umbrella of ASAS, the COMOrbidities in SPondyloArthritis (COMOSPA) study was 
initiated. This is an international, observational study with a cross-sectional design in which 
patients diagnosed with SpA (according to the treating rheumatologist) were included.59 The 
primary aim of this study was to evaluate the prevalence of comorbidities and risk factors in 
different countries worldwide and to evaluate the gap between available recommendations 
and daily practice for management of these comorbidities. The worldwide character of this 
study makes it unique: inclusion took place in 22 countries from five different regions across 
the world: Asia, North Africa, Latin America, North America, Central Europe and Western 
Europe. This interesting feature of the study paved the way for the investigation of other 
research questions.
OUTLINE OF THE THESIS
Classification criteria are frequently used to include patients in clinical trials and cohort studies. 
Validation was predominantly done in restricted patient populations. In chapter 2 we compare 
the performance of various SpA classification criteria sets in a worldwide population of 
patients (the above described COMOSPA study). By testing the fulfilment of the different 
criteria sets, we investigate similarities and phenotypical overlap in patients that were 
worldwide diagnosed with SpA. It is relevant to investigate if rheumatologists worldwide 
diagnose patients with a similar clinical picture of disease. Since there is debate in the 
literature among SpA-experts in the field concerning the relevance and validity of the clinical 
arm of the axSpA-criteria, disease characteristics of patients fulfilling the imaging and clinical 
arm are also compared.
Due to the heterogeneous character of the disease and the high prevalence of CBP, the 
diagnostic process of axSpA can be challenging for rheumatologists and other physicians. 
The modified Berlin algorithm (Figure 5) may facilitate clinicians in establishing an early 
diagnosis of axSpA with greater confidence. A downside of the algorithm is that conventional 
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radiographs are advised in all referred patients with CBP of a certain duration and onset <45 
years of age, regardless of the presence of other SpA features. But it is currently unclear if 
additional investigations (besides conventional radiographs, also sacroiliac joint MRI and 
HLA-B27 testing) are necessary to perform in all patients. This is of particular importance 
in the subgroup of patients with only zero or one SpA feature after clinical examination and 
measurement of acute phase reactants in serum. Therefore, in chapter 3, we investigate in 
this subgroup of patients the incremental value of HLA-B27 testing and both sacroiliac joint 
imaging modalities: conventional radiographs and MRI of the sacroiliac joints. 
Figure 5: Modified Berlin algorithm.
AS, ankylosing spondylitis; SpA, spondyloarthritis; pos, positive; neg, negative; MRI, magnetic 
resonance imaging; X-rays, conventional radiographs; HLA-B27, human leukocyte antigen B27; 
NSAIDs, non-steroidal anti-inflammatory drugs. 
Van den Berg R, de Hooge M, Rudwaleit M, et al. Ann Rheum Dis 2013;72:1646-1653.
Both conventional radiographs and MRI of the sacroiliac joints are commonly used imaging 
modalities in the detection of sacroiliitis. Over the last decade, major advances in sacroiliac 
joint imaging have led to a better understanding of its role in the early detection of axSpA. 
To provide an overview of these recent advances in sacroiliac joint imaging, a systematic 
literature review was performed and results are described in chapter 4. The aim of this 
review was mainly two-fold: to summarize studies evaluating the reliability of conventional 
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radiographs of the sacroiliac joints and to wrap-up evidence on the diagnostic value of MRI 
of the sacroiliac joints in SpA.
In 2009 the ASAS definition for a positive MRI (described above) was introduced. Since 
only 30-50% of axSpA patients have active sacroiliitis on MRI, it was questioned whether 
the wording of the definition for a positive MRI was still appropriate. Therefore, a consensus 
exercise (chapter 5) was initiated in which recently published data on this respect were 
examined and discussed. Four questions were relevant: how does the current ASAS definition 
for a positive MRI perform? (1) Do we need an update of the existing definition (2) Do we 
need to add MRI features of structural changes of the SI-joint (3) Do we need to include 
features of the spine in the definition (4).
An important conclusion of the above described consensus exercise was that the additional 
value of using structural lesions in the ASAS axSpA criteria needs to be further investigated. 
Besides inflammatory lesions, on MRI structural lesions (fatty lesions, erosions, sclerosis 
and ankylosis) are visible on MRI. Therefore, MRI has the great potential for the assessment 
of both active inflammatory lesions and structural damage by means of one single imaging 
technique. The EULAR recommendations60 for the use of imaging in the diagnosis and 
management of axSpA in clinical practice, advocated to take structural lesions into account 
in the diagnostic process. However, the utility of adding structural lesions seen on MRI of 
the sacroiliac joints to the imaging criterion of the ASAS axSpA classification is yet unknown. 
This was investigated in two different cohorts (DESIR and SPACE) in chapter 6 and chapter 
7. An even more drastic approach would be the replacement of radiographic sacroiliitis by 
structural lesions in the ASAS axSpA criteria and this was also assessed.
The increased attention for MRI of the sacroiliac SI joints in the diagnostic work-up of 
axSpA also leads to new opportunities and research questions. We know that in contrast to 
radiographic abnormalities, inflammatory, bone marrow edema (BME) lesions are volatile and 
can change over time. But not much data is present on the repeated performance of MRI-SI 
in the diagnostic process and how BME develops over time: it can become quiescent after 
an initial phase of activity or newly positive MRIs can be seen. This could have implications, 
for example the question if repeating MRI is necessary in the diagnostic process. If an MRI is 
completely normal at the first investigation, but there is still a persistent clinical suspicion of 
SpA, should the MRI be repeated? If so, after what period of follow-up and in which patients? 
These questions are all subject of study in chapter 8.
As described above, genetic factors influence AS susceptibility. While HLA-B27 is known 
to be the major risk factor, interaction with other genes is suggested. HLA-B*4001 (an allele 
that corresponds to HLA-B60 at the serological or protein level) is identified as another 
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genetic risk factor for AS. In three independent AS populations, it was investigated if 
HLA-B*4001 was increased in HLA-B27 positive AS patients.61-63 The combined high risk AS 
genotype HLA-B27+/HLA-B*4001+ was found to have a high specificity in three different AS 
populations (sensitivity varying between 10.1%-18.7% and specificities: 98.7-99.7%) and 
epistatic interaction was also found in one other study.61-63
However, the high specificity of the HLA-B27+/HLA-B*4001+ genotype has only been 
investigated in late stage AS patients. In chapter 9 we study the prevalence of the HLA-B27+/
HLA-B*4001+ genotype in the SPACE and DESIR cohort and two matched populations of 
healthy controls; evaluate the additional value of testing in the detection of early axSpA.
Finally, in chapter 10 the findings of this thesis are summarized and discussed. A Dutch 
summary is provided in chapter 11.
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In this study, we sought to compare the performance of spondyloarthritis (SpA) classification 
criteria sets in an international SpA cohort with patients included from five continents around 
the world.
Methods
Data from the (ASAS) COMOrbidities in SPondyloArthritis (ASAS-COMOSPA) study were 
used. ASAS-COMOSPA is a multinational, cross-sectional study with consecutive patients 
diagnosed with SpA by rheumatologists worldwide. Patients were classified according to the 
European Spondyloarthropathy Study Group (ESSG), modified European Spondyloarthropathy 
Study Group (mESSG), Amor, modified Amor, Assessment of SpondyloArthritis international 
Society (ASAS) axial Spondyloarthritis (axSpA), ASAS peripheral spondyloarthritis (pSpA) 
and ClASsification criteria for Psoriatic Arthritis (CASPAR) criteria. Overlap between the 
classification criteria sets was assessed for patients with and without back pain. Furthermore, 
patients fulfilling different arms of the ASAS axSpA criteria (imaging arm, clinical arm, both 
arms) were compared on the presence of SpA features.
Results
A total of 3942 patients (5 continents, 26 countries) were included. The mean age was 43.6 
years, 65.0% were male, 56.2% were human leucocyte antigen B27-positive and 64.4% had 
radiographic sacroiliitis (based on modified New York criteria). Of the patients, 85.5% were 
classified by the ASAS SpA criteria (87.7% ASAS axSpA,12.3% ASAS pSpA). Fulfilment of 
the Amor, ESSG and CASPAR criteria was present in 83.3%, 88.4% and 21.6% of patients, 
respectively. Of the patients with back pain (n = 3227), most were classified by all three of 
Amor, ESSG and ASAS axSpA criteria (71.4%). Patients fulfilling the imaging arm and the 
clinical arm of the ASAS axSpA criteria had similar presentations of SpA features. In patients 
without back pain, overlap between classification criteria sets was seen, although to a lesser 
extent.
Conclusions
Most patients with a clinical diagnosis of axSpA in the worldwide ASAS-COMOSPA study 
fulfil several classification criteria sets, and a substantial overlap between different criteria 
sets is seen, which suggests a high level of credibility of the criteria. Large inter-regional 
differences in the fulfilment of classification criteria were not found. Patients fulfilling the 
clinical arm were remarkably similar to patients fulfilling the imaging arm with respect to the 
presence of most SpA features.
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INTRODUCTION
Spondyloarthritis (SpA) encompasses a group of interrelated rheumatic conditions: 
ankylosing spondylitis (AS), including earlier forms of the disease that do not yet exhibit 
definitive structural damage on radiographs; psoriatic arthritis (PsA); arthritis associated 
with inflammatory bowel disease (IBD); and reactive arthritis.1 Because SpA may have a 
heterogeneous presentation, a correct diagnosis is challenging. Rheumatologists make a 
diagnosis on the basis of what they have been taught during rheumatology training. The 
‘art of diagnosing’ starts with a list of potential differential diagnoses, from among which the 
trained clinician deducts the most appropriate disease based upon the recognition of the 
‘Gestalt’ and exclusion of other diagnoses.
Classification serves a completely different purpose, and several classification criteria sets 
of SpA are available. These classification criteria should be applied only in patients who 
have been diagnosed with SpA by a rheumatologist, and they cannot be used as a check 
box to be ticked in order to make the diagnosis. But the components of classification criteria 
may remind the clinician of the clinical picture of the disease. Different criteria sets put an 
emphasis on different features, and we do not know to what extent different criteria sets have 
penetrated different parts of the world. Therefore, we do not know which sets have influenced 
clinicians in particular regions most or to what extent these various sets of criteria describe 
more or less similar patients. Consequently, we do not know if rheumatologists around the 
world diagnose patients with a similar clinical picture of the disease.
The European Spondyloarthropathy Study Group (ESSG) criteria and the Amor criteria were 
developed to classify patients with SpA as a whole.2,3 In clinical practice, rheumatologists 
tend to distinguish patients with SpA according to their primary clinical presentation as 
patients with predominantly axial or predominantly peripheral complaints (with some overlap 
between these subtypes). The Assessment of SpondyloArthritis international Society (ASAS) 
has developed new criteria to better accommodate this distinction.4,5 These criteria sets can 
classify patients with predominantly axial symptoms as having axial spondyloarthritis (axSpA) 
and patients with predominantly peripheral symptoms as having peripheral spondyloarthritis 
(pSpA). The ASAS axSpA criteria consist of two arms: the imaging arm classifies patients 
who have sacroiliitis visualised on conventional radiographs and/or bone marrow oedema 
on magnetic resonance imaging (MRI), and the clinical arm classifies patients with normal 
imaging results. In 2006, a specific classification criteria set for PsA was developed, known 
as the ClASsification criteria for Psoriatic ARthritis (CASPAR).6
Classification criteria are used to include patients in clinical trials, cohort studies and other 
types of research. These criteria are frequently validated in restricted patient populations. 
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We took the opportunity to investigate if rheumatologists worldwide diagnosed similar types 
of patients as having SpA by testing if patients fulfil similar criteria sets in the Assessment 
of SpondyloArthritis international Society COMOrbidities in SPondyloArthritis (ASAS-
COMOSPA) study. Our assumption was that the more criteria sets a patient fulfils, the higher 
the likelihood that a patient with a diagnosis of SpA truly has SpA. The ASAS-COMOSPA 
study provides a unique opportunity to investigate this research question because it is, to our 
knowledge, the first observational study with such a large, worldwide population of patients 
with SpA, with axial and/or peripheral symptoms included.7
METHODS
Study population
The ASAS-COMOSPA study is an observational, cross-sectional, multicentre study which 
has been introduced elsewhere.7 Participating rheumatologists were asked to include 
consecutive patients with a diagnosis of SpA from routine care. These patients had to fulfil 
the ASAS axSpA or pSpA criteria, but fulfilment of the ASAS criteria was not checked before 
inclusion. All information required to judge the fulfilment of various criteria sets, including 
the ASAS criteria, was collected in a random order (not grouped by criteria set) in the case 
report form.
Patients from 26 participating countries in 6 regions across the world (Western Europe, 
Central Europe, North America, Latin America, North Africa and Asia) were included. Western 
Europe was represented by Belgium, France, Germany, Hungary, Italy, the Netherlands, 
Portugal, Spain and the United Kingdom. Poland, Russia, Turkey and Ukraine were grouped 
into Central Europe. North America encompasses Canada and the United States, and 
Argentina, Brazil, Colombia and Mexico were summarized as Latin America. North Africa 
comprised Egypt and Morocco. China, Japan, Korea, Singapore and Taiwan were grouped 
and referred to as Asia. Approval by the local medical ethics committees, as well as written 
informed consent from all patients, was obtained before inclusion.
Classification criteria
Patients were classified according to the following criteria sets: ESSG, Amor, ASAS SpA, 
ASAS axSpA, ASAS pSpA, imaging arm of ASAS axSpA, clinical arm of ASAS axSpA and 
CASPAR criteria.8 The presence of either inflammatory back pain (IBP) or peripheral arthritis 
is a mandatory entry criterion of the ESSG criteria. According to the ESSG criteria, patients 
with at least one of the entry criteria in combination with one other minor criterion, such 
as enthesitis or psoriasis, are classified as having SpA.2 Human leukocyte antigen B27 
(HLA-B27) is not incorporated in this criteria set. The Amor criteria include a list of features 
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with different weights, none of which is essential to classify a patient as having SpA, but a 
classification of SpA depends on the sum of weights.3 Because patients in the COMOSPA 
study were not asked about the presence of balanitis, night pain and buttock pain, these 
items have not been taken into account, and therefore patients cannot collect points on 
these items in the Amor and ESSG criteria. The ESSG and Amor criteria were developed 
before MRI became widely available. In the present analysis, we also investigated the 
possibility of including inflammatory findings on MRI (ASAS definition)9 as a feature in both 
the ESSG and Amor criteria, resulting in the modified Amor (mAmor) and modified European 
Spondyloarthropathy Study Group (mESSG) criteria.
The ASAS axSpA criteria consist of two arms, the imaging arm and the clinical arm, and can 
be applied only to patients with back pain of ≥3 months’ duration and an age of onset <45 
years.10 In patients with sacroiliitis visualised on pelvic radiographs or MRI, at least one other 
SpA feature should be present in order to be classified as axSpA according to the imaging 
arm.4 In HLA-B27-positive patients, at least two other additional SpA features should be 
present in order to be classified as axSpA according to the clinical arm.4 In patients without 
current back pain but with current peripheral manifestations, the classification for peripheral 
SpA can be applied. If a patient satisfies the entry criterion (current arthritis, enthesitis or 
dactylitis), the patient should have at least one other SpA feature if this is a specific SpA 
feature or at least two SpA features for less specific features.5 Altogether, when current back 
pain (as defined above) is the presenting symptom, the ASAS axSpA criteria should be 
applied. If arthritis/enthesitis/dactylitis is the presenting symptom, the peripheral SpA criteria 
should be applied. Together, these two sets form the ASAS SpA criteria.
A separate classification criteria set has been developed for PsA: the CASPAR criteria.6 To 
meet the CASPAR criteria, the stem of the criteria demands first the presence of inflammatory 
articular disease and a score of at least 3 points derived from the presence of features 
such as skin psoriasis, dactylitis, nail lesions or juxta-articular bone formation visualised 
on radiographs (each feature is assigned a certain number of points). All above-described 
criteria sets are depicted in the supplementary material: Supplementary Tables 1-4.
Data analysis
Disease characteristics were described using descriptive statistics. The fulfilment of 
classification criteria was calculated for the cohort as a whole and thereafter per region. 
Subsequently, overlap between the different classification criteria was investigated and 
presented in Venn diagrams. This was done for patients with back pain and patients without 
back pain separately. Next, we looked in detail at the fulfilment of the ASAS axSpA criteria, 
comparing patients fulfilling only the clinical arm, patients fulfilling only the imaging arm and 
patients fulfilling both the clinical and imaging arms with regard to demographics and the 
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presence of SpA features. Information on HLA-B27 must be available to be able to classify 
patients in the ‘imaging arm-only’ group, and information on imaging must be available to 
be able to classify patients in the ‘clinical arm-only’ group. IBM SPSS Statistics version 20.0 
software (IBM, Armonk, NY, USA) was used for statistical analysis.
RESULTS
In total, 3984 patients were included in the COMOSPA study, with a mean number of SpA 
features of 5.5 (SD 1.8). The most common missing items were MRI of the sacroiliac joints 
(missing in 1951 patients), the presence of juxta-articular bone formation (missing in 999 
patients) and HLA-B27 status (missing in 882 patients). There were 251 patients (6.4%) for 
whom both sacroiliac joint MRI and radiographs were not performed and 180 patients (4.6%) 
for whom HLA-B27 in addition was missing.








Age (years), mean ±SD 43.6 (13.9) 0
Male, n (%) 2563 (65.0%) 0
HLA-B27 positive, n (%) 2217 (56.2%) 72.0% 882
IBP, n (%) 3219 (81.7%) 52
Morning stiffness, n (%) 2497 (63.3%) 22
Enthesitis, n (%) 1354 (34.3%) 0
Dactylitis, n (%) 610 (15.5%) 3
Psoriasis, n (%) 843 (21.4%) 0
Uveitis, n (%) 771 (19.6%) 0
Peripheral Arthritis, n (%) 2424 (61.5%) 0
IBD, n (%) 209 (5.3%) 0
Positive family history, n (%) 1475 (37.4%) 117
Good response to NSAIDs, n (%) 2433 (61.7%) 77.5% 803
Elevated CRP, n (%) 2109 (53.5%) 57.7% 287
Preceding infection, n (%) 271 (6.9%) 74
Sacroiliitis radiograph (mNY), n (%) 2539 (64.4%) 70.0% 341
Sacroiliitis MRI, n (%) 1326 (33.6%) 65.7% 1951
Negative rheumatoid factor, n (%) 3177 (80.6%) 94.8% 613
Psoriatic nail dystrophy, n (%) 460 (11.7%) 28
Juxta-articular bone formation, n (%) 526 (13.3%) 17.7% 999
HLA-B27, human leukocyte antigen B27; IBP, inflammatory back pain (according to the Assessment of 
SpondyloArthritis international Society (ASAS) definition; ); IBD, inflammatory bowel disease; NSAIDs, 
non-steroidal anti-inflammatory drugs; CRP, C-reactive protein; mNY, modified New York criteria, MRI, 
magnetic resonance imaging.
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On the other hand, information on extra-articular manifestations was missing in none of the 
cases. Arbitrarily, a maximum of 6 missing items (total number of 18 items) per patient was 
accepted. Patients with 7 or more missing items (n = 42) were left out of the analysis, which 
brings the total number of patients for this analysis to 3942. To define SpA features as present 
or absent, in order to apply the classification criteria, missing items were regarded as absent.
Demographics and disease characteristics are depicted in Table 1. Patients had a mean age 
of 44 years, and 65% were male. In the total cohort (patients with available data), HLA-B27 
positivity was seen in 56% (73.0%) of the patients, and 54% (57.7%) had an elevated 
C-reactive protein level. Regarding the presence of sacroiliitis visualised on imaging, 64% 
(70.0%) presented with sacroiliitis seen on radiographs and 34% (94.8%) with sacroiliitis 
seen on MRI.
Fulfilment of classification criteria
Most (92.6%) of the 3942 patients fulfilled the mESSG criteria. Fulfilment of Amor, mAmor, 
ESSG and ASAS criteria was all above 80% (Table 2). A minority (12.3%) of the patients 
fulfilled the ASAS pSpA criteria, whereas 21.6% of the patients fulfilled the CASPAR criteria. 
We emphasise that the criteria were applied to all patients; only the patients with seven or 
more missing values were left out, and missing items were regarded as absent.
Table 2: Fulfilment of classification criteria
Classification criteria Patients that fulfil the classification criteria, n (%)




ASAS SpA total 3370 (85.5%)
   ASAS axial SpA  2955 (87.7%) 
      Both arms (imaging & clinical)      1737 (58.8%)
          mNY+          976 (56.2%)
          MRI+          169 (9.7%)
          Both          592 (34.1%)
      Imaging arm only      984 (33.3%)
          mNY+          539 (54.8%)
          MRI+          245 (24.9%)
          Both          200 (20.3%)
      Clinical arm only      234 (7.9%)
   ASAS peripheral SpA no current back pain  415 (12.3%)
CASPAR 852 (21.6%)
mAmor, modified Amor; ESSG, European Spondylarthropathy Study Group; mESSG, modified European 
Spondyloarthropathy Study Group; ASAS, Assessment of SpondyloArthritis international Society; SpA, 
spondyloarthritis; mNY, modified New York; MRI, magnetic resonance imaging; CASPAR, ClASsification 
criteria for Psoriatic Arthritis.
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Most patients (n = 1507) were included in Western Europe (85 centres from 26 countries), 
followed by 1073 patients in Asia, 438 patients in Central Europe, 337 patients in Latin 
America, 337 patients in North Africa and 239 patients in North America. Regional differences 
in fulfilment of classification criteria are depicted in Table 3. When we looked in detail at the 
ASAS SpA criteria, we found that in Central Europe, 84% of the patients fulfilled the ASAS 
axSpA criteria (ASAS peripheral criteria 5.3%), whereas in contrast, in North America, 51% 
of the patients fulfilled the axSpA criteria (ASAS peripheral criteria 22.6%). In both Asia and 
Central Europe, a small minority of the patients fulfilled the ASAS pSpA criteria, and the 
axial complaints were by far the predominant symptoms. A relatively high percentage of 
patients fulfilled the CASPAR criteria in North America compared with the other regions. 
Less pronounced regional differences were seen regarding criteria sets that cover the whole 
spectrum of SpA, namely the Amor and ESSG criteria.
Overlap in classification criteria
Venn diagrams representing the overlap between the different criteria sets are shown 
in Figures 1 and 2. Figure 1 reveals that the majority of the patients with back pain were 
classified by all three criteria sets: Amor, ESSG and ASAS axSpA criteria (n = 2392 [74.1%]). 
Most patients who fulfilled two criteria sets fulfilled both the ASAS axSpA criteria and the 
ESSG criteria (n = 268 [8.3%]). Few patients fulfilled only one criteria set. Most of the patients 
who were picked up by one criteria set only were classified by the ASAS axSpA criteria 
(n = 179 [5.5%] compared with 1.3% by the ESSG criteria only and 0.2% by the Amor criteria 
only). The major overlap of the criteria points to the typical clinical pattern of SpA the included 
patients have.
Regarding the patients without current back pain (peripheral complaints), again substantial 
overlap between the criteria was seen (ASAS pSpA, Amor, ESSG, CASPAR) (Figure 2). Most 
of the patients fulfilled all four criteria sets (n = 224 [31.3%]). Subsequently, 125 patients 
(17.5%) fulfilled all criteria, except those for PsA-specific CASPAR criteria, which is not 
surprising, because the CASPAR criteria are focussed on the clinical disease PsA and not 
on other forms of pSpA. Only six patients (0.8%) fulfilled only the CASPAR criteria, and only 
four patients (0.6%) fulfilled only the ASAS pSpA criteria. Regarding overlap between the 
different criteria sets in the different regions, the same trends were seen, and no substantial 
interregional differences were found (data not shown).
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Figure 1: Overlap between ESSG, AMOR, and axSpA criteria in patients with current back pain 
(n=3227)
ESSG, European Spondylarthropathy Study Group; ASAS, Assessment of SpondyloArthritis international 
Society; axial SpA, axial spondyloarthritis.
Figure 2: Overlap between the ESSG, AMOR, CASPAR, and pSpA criteria in patients without 
current back pain (n=715)
ESSG, European Spondylarthropathy Study Group; ASAS, Assessment of SpondyloArthritis international 
Society; pSpA, peripheral SpondyloArthritis; CASPAR, ClASsification criteria for Psoriatic Arthritis.
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Comparison between patients fulfilling the ASAS imaging arm split by presence of 
HLA-B27 and the clinical arm only
Disease characteristics of patients fulfilling the imaging arm or the clinical arm only are 
depicted in Table 4. In addition, characteristics of patients fulfilling the imaging arm are 
presented on the basis of the presence or absence of HLA-B27. Only patients who have 
data available on HLA-B27 and imaging are included in Table 4. There were more male 
patients in the HLA-B27-positive imaging arm (74.1%) than in the HLA-B27-negative imaging 
arm (50.4%) and the clinical arm (53.1%). Psoriasis was seen more frequently in the group 
of HLA-B27-negative patients fulfilling the imaging arm. On the contrary, enthesitis and 
dactylitis were relatively more common in the patients who fulfilled only the clinical arm. A 
positive family history was also more frequently seen in the clinical arm than in the imaging 
arm (independent of HLA-B27 status).
Table 4: Comparison between the imaging arm and clinical arm of the ASAS axSpA criteria, with 
the required presence of HLA-B27 and imaging
Imaging arm (%),
HLA-B27 always available
Clinical arm alone (%)
Imaging always available
N total =  98
HLA-B27+ 
N total = 1746
HLA-B27-
N total = 546
Age 40.3 (13.0) 42.7 (13.0) 42.8 (13.0)
Sex (male) 1294 (74.1%) 275 (50.4%) 52 (53.1)
IBP 1639 (93.3%) 529 (96.9%) 87 (88.8%)
Peripheral arthritis 904 (51.8%) 302 (55.3%) 57 (58.2%) 
Psoriasis  147 (8.4%) 105 (19.2%) 14 (14.3%)
Uveitis  453 (25.9%) 49 (9.0%) 27 (27.6%) 
Enthesitis 563 (32.2%) 164 (30.0%) 44 (44.9%) 
Dactylitis 137 (7.8%) 55 (10.1%) 17 (17.3%)
IBD  73 (4.2%) 46 (8.4%) 6 (6.1%)
Positive family history 669 (38.3%) 166 (30.4%) 52 (53.1%)
Good response to NSAIDs 1180 (67.6%) 265 (48.5%) 64 (65.3%)
Elevated CRP 1094 (62.7%) 256 (46.9%) 41 (41.8%)
HLA-B27, human leukocyte antigen B27; IBP, inflammatory back pain; IBD, inflammatory bowel disease; 
NSAIDs, non-steroidal anti-inflammatory drugs; CRP, C-reactive protein.
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DISCUSSION
Appropriate diagnostic criteria for axSpA and pSpA do not exist and, in the absence of 
an unequivocal gold standard, will never be developed, but various classification criteria 
are available. These classification criteria have in common that they have been developed 
using the external standard ‘expert opinion’. But expert opinion is not an equivocal and 
homogeneous construct and may potentially integrate different pictures of the disease SpA.
The present study reveals that, in our cohort, most patients diagnosed as having SpA fulfilled 
multiple classification criteria sets, which adds to the credibility of the construct of SpA as 
a recognizable entity. Although the substantial overlap between the different criteria sets 
for patients with both axial and with peripheral symptoms could be expected, the fact that 
different criteria sets have been developed for different target populations (e.g., the ESSG, 
focussed on the whole concept of SpA; the ASAS axSpA criteria for patients with SpA axial 
symptoms) could have precluded overlap in different regions of the world. In the present 
study, we have shown that the significant overlap was consistent all over the world, thus 
suggesting that rheumatologists worldwide use similar ‘pictures’ of what SpA is. In other 
words, they operationalise the construct of SpA approximately similarly. In addition, the huge 
overlap (e.g., 74.1% of the patients fulfilled all three criteria sets, and only 7.6% fulfilled one 
set only) confirms that the criteria for SpA are highly credible.
As mentioned already, large interregional differences in the fulfilment of classification criteria 
were not found. This is remarkable in the light of all genetic and environmental differences, 
as well as differences in resources and health care systems around the world. In fact, it 
appears that the clinical picture—and consequently the diagnosis—of SpA is remarkably 
homogeneous around the world, despite all possible differences in, for example, genetic 
background, prevalence and medical training.
Of course, there were some notable differences. The most important one was that more 
patients with PsA and fewer patients with axial disease were included in North America 
than in other regions. We do not think this reflects a true difference in the prevalence of 
the different subtypes of the disease. This is supported by a recent systematic review that 
pooled population prevalence estimates for SpA, AS and PsA in geographic areas.11 The 
prevalence of both the axial and peripheral subtypes was, on average, comparable in North 
America to other parts of the world. More likely, the difference could be due to local factors, 
such as a difference in areas of interest of the doctors including patients or referral centres 
for a certain disease. One reason may be the perception of PsA as belonging to SpA or not. 
It is well known that some rheumatologists view PsA as a separate entity and others view PsA 
as a subtype of SpA. Apparently, more doctors in North America than in other parts of the 
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world consider patients with PsA as having SpA.
Regarding the inclusion criteria of the study, doctors were required to include patients with 
SpA only if they thought the patient would fulfil the ASAS SpA criteria (either peripheral or 
axial). However, fulfilment of the ASAS criteria was not formally checked before inclusion, 
as described in the Methods section above. When analysing the data, it became clear that 
only 85.5% of the patients actually did fulfil the ASAS SpA criteria, ranging from 73.6% in 
North America to 91.4% in North Africa. This implies that the large majority of patients with 
SpA are indeed covered by the criteria, pointing to high sensitivity but also indicating that 
doctors diagnose SpA in patients who do not fulfil the ASAS criteria. However, we would 
like to make a critical comment which relates to a limitation of the present study. The fact 
that rheumatologists were initially asked to include ASAS SpA patients (although fulfilment 
of the ASAS criteria was not met in all patients) could very well have led to an ‘a priori’ high 
percentage of ASAS classification criteria fulfilment. This could have led to an overestimation 
of performance of sensitivity of the criteria.
The ASAS classification criteria were developed in recent history. The criteria were validated 
in an international study of more than 600 patients with chronic back pain of unknown origin. 
In the ASAS study population, the ASAS criteria compared favourably with other previously 
established criteria sets with regard to sensitivity and specificity. In our study, if patients with 
axial symptoms were picked up by one criteria set only, of all sets tested, the ASAS axSpA 
criteria were most sensitive (although the others performed well, too). The latter could be due 
to the fact that the ASAS-COMOSPA study is not a cohort of early disease (as reflected by 
65% modified New York criteria positivity). Prior studies have shown that performances of, 
for example, ESSG and Amor criteria in early disease were (slightly) worse than the ASAS 
criteria.12 A more likely explanation is that the rheumatologists were asked to include patients 
fulfilling the ASAS criteria.
Although the imaging arm of the ASAS classification criteria is broadly recognized as highly 
specific, there has been debate on the validity of the clinical arm of the ASAS criteria, which 
has not been well received by different national and international health care systems. In the 
literature, it has been argued that patients fulfilling only the clinical arm of the ASAS axSpA 
criteria should not be considered as having ‘true axSpA’. A reason why the clinical arm of 
the ASAS axSpA criteria has been developed is that MRI is not universally available. In our 
cohort, in which a large proportion of patients did not undergo MRI, our results demonstrate 
the value of the clinical arm of the ASAS criteria for scientific research. We found that patients 
fulfilling the clinical arm were remarkably similar to patients fulfilling the imaging arm with 
respect to the presence of many SpA features.
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Strengths of the study are the multi-national cohort and the large number of patients included, 
which is unique, to our knowledge. Unfortunately, no control group was available, and 
therefore true specificity of the different classification criteria sets could not be calculated. 
Another limitation of the study is the relatively high number of missing values, especially when 
it comes to key items such as HLA-B27 and MRI. Unfortunately, this is a direct consequence 
of normal clinical practice: If sufficient information has been collected to make a diagnosis, 
further testing is often not performed (e.g., to save expenses).
We can conclude that, despite the heterogeneous character and varying prevalence of SpA 
as a disease across the world, similar patients are identified as having SpA by rheumatologists 
worldwide. Moreover, patients with the diagnosis of SpA usually fulfil multiple criteria sets, 
providing validity to the criteria, including the relatively new ASAS SpA criteria as well as to 
the concept of SpA. We emphasize that classification criteria for SpA were developed for 
use in epidemiological and clinical research and are not suitable for use as diagnostic tools 
in clinical practice.
CONCLUSIONS
Most patients diagnosed with SpA by rheumatologists in five continents across the world 
fulfilled multiple classification criteria sets. To our knowledge, this is the first study confirming 
the validity of the ASAS axSpA criteria in a large, worldwide population of patients. Patients 
fulfilling the clinical and/or imaging arms of the ASAS axSpA criteria have comparable SpA 
features.
For the first time, to our knowledge, the performance of the various SpA classification criteria 
sets is assessed in a worldwide setting with a very large number of patients included from five 
different continents. We also took the opportunity to phenotypically compare patients fulfilling 
the different arms of the ASAS axSpA criteria in terms of demographics and presence of SpA 
features, among others.
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Pain at night (spine) or morning stiffness 1
Asymmetrical oligoarthritis 2
Gluteal (buttock) pain (any) or alternating gluteal pain 1 or 2
Sausage like digit or toe (dactylitis) 2
Enthesitis (heel) 2
Uveitis 2
Urethritis/cervicitis within 1 month before onset of arthritis 1
Diarrhea within 1 month before onset of arthritis 1
Psoriasis, balanitis or inflammatory bowel disease 1
X-rays
Sacroiliitis (grade 2 bilaterally or grade 3 unilaterally) 3
Genetic background
HLA-B27 positive or positive family history for AS, ReA, uveitis, 
psoriasis or inflammatory bowel disease
2
Good response to NSAIDs
NSAIDs show a good response within 48 hours, or relapse within 
48 hours after NSAIDs are stopped
2
At least 6 points are necessary
HLA-B27, human leukocyte antigen B27; AS, ankylosing spondylitis; ReA, reactive arthritis; NSAIDs, 
non-steroidal anti-inflammatory drugs.
Supplementary Table 2: ESSG criteria




Asymmetric or Predominantly 
in the lower limbs




Crohn’s disease, colitis ulcerosa
Urethritis/cervicitis or acute diarrhea within 
one month before arthritis
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Supplementary Table 3a: ASAS axSpA criteria
ASAS Classification Criteria for Axial Spondyloarthritis (SpA)4
In patients with ≥3 months back pain and age at onset <45 years
Sacroiliitis on imaging**
plus ≥1 SpA feature
OR HLA-B27









Good response to NSAIDs




• Active (acute) inflammation on MRI highly suggestive of sacroiliitis associated with SpA
• Definite radiographic sacroiliitis according to the modified New York criteria
SpA, spondyloarthritis; SpA feature, spondyloarthritis feature; NSAIDs, non-steroidal anti-inflammatory 
drugs; HLA-B27, human leukocyte antigen B27; CRP, C-reactive protein.
Supplementary Table 3b: ASAS pSpA criteria
ASAS Classification Criteria for Peripheral Spondyloarthritis (SpA)5
Arthritis or enthesitis or dactylitis 
plus




Preceding infection IBP (ever)
HLA-B27 Family history for SpA
Sacroiliitis on imaging
Peripheral arthritis usually predominantly lower limbs and/or asymmetric arthritis
Enthesitis: clinically assessed
Dactylitis: clinically assessed
IBP: inflammatory back pain 
ASAS, Assessment of SpondyloArthritis international Society; SpA, spondyloarthritis; SpA-feature, 
spondyloarthritis feature; IBP, inflammatory back pain.
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Supplementary Table 4: CASPAR criteria
Classification of Psoriatic Arthritis: CASPAR criteria6
ClASsification criteria for Psoriatic ARthritis
To meet the CASPAR criteria for PsA, a patient must have inflammatory articular disease 




Personal history of psoriasis







Negative result for rheumatoid factor 1
Dactylitis




Radiologic evidence of juxta-articular new bone formation: 
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Are additional tests needed to rule out axial 
spondyloarthritis in patients ages 16 - 45 
years with short-duration chronic back 












Désirée van der Heijde
Floris van Gaalen 





To investigate whether HLA–B27 testing and imaging of the sacroiliac joints are needed in 
patients with ≤1 spondyloarthritis (SpA) feature, referred to a secondary care setting, after 
medical history collection, clinical examination, and measurement of acute phase reactants.
Methods
Baseline data from patients in the Spondyloarthritis Caught Early (SPACE) cohort visiting the 
rheumatology outpatient clinic of 5 centers across Europe (with back pain ≥3 months, ≤2 
years, onset at ages <45 years) were used. All patients underwent a full diagnostic work-
up: magnetic resonance imaging (MRI) and radiographs of the sacroiliac joints, HLA–B27 
testing, and assessment of all other SpA features. Patients were diagnosed according to 
the treating rheumatologist and classified according to the Assessment of SpondyloArthritis 
international Society (ASAS) axial SpA criteria.
Results
Of the 354 patients, 133 (37.5%) showed 0 or 1 SpA feature after medical history collection, 
physical examination, and measurement of acute phase reactants (38 without SpA features, 
95 with 1 SpA feature). Of the patients with ≤1 SpA feature, 18.4% (with 0 SpA features) and 
17.9% (with 1 SpA feature) were diagnosed with axial SpA according to the rheumatologist 
after additional investigations (HLA–B27 testing and sacroiliac joint imaging). Additionally, 4 
of 38 patients (10.5%) without SpA features fulfilled the ASAS axial SpA criteria (all according 
to the imaging arm only: 2 as MRI+/modified New York criteria (mNY)+,1 as MRI+/mNY-, and 
1 as MRI-/mNY+). Of the 95 patients with 1 SpA feature, 22 (23.2%) fulfilled the ASAS axial 
SpA criteria (all according to the imaging arm only: 3 as MRI+/mNY+, 15 as MRI+/mNY-, and 
4 as MRI-/mNY+). 
Conclusions
In these patients in a secondary care setting with ≤1 SpA feature, axial SpA could not be 
ruled out without sacroiliac joint imaging and/or HLA–B27 testing.
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INTRODUCTION
Axial spondyloarthritis (SpA) is a heterogeneous disease, and the diagnostic process can 
be challenging, since chronic back pain (CBP) is a very common symptom.1 Nevertheless, 
diagnosis is important, as effective treatments are available and treatment at an early stage 
may lead to a better outcome, i.e., achieving low disease activity or even remission and 
possibly the prevention of structural damage as well.2–6 Additionally, an early diagnosis 
reduces uncertainties in patients and prevents unnecessary diagnostic procedures.
In clinical practice, axial SpA can be diagnosed by recognition of a characteristic pattern 
of clinical, laboratory, and imaging findings. Through medical history collection, physical 
examination, and measurement of acute phase reactants, information on the presence 
of SpA features should be obtained in patients suspected of axial SpA (e.g., presence of 
enthesitis or uveitis anterior).7 Additionally, testing for the presence of HLA–B27 and imaging 
of the sacroiliac (SI) joints using pelvic radiographs and/or magnetic resonance imaging 
may provide essential clues on the presence of axial SpA. The presence or absence of all 
those different SpA features determines the likelihood of diagnosis.8 Unfortunately, there is 
no single SpA feature with sufficient specificity to establish the diagnosis early, and no formal 
diagnostic criteria exist.9,10
The modified Berlin algorithm may aid clinicians in establishing an early diagnosis of axial 
SpA with greater confidence.11 According to the algorithm, an SI radiograph should be 
obtained in all patients with CBP (duration ≥3 months and ≤2 years, age at onset at ages <45 
years) visiting the rheumatologist. Afterward, the presence of other SpA features should be 
evaluated. In case of 0 or 1 SpA feature, HLA–B27 testing is suggested, and if positive an 
MRI of the SI joints should be performed.
A downside of the algorithm is that radiographs are advised in all referred patients, regardless 
of the presence of other SpA features, meaning that all patients are subjected to ionizing 
radiation. Furthermore, after performing SI radiographs, medical history collection, physical 
examination, and measurement of acute phase reactants, the algorithm does not distinguish 
between patients with 0 or 1 SpA feature and recommends HLA–B27 testing in all patients, 
even though patients with no SpA features at that point may have a very low likelihood of 
axial SpA.
To address these issues, this study aimed to investigate whether additional investigations 
are useful in patients ages 16–45 years with back pain and ≤1 SpA feature (after clinical 
examination, physical examination, and C-reactive protein [CRP] level/erythrocyte 
sedimentation rate [ESR] measurement, but before HLA–B27 testing and imaging of the SI 
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joints). The study also aimed to investigate whether results are different in patients without 
SpA features or with 1 SpA feature.
METHODS
Study population
Baseline data from the Spondyloarthritis Caught Early (SPACE) cohort of patients included 
between January 2009 and October 2014 were used for this analysis. For this study, a 
subgroup of the SPACE cohort was used, namely patients with 0 or 1 SpA feature after 
medical history and physical examination, but before imaging and HLA–B27 testing. An 
extensive description of the cohort as a whole is available elsewhere.12 In short, SPACE 
is a multinational, multicenter inception cohort study of young patients with CBP of a short 
duration (≥3 months but ≤2 years, with the onset at ages <45 years), with a suspicion of SpA 
referred to a rheumatologist.
Inclusion took place at 5 participating centers in The Netherlands (Leiden, Amsterdam, 
Gouda), Norway (Oslo), and Italy (Padua). Approval for the study was obtained from the 
local medical ethics committees. Patients were referred to the outpatient clinic of the different 
participating centers. All patients were first assessed by the rheumatologist. In case of 
suspected SpA, patients could be included in the SPACE cohort. Before inclusion, patients 
gave written informed consent in accordance with the declaration of Helsinki.
Diagnostic work-up
All patients underwent a full diagnostic work-up according to a fixed protocol. This work-up 
consisted of SI MRI and radiographs, HLA–B27 testing, and assessment of all other SpA 
features: inflammatory back pain (IBP), peripheral arthritis, enthesitis, acute anterior uveitis, 
dactylitis, psoriasis, inflammatory bowel disease (IBD), good response to nonsteroidal anti-
inflammatory drugs (NSAIDs), a positive family history for SpA, and elevated CRP level and/
or ESR.
Imaging of the SI joints
The MRIs were performed on a 1.5T machine. The acquired sequences were coronal 
oblique T1-weighted turbo spin-echo (repetition time [TR] 550/ echo time [TE] 10) and STIR 
(TR 2500/TE 60) with a slice thickness of 4 mm. The images were performed in a coronal 
oblique view. Radiologists of the different centers interpreted the radiographs and MRIs of 
the SI joints for the presence of sacroiliitis. This process was done as part of routine clinical 
practice, interpreting MRI using global assessment of the images (sacroiliitis yes/no) and 
interpreting radiographs according to the modified New York criteria. While reviewing the 
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images, radiologists took differential diagnoses such as hernia, osteoarthritis, and so on, into 
account.
Outcome: diagnosis of axial SpA and classification according to the Assessment of 
SpondyloArthritis international Society (ASAS) axial SpA criteria 
Following the work-up discussed before (including HLA–B27 testing and imaging), the 
treating rheumatologist was asked to provide a diagnosis of axial SpA (yes/no) and provide 
a certainty of assessment for that diagnosis on a 1–10 scale. In addition, patients were 
classified according to the ASAS axial SpA criteria (yes/no).13 This classification was done 
after all information, including imaging and HLA–B27 testing results, was obtained. Data 
were analyzed using Stata SE software, version 12.
RESULTS
In the SPACE cohort, after medical history collection, physical examination, and measurement 
of acute phase reactants, 133 of 355 patients (37.5%) had 0–1 SpA features, 44.7% had 2–3 
SpA features, and 17.9% had ≥4 SpA features. For this study, the 133 patients with ≤1 SpA 
feature were included (95 with 1 SpA feature, 38 without SpA features). Patient characteristics 
for both groups are described in Table 1. 
Table 1: Baseline characteristics of patients with ≤1 SpA feature








All patients in 
the cohort
Total number n 
(n=354)
Age (years) at inclusion, mean (SD) 29.7 (9.6) 32.1 (8.4) 31.1 (8.4)
Male, n (%) 14 (36.8) 26 (27.4) 119 (33.6)
Symptom duration (months), mean (SD) 10.4 (6.1) 13.3 (7.5) 12.9 (7.2)
IBP, n (%) - 38 (40.0) 220 (62.2)
Good response to NSAIDs, n (%) - 12 (12.6) 119 (33.6)
Positive family history SpA, n (%) - 20 (21.1) 130 (36.7)
Peripheral arthritis, n (%) - 2 (2.1) 45 (12.7)
Dactylitis, n (%) - 0 (0) 15 (4.2)
Enthesitis, n (%) - 2 (2.1) 52 (14.7)
Uveitis, n (%) - 1 (1.1) 26 (7.3)
IBD, n (%) - 8 (8.4) 29 (8.2)
Psoriasis, n (%) - 2 (2.1) 34 (9.6)
Elevated CRP, n (%) - 8 (8.4) 76 (21.5)
HLA-B27 positive, n (%) 7 (18.4) 22 (23.2) 127 (35.9)
Sacroiliitis radiograph mNY, n (%) 3 (7.9) 7 (7.4) 36 (10.2)
Sacroiliitis MRI, n (%) 8 (21.1) 18 (19.0) 88 (24.9)
SpA, spondyloarthritis; IBP, inflammatory back pain; NSAIDs, non-steroidal anti-inflammatory drugs; 
IBD, inflammatory bowel disease; CRP, C-reactive protein; HLA-B27, human leukocyte antigen B27; 
mNY, modified New York criteria; MRI, magnetic resonance imaging.
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Patients with 0 or with 1 SpA feature had a mean ± SD age of 29.7 ± 9.6 years and 32.1 ± 8.4 
years, respectively. Mean duration of back pain was 10.4 ± 6.1 months and 13.3 ± 7.5 months, 
respectively. For comparison, disease characteristics of the SPACE cohort as a whole are 
shown in Table 1. In the group without SpA features, 18.4% was HLA-B27 positive versus 
23.2% in the group with 1 SpA feature. Sacroiliitis on radiographs was seen in 7.9% and on 
MRI in 21.1% of patients without SpA features versus 7.4% and 19.0% (radiographs and MRI, 
respectively) of patients with 1 SpA feature (Table 1). Notable differences among the extra-
articular manifestations in the group of patients with 1 SpA feature were seen: specifically, 
IBD (8.4%) was more frequently present, compared to uveitis (1.1%) and psoriasis (2.1%). 
Of the 38 of 133 patients (28.6%) with no SpA features after additional investigations, 4 
(10.5%) were classified according to the ASAS axial SpA criteria (Table 2). Three of those 
4 were also diagnosed as having axial SpA by the rheumatologist. Four additional patients 
were diagnosed as having axial SpA by the rheumatologist but did not fulfill the ASAS axial 
SpA criteria.
A striking finding is that two of these patients were diagnosed as having axial SpA in the 
absence of both HLA–B27 positivity and sacroiliitis on both imaging modalities. In these two 
patients, certainty of diagnosis was 3 and 8, respectively (on a 1–10 scale, with 10 implying 
great certainty and 1 little certainty about diagnosis). Review of the MRI showed that the 
patient with a diagnosis of axial SpA with a high certainty (8 of 10) had clear evidence of SpA-
associated structural lesions in the absence of inflammatory lesions on MRI or radiographic 
sacroiliitis. This evidence could have contributed to the SpA diagnosis.
Of the 95 of 133 patients (71.4%) with 1 SpA feature, 22 (23.2%) fulfilled the ASAS axial SpA 
criteria. Seventeen of the 95 patients (17.9%) were diagnosed as having axial SpA by the 
rheumatologist. Of these 17 patients, 14 were also classified via the ASAS axial SpA criteria, 
and the remaining 3 patients were not. In contrast, 5 patients were classified according to 
the ASAS axial SpA criteria, while not being diagnosed as having axial SpA according to the 
rheumatologist (data on diagnosis missing in 2 patients).
Of the patients with 1 feature who were classified according to the ASAS axial SpA criteria, 
the SpA features that were present before imaging and HLA–B27 testing were as follows: 7 
patients had IBP, 5 had IBD, 4 had a positive family history for SpA, 3 had a good response 
to NSAIDs, 2 had elevated CRP levels and/or ESR, and 1 patient had enthesitis. The SpA 
features present in the patients who were diagnosed by a rheumatologist with axial SpA 
(among patients with 1 SpA feature) were as follows: 4 had a positive family history of SpA, 4 
had IBP, 4 had IBD, 3 had an elevated CRP level and/or ESR, 1 had enthesitis, and 1 patient 
had a good response to NSAIDs.
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In the 133 patients with ≤1 SpA feature, radiographic results were negative in 123 patients. 
Nineteen of those 123 patients (15%) were eventually diagnosed as having axial SpA after 
MRI and HLA–B27 testing were done. Of the 133 patients with ≤1 SpA feature, HLA–B27 
was negative in 104 patients, of which 14 (13.5%) were eventually diagnosed with axial 
SpA. However, of the 133 patients, MRI was negative in 107, of which only 7 (6.5%) were 
diagnosed as having axial SpA.






















MRI+ mNY+ 2 2
MRI+ mNY- 1 1
MRI- mNY+ 1 1




MRI+ mNY- 2 2* 5
MRI- mNY+





MRI+ mNY+ 2 1*
MRI+ mNY- 3 4 1
MRI- mNY+ 1 *
MRI- mNY- 2 12* 15
HLA-B27 –
(n=73)
MRI+ mNY+ 1 1
MRI+ mNY- 8 11 3
MRI- mNY+ 2 3 1
MRI- mNY- 1 57 58
Total 24 26 105 107
Asterisk (*) diagnosis by rheumatologist is missing.
SpA, spondyloarthritis; axSpA, axial spondyloarthritis; HLA-B27, human leukocyte antigen B27; ASAS, 




In patients with CBP referred to a rheumatologist and with ≤1 SpA feature, after full medical 
history collection, physical examination, and CRP level/ESR measurement, subsequent 
HLA–B27 testing and imaging led to a diagnosis of axial SpA in almost 20% of both patient 
groups. In both the group of patients with 0 SpA features and patients with 1 SpA feature, 
20% were diagnosed with axial SpA, and therefore the number of SpA features present was 
not a differentiating factor in this study. Additionally, fulfilment of the ASAS axial SpA criteria 
was seen in 11% and 23% of the patients without SpA features and with 1 SpA feature, 
respectively.
Although we were expecting some patients to have a diagnosis of axial SpA, we were 
surprised by the relatively high percentages, in particular in the group with no SpA features. 
Several factors may have contributed to this unexpected finding. The preselection of patients 
could be an important explanation for this result: only patients ages <45 years were included 
and with a short duration of back pain (≤2 years). Diagnosis could also be influenced by 
the presence of SpA features that are not incorporated in the criteria, i.e., the presence of 
syndesmopohytes, inflammation on an MRI of the spine, or structural lesions on MRI of the 
SI joints. On the other hand, it is important to put the high percentages of an SpA diagnosis 
into perspective. Diagnosing SpA can be a challenge, especially in the absence of sacroiliitis 
on imaging. This clinical manifestation of SpA is heterogeneous, and diagnostic criteria are 
lacking.
A strength of this study is that we applied both diagnosis and classification. Taken together, 
these data support the ASAS modified Berlin algorithm in its recommendation to perform 
additional investigations in patients with 0 and 1 SpA feature in a secondary setting. Although 
differences exist between patients without and patients with 1 SpA feature, even in patients 
without SpA features, after medical history collection, physical examination, and CRP level/ 
ESR measurement, we cannot entirely rule out axial SpA.
However, it should be taken into account that the SPACE cohort consists of patients with CBP 
with ≤2 years of symptoms. As radiographic changes may develop over time14 radiography 
may not be the ideal first diagnostic step (as the modified Berlin algorithm suggests) in these 
young patients with a short symptom duration. This conclusion was underlined by the fact 
that the yield of radiographs was very low in this study, and as a comparison the yield of MRI 
is much higher. For future studies, investigating the additional benefit of structural lesions on 
a T1-weighted MRI of the SI joints should be relevant.
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A limitation of this study is that the radiologists performed a global assessment of sacroiliitis 
rather than the ASAS definition for a positive MRI, and that we used this global assessment 
while applying the ASAS axial SpA classification criteria.15 In addition, and in line with 
common clinical practice, only one reader interpreted the images instead of reading by 
several readers, although we assume that in the majority of cases the treating rheumatologist 
read the images as well.
An important strength of the study is that SPACE is an inception cohort for young patients 
with CBP (duration ≥3 months and ≤2 years, onset at ages <45 years), allowing us to 
investigate whether patients with very few symptoms can still be diagnosed and classified 
as having axial SpA. To our knowledge, SPACE is currently one of the very few, if not the 
only, sufficiently large longitudinal cohort study in the field of spondyloarthritis where patients 
without SpA features can also be included, which has allowed us to perform the current 
study. Since this study was performed in a secondary-care setting (patients referred to a 
rheumatologist, with a suspicion for axial SpA), we would like to emphasize that the results of 
this study cannot be extrapolated to CBP patients where the prevalence of axial SpA is much 
lower, as in primary care.
In conclusion, in a secondary-care setting, in patients with ≤1 SpA feature, after full medical 
history collection, physical examination, and CRP level/ESR measurement, axial SpA cannot 
be ruled out without additional imaging and/or HLA–B27 testing. In addition, these results also 
show that in selected cases diagnosis is entirely based on HLA–B27 testing and imaging.
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Assessment of sacroiliitis by radiographs and 
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Both MRI and plain radiography are used to assess sacroiliitis. A weakness of radiography, 
apart from its inability to detect early disease, is reader variability. On the contrary, experience 
with MRI is relatively limited by comparison.
Recent findings
This review summarizes recent advances in sacroiliac joint imaging using radiography and 
MRI in spondyloarthritis.
Summary
Observer variation in reading radiographs of sacroiliac joints remains an unresolved issue. 
In recent years, more studies on MRI in the diagnosis of axial spondyloarthritis have become 
available. Incorporating structural lesions in the sacroiliac joint and spine and inflammatory 
lesions in the spine in the definition of a positive MRI are hot topics in research.
Keypoints
 □ Reader variability in reading radiographs of the sacroiliitis joints remains unresolved. 
 □ As a result, there is concern about the reliability of radiographs of the sacroiliac joints in 
diagnosing axial SpA. 
 □ Although more data are becoming available, the number of high-quality studies on the 
diagnostic utility of MRI of the sacroiliac joints is relatively limited. 
 □ Incorporation of structural changes into the definition of a positive sacroiliac MRI is an 
important line of current research.
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INTRODUCTION
Sacroiliitis is the hallmark of axial spondyloarthritis (SpA).1 Axial SpA is called non-radiographic 
axial SpA when there are no (definite) abnormalities detected on plain film radiographs of 
the sacroiliac joint and is called radiographic axial SpA or ankylosing spondylitis (AS) when 
definite signs of sacroiliitis are seen on radiographs of the sacroiliac joints.2
Radiography is the method most commonly used to assess involvement of the sacroiliac joint, 
but it is often inadequate to detect early disease, as patients may have symptoms for several 
years before abnormalities can be seen on radiography.3 Moreover, reading radiographs of 
the sacroiliac joints are considered difficult. Interobserver and intraobserver variations are 
substantial, which implies that sacroiliitis is often missed or incorrectly diagnosed.4 
van Tubergen et al. set out to investigate if training could improve performance of 
radiologists and rheumatologists in reading radiographs of the sacroiliac joints.4 One 
hundred rheumatologists and 23 radiologists took part in the study wherein sensitivity was 
assessed using sacroiliac joint radiographs of Human Leukocyte Antigen (HLA)-B27-positive 
AS patients, and specificity was assessed using radiographs of healthy HLA-B27-negative 
relatives. Participants scored radiographs at baseline, 3 months later after following a self-
education program and again 3 months later after attending a workshop.
At baseline, median sensitivity of rheumatologists for detecting sacroiliitis on radiographs 
was 81% (range 31–100%) with a specificity of 75% (range 38–100%). After self-education, 
median sensitivity dropped to 75% (range 25–100%), whereas specificity increased to 78% 
(range 44–100%). After the workshop, the sensitivity then returned to 81% (range 25–100%), 
and specificity was stable at 79% (range 39–96%). The results of the radiologists showed 
similar fluctuations. At baseline, median sensitivity of radiologists for detecting sacroiliitis on 
radiographs was 88% (range 25–100%) with a specificity of 71% (range 46–100%). After 
self-education, median sensitivity dropped to 78% (range 44–100%), whereas specificity was 
73% (range 38–96%). After the workshop, the sensitivity  and specificity then increased to 
84% (range 50–100%) and 85% (range 50–96%), respectively.
Intraobserver variation was tested using a set of 10 radiographs with various degrees of 
sacroiliitis. Agreement was high for radiographs without signs of sacroiliitis or complete 
ankylosis of sacroiliac joints (range of means 94–100%), but much lower for radiographs with 
more subtle changes (grade 1 or 2 sacroiliitis) with mean agreements ranging from 52 to 87%.
This study is important for several reasons. First, it shows that rheumatologists and radiologists 
have only modest sensitivity and specificity for diagnosing sacroiliitis using radiographs 
alone. In addition, there is considerable intraobserver variability particularly when changes 
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because of sacroiliitis are subtle. Most importantly, however, this study shows that training of 
readers of radiographs does not improve their sensitivity or specificity. This means that, in its 
current form, there is concern about the reliability of conventional radiographs of sacroiliac 
joints when used for diagnosis.
MRI has proven capable of detecting inflammatory lesion in the sacroiliac joints in SpA before 
changes are seen on radiographs. An indication of the increased use of MRI in SpA is the 
inclusion of MRI of the sacroiliac joints in the Assessment of SpondyloArthritis international 
Society (ASAS) axial SpA classification criteria.5 MRI of the sacroiliac joints is able to detect 
several features associated with sacroiliitis, such as ankylosis, bone marrow edema (BME)/
osteitis, capsulitis, enthesitis, erosions, fat deposition and synovitis. However, a 2009 report 
by radiologists and rheumatologists from the ASAS/ Outcome Measures in Rheumatology 
(OMERACT) MRI working group considered clear presence of BME essential for defining 
active sacroiliitis. In what has become known as the ASAS definition for a positive MRI, a BME 
lesion highly suggestive of sacroiliitis needs to be present in subchondral or periarticular 
bone. If there is only one signal (BME lesion) on an MRI slice, this BME lesion should be 
present on at least two consecutive slices, although when there are two or more BME lesions 
on a single slice, one slice is sufficient.6
A systematic review published in 2012 reviewed the literature on MRI in SpA published until 
November 2011. The aim of the review was to determine the level of evidence for the utility 
of MRI in relation to the clinical diagnosis of SpA.7 Studies included in the review had to 
be case–control or cohort studies and had to include the arbitrary number of more than 20 
patients and 20 controls. After literature search, 76 full text articles were reviewed with only 
nine studies included in the review. Of these nine studies, only two met the authors’ criteria 
for a high-quality report. Of these two reports, one reported on MRI abnormalities in the spine 
and one on MRI abnormalities in the sacroiliac joints. The authors of the review concluded that 
because of the small number of high-quality studies, current evidence for MRI in the diagnosis 
of axial SpA is limited.
With data showing that education does not improve reading radiographs of the sacroiliac 
joints and a review concluding that there are not enough studies demonstrating the diagnostic 
utility of MRI for sacroiliitis, we searched the literature for recent studies to see what progress 
has been made in recent years on the two most commonly used imaging modalities for 
detecting sacroiliitis.
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LITERATURE SEARCH
PubMed, Embase, Web of Science and the Cochrane Library were searched in November 
of 2013 for articles on interobserver and intraobserver variability of radiographs of the 
sacroiliac joints in SpA and on the diagnostic value of MRI of the sacroiliac joints in SpA 
using two separate search strategies. The search strategy used for PubMed can be found 
in Supplementary Table 1. All articles were reviewed by title and abstract by two out of three 
assessors (F.G., P.B. and M.H.), and an article was selected if both assessors agreed that the 
study contained data relevant to the search. The literature search for articles on radiographs 
was limited to publications after the study by Van Tubergen et al. was published in 2003, and 
the search for MRI was limited to publication from 2010 onward, as the review by Arnbak et 
al. had covered all articles published before 2011.4,7
RECENT LITERATURE ON OBSERVER VARIATION IN 
READING RADIOGRAPHS OF THE SACROILIAC JOINTS
With the search strategy for radiographs, 800 articles were found in the databases. After 
review, five full text articles and one meeting abstract were identified as containing relevant 
data.
In their 2004 study, Spoorenberg et al. compared reliability and change over time of several 
radiological scoring methods in AS, including grading of sacroiliac joints using the 0–4 New 
York method and the almost identical Stoke Ankylosing Spondylitis Spine Score.8 Radiographs 
of 217 AS patients at baseline, 12 and 24 months were scored by two observers. Kappa values 
for intraobserver variability ranged from 0.36 to 0.76 and interobserver variability ranged from 
0.66 to 0.70. Kappa coefficients are a statistical measure of interreader agreement that are 
thought to be more robust than simple agreement calculation as kappa takes agreement 
occurring by chance into account. Using the cutoff values proposed by Landis and Koch, in 
this study, the kappa for intraobserver variability indicates fair to substantial agreement and 
moderate-to-substantial agreement for interobserver variability.9 In the same year, another 
study on radiological scoring methods for AS by the same group was published, but this did 
not provide separate results on variability of scoring sacroiliac joints radiographs.10
An example of how variability in grading sacroiliac radiographs may affect clinical practice is 
provided by data from the multicenter German Spondyloarthritis Inception cohort (GESPIC) 
cohort.11 Radiographs of the sacroiliac joints of 149 non-radiographic SpA and 182 AS patients 
were rescored by two central readers. After rescoring, 11.4% AS patients were reclassified 
into non-radiographic axial SpA, and 15.5% non-radiographic axial SpA were reclassified into 
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AS. Agreement between the two readers was modest [intraclass correlation coefficient (ICC)] 
for the left sacroiliac joint, 0.36 [95% confidence interval (CI) 0.22–0.49] and for the right 
sacroiliac joint, ICC 0.36 (95% CI 0.22–0.49). In a more recent study from the GESPIC cohort 
kappa values for scoring the sacroiliac joints ranged from 0.51 to 0.59 between two readers 
indicating moderate agreement.12
In a study assessing the performance of computed tomography (CT) of the sacroiliac joints 
in patients with suspected SpA, two radiologists independently read 100 paired radiographs 
and CT scans. Similarly to previous studies, interreader variability was moderate for sacroiliitis 
on radiographs (kappa 0.59) but was much better for CT scans of the sacroiliac joints 
(interobserver kappa 0.91).13
In summary, all studies published in the past 10 years confirm the substantial interobserver 
and intraobserver variability in grading radiographs of the sacroiliac joints for sacroiliitis, 
but we found no progress in solving or reducing the problem by education or technical 
innovation. A possible exception was a meeting abstract reporting slightly better performance 
of posterior-anterior projection as compared with anterior-posterior projection in radiographs 
of the sacroiliac joints, but the data have not yet been published.14
RECENT LITERATURE ON THE DIAGNOSTIC UTILITY 
OF MRI FOR SACROILIITIS IN SPONDYLOARTHRITIS
With the search strategy for MRI, 1094 articles and meeting abstracts published since 2010 
were found in the databases. After review, four full text articles were identified as containing 
relevant data.
Because of several months’ overlap of the literature search, the first article found was the one 
high-quality study described in the aforementioned systematic review.7 Weber et al. published 
data from a cross-sectional, international multicenter study called MORPHO.15 Aim of the 
study was to assess the diagnostic utility of MRI in SpA and construct a definition for a positive 
MRI. After calibrating readers using a training set, five readers independently read MRI scans 
from 75 patients with AS, 27 patients with inflammatory back pain (IBP) suspected of having 
SpA, 26 patients with nonspecific back pain and 59 healthy controls. AS was diagnosed 
according to the modified New York criteria, IBP was defined by expert opinion, the Calin IBP 
criteria or the Berlin IBP criteria, and nonspecific back pain was defined on clinical grounds. 
For all MRIs, BME, erosions, fat infiltration and ankylosis were scored by the readers, and 
readers were asked if they thought the MRI scan confirmed the presence of SpA by global 
assessment. Using global assessment of the MRI, agreement for the diagnosis of SpA in 
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IBP patients was 85% for all five readers and agreement for the absence of SpA was 92% in 
nonspecific back pain patients and 95% in healthy controls.
Comparing IBP patients with patients with non-specific back pain and controls, the global 
assessment of the readers had a sensitivity of 51% and a specificity of 98%. The ASAS 
definition of a positive MRI using BME only had a sensitivity of 67% and a specificity of 88% 
and a new proposed definition based on BME and erosions (MORPHO definition) had a 
sensitivity of 81% and a specificity of 88%. Comparing AS patients with nonspecific back pain 
patients and controls, global assessment had a sensitivity of 90% and a specificity of 97%, 
and the ASAS definition had a sensitivity of 85% and a specificity of 88%.
In a study from the same group, the same number of MRIs was scored by a different number 
of readers, and this study showed that besides BME structural lesions, such as erosions, are 
commonly seen in AS and IBP although erosions were now more often scored in nonspecific 
back pain patients and controls than in their previous study.16 The authors subsequently 
published a study using selected patients and controls from the previous two studies.17 MRIs 
of the sacroiliac joints of 30 AS patients and 30 controls were used to assess the reproducibility 
of scoring erosions using four readers. The kappa value for scoring erosions was 0.72, which 
was slightly higher than the kappa of 0.61 for scoring BME.
In their next article, Weber et al. took a slightly different approach by using both the consensus 
classification of an MRI as SpA or no-SpA using global assessment and the clinical diagnosis 
as the gold standard for disease.18 In the consensus classification, an MRI was marked as 
consistent with SpA when at least three out of four readers thought the images showed signs 
of SpA. An MRI was marked as no-SpA when all readers thought that the images showed no 
signs of SpA with a high confidence.
MRIs of the sacroiliac joints from two inception cohorts were scored for presence of BME, 
erosions and fat infiltration by all four readers using a scoring system wherein the sacroiliac 
joint is represented by four quadrants (upper ilium, lower ilium, upper sacrum and lower 
sacrum). Cohort A consisted of 10 healthy controls and 79 patients of which 10 had AS, 20 
non-radiographic axial SpA and 39 nonspecific back pain. Cohort B consisted of 88 patients 
with an acute uveitis and back pain who were referred to a rheumatologist. Diagnosis was 
made based on the clinical opinion of a rheumatologist. In this cohort, 31 patients had non-
radiographic axial SpA, 24 AS and 33 patients with nonspecific back pain.
Using the consensus classification of sacroiliac joint MRI as the gold standard, to reach a 
preset specificity of 90%, BME had to be present in two sacroiliac joint quadrants. At this 
cutoff which the authors state is similar to the ASAS definition, sensitivity was 91% in cohort 
A and 83% in cohort B. To reach 90% specificity, only one erosion had to be present in both 
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cohorts giving a perfect sensitivity of 100%. Using the clinical diagnosis as the standard, BME 
had to be present in three sacroiliac quadrants in cohort A and in four sacroiliac quadrants in 
cohort B to reach a specificity of 90%. At this cutoff, sensitivities were 73% for cohort A and 
39% for cohort B. To reach 90% specificity, one erosion had to be present in cohort A and two 
erosions in cohort B, and this had a sensitivity of 77 and 54%, respectively. The combined 
features of BME and/or erosion had a sensitivity of 82% for cohort A and 51% for cohort B with 
a specificity of 90%. Irrespective of the standard used, fat infiltration performed worse than 
BME and erosions. The authors conclude that these results support the use of both BME and 
erosions in defining a positive MRI sacroiliac in axial SpA.
DISCUSSION
The literature of the past 10 years confirmed reader variability in reading radiographs of 
the sacroiliac joints, but no progress was made in reducing the variability. As the example 
of reclassification of AS and non-radiographic axial SpA patients by central readers in the 
GESPIC cohort exemplifies, physicians should be careful in making or rejecting the diagnosis 
of axial SpA based on radiographs of the sacroiliac joints alone.
Given the curved shape of the sacroiliac joint, which complicates radiography, CT has been 
investigated as an alternative imaging modality in suspected SpA and AS.13,19 However, a 
disadvantage of CT scans is that the radiation dose is higher than for radiographs. Given 
that axial SpA usually start in young adults: this is particularly an issue for young women in 
whom the ovaries are within the primary CT beam. Low radiation CT scanning protocols of the 
sacroiliac joints have been developed but are not in widespread use.20
The literature on MRI of the sacroiliac joints in SpA of the last 3 years consisted of 
publications from a consortium from Switzerland, Denmark and Canada. One thing that is 
clearly encouraging about their data is that they showed that their expert readers had a good 
agreement on diagnosing SpA or no-SpA using MRI. In addition, another group reported 
substantial or almost perfect interreader variability in scoring MRI sacroiliac changes.21 So, 
the available data indicate that MRI of the sacroiliac joints has an acceptable interreader 
variability.
Weber and colleagues advocate the incorporation of structural changes into the definition of 
a positive sacroiliac MRI for SpA, as this could improve sensitivity and specificity. However, 
more studies are needed, and a generally accepted definition of what constitutes structural 
changes consistent with SpA has yet to be decided.
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Another possibility to improve the diagnostic utility of MRI scanning is to look for inflammatory 
or structural lesions in the spine. A consensus-based definition of a positive spinal MRI for 
inflammatory lesions (spondylitis) and structural changes (fat deposition) has been published, 
and spinal inflammation detected in the absence of inflammation in the sacroiliac joints has 
been observed in SpA patients, but more studies are needed.22,23
The number of high-quality studies on the diagnostic utility of MRI of the sacroiliac joints 
remains relatively limited. However, following the publication of the ASAS axial SpA 
classification criteria, interest in the early stage of axial SpA has increased greatly in recent 
years. Therefore, it is to be expected that the number of studies on MRI imaging in axial SpA 
from cross-sectional studies, clinical trials and inception cohorts will increase in the coming 
years. 
CONCLUSION
In axial SpA, no progress has been made in radiography of the sacroiliac joints in recent 
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Supplementary Table 1: Search strategy used in the Pubmed database for observer variability in 
reading radiographs of the sacroiliac joint (A) and the diagnostic utility of magnetic resonance imaging 
for sacroiliitis (B). All articles in the article were found using these strategies. 
A: Observer variability in reading radiographs of the sacroiliac joint
(((“Sacroiliac Joint”[Mesh] OR “sacroiliac”[all fields] OR “sacro-iliac”[all fields] OR 
“Sacroiliitis”[Mesh] OR “Sacroiliitis”[all fields] OR sacroili*[all fields]) AND (“X-Rays”[majr] 
OR “Radiography”[majr:noexp] OR “Radiographic Image Enhancement”[majr] OR 
“Radiographic Image Interpretation, Computer-Assisted”[majr] OR “Radiographic 
Magnification”[majr] OR “Radiography, Interventional”[majr] OR “Tomography, X-Ray 
“[majr] OR “Xeroradiography”[majr] OR “x rays”[ti] OR “x ray”[ti] OR “x-rays”[ti] OR 
“x-ray”[ti] OR “xrays”[ti] OR “xray”[ti] OR “x rayed”[ti] OR “x-rayed”[ti] OR “xrayed”[ti] 
OR “roentgen”[ti] OR “rontgen”[ti] OR “röntgen”[ti] OR roentgen*[ti] OR rontgen*[ti] OR 
röntgen*[ti] OR radiograph*[ti]) AND (“Spondylarthritis”[mesh] OR “spondyloarthritis”[all 
fields] OR “Spondylarthritides”[all fields] OR “Spinal Arthritis”[all fields] OR “Spondylitis, 
Ankylosing”[mesh] OR “ankylosing spondylitis”[all fields] OR “Bechterew Disease”[all fields] 
OR “Bechterew’s Disease”[all fields] OR “Bechterews Disease”[all fields] OR “Ankylosing 
Spondyloarthritis”[all fields] OR “Rheumatoid Spondylitis”[all fields] OR “Spondylarthritis 
Ankylopoietica”[all fields] OR “Ankylosing Spondylarthritis”[all fields] OR “Ankylosing 
Spondylarthritides”[all fields] OR “Ankylosing Spondylitis”[all fields] OR “Marie-Struempell 
Disease”[all fields] OR “Marie Struempell Disease”[all fields] OR “Spondylarthropathies”[all 
fields] OR “Spondyloarthropathies”[all fields] OR “Marie-Strumpell Spondylitis”[all 
fields] OR “Marie Strumpell Spondylitis”[all fields] OR “Spondyloarthropathy”[all 
fields] OR “Spondyloarthropathies”[all fields] OR “Spondylarthropathy”[all fields] OR 
“Spondyloarthropathy”[all fields] OR “Sacroiliitis”[mesh] OR “sacroiliitis”[all fields] OR 
“Arthritis, Psoriatic”[mesh] OR “psoriasis arthritis”[all fields] OR “psoriatic arthritis”[all fields] 
OR “Psoriasis Arthropathica”[all fields] OR “Arthritic Psoriasis”[all fields] OR “Arthritis, 
Reactive”[mesh] OR “Reactive Arthritides”[all fields] OR “Reactive Arthritis”[all fields] OR 
“Post-Infectious Arthritis”[all fields] OR “Post Infectious Arthritis”[all fields] OR “Postinfectious 
Arthritis”[all fields] OR “Postinfectious Arthritides”[all fields] OR “Reiter Syndrome”[all fields] 
OR “Reiter’s Disease”[all fields] OR “Reiters Disease”[all fields] OR “Reiter Disease”[all 
fields] OR “inflammatory back pain”[all fields] OR ((“Arthritis”[mesh] OR “arthritis”[all fields]) 
AND (“Inflammatory Bowel Diseases”[mesh] OR “inflammatory bowel disease”[all fields] OR 
“inflammatory bowel diseases”[all fields] OR “ibd”[all fields] OR “crohn disease”[all fields] 
OR “crohns disease”[all fields] OR “crohn’s disease”[all fields] OR “Ulcerative Colitis”[all 
fields])))) AND (“2002/01/01”[PDAT] : “3000/12/31”[PDAT])) OR ((“Sacroiliac Joint”[Mesh] OR 
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“sacroiliac”[all fields] OR “sacro-iliac”[all fields ]OR “Sacroiliitis”[Mesh] OR “Sacroiliitis”[all 
fields] OR sacroili*[all fields) AND (((“X-Rays”[mesh] OR “Radiography”[mesh:noexp] 
OR “Radiographic Image Enhancement”[mesh] OR “Radiographic Image Interpretation, 
Computer-Assisted”[mesh] OR “Radiographic Magnification”[mesh] OR “Radiography, 
Interventional”[mesh] OR “Tomography, X-Ray “[mesh] OR “Xeroradiography”[mesh] OR “x 
rays”[all fields] OR “x ray”[all fields] OR”x-rays”[all fields] OR”x-ray”[all fields] OR”xrays”[all 
fields] OR”xray”[all fields] OR “x rayed”[all fields] OR”x-rayed”[all fields] OR”xrayed”[all 
fields] OR “roentgen”[all fields] OR “rontgen”[all fields] OR “röntgen”[all fields] OR 
roentgen*[all fields] OR rontgen*[all fields] OR röntgen*[all fields] OR radiograph*[all 
fields]) AND (“Spondylarthritis”[majr] OR “spondyloarthritis”[ti] OR “Spondylarthritides”[ti] 
OR “Spinal Arthritis”[ti] OR “Spondylitis, Ankylosing”[majr] OR “ankylosing spondylitis”[ti] 
OR “Bechterew Disease”[ti] OR “Bechterew’s Disease”[ti] OR “Bechterews Disease”[ti] 
OR “Ankylosing Spondyloarthritis”[ti] OR “Rheumatoid Spondylitis”[ti] OR “Spondylarthritis 
Ankylopoietica”[ti] OR “Ankylosing Spondylarthritis”[ti] OR “Ankylosing Spondylarthritides”[ti] 
OR “Ankylosing Spondylitis”[ti] OR “Marie-Struempell Disease”[ti] OR “Marie Struempell 
Disease”[ti] OR “Spondylarthropathies”[ti] OR “Spondyloarthropathies”[ti] OR “Marie-
Strumpell Spondylitis”[ti] OR “Marie Strumpell Spondylitis”[ti] OR “Spondyloarthropathy”[ti] 
OR “Spondyloarthropathies”[ti] OR “Spondylarthropathy”[ti] OR “Spondyloarthropathy”[ti] OR 
“Sacroiliitis”[majr] OR “sacroiliitis”[ti] OR “Arthritis, Psoriatic”[majr] OR “psoriasis arthritis”[ti] 
OR “psoriatic arthritis”[ti] OR “Psoriasis Arthropathica”[ti] OR “Arthritic Psoriasis”[ti] OR 
“Arthritis, Reactive”[majr] OR “Reactive Arthritides”[ti] OR “Reactive Arthritis”[ti] OR “Post-
Infectious Arthritis”[ti] OR “Post Infectious Arthritis”[ti] OR “Postinfectious Arthritis”[ti] OR 
“Postinfectious Arthritides”[ti] OR “Reiter Syndrome”[ti] OR “Reiter’s Disease”[ti] OR “Reiters 
Disease”[ti] OR “Reiter Disease”[ti] OR “inflammatory back pain”[ti] OR ((“Arthritis”[majr] 
OR “arthritis”[ti]) AND (“Inflammatory Bowel Diseases”[majr] OR “inflammatory bowel 
disease”[ti] OR “inflammatory bowel diseases”[ti] OR “ibd”[ti] OR “crohn disease”[ti] 
OR “crohns disease”[ti] OR “crohn’s disease”[ti] OR “Ulcerative Colitis”[ti])))) OR 
((“Spondylarthritis/radiography”[majr] OR “Spondylitis, Ankylosing/radiography”[majr] OR 
“Sacroiliitis/radiography”[majr] OR “Arthritis, Psoriatic/ radiography”[majr] OR “Arthritis, 
Reactive/radiography”[majr] OR (“Arthritis/radiography”[majr] AND (“Inflammatory Bowel 
Diseases”[majr] OR “inflammatory bowel disease”[ti] OR “inflammatory bowel diseases”[ti] 
OR “ibd”[ti] OR “crohn disease”[ti] OR “crohns disease”[ti] OR “crohn’s disease”[ti] OR 
“Ulcerative Colitis”[ti]))))) AND (“2002/01/01”[PDAT] : “3000/12/31”[PDAT]))
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B: The diagnostic utility of magnetic resonance imaging for sacroiliitis
(“Magnetic Resonance Imaging”[Mesh] OR “magnetic resonance imaging”[all fields] OR 
“NMR Imaging”[all fields] OR “MR Tomography”[all fields] OR “MR Imaging”[all fields] OR 
“MRI Imaging”[all fields] OR “NMR Tomography”[all fields] OR “Proton Spin Tomography”[all 
fields] OR “Magnetization Transfer Contrast Imaging”[all fields] OR “MRI Scans”[all 
fields] OR “MRI Scan”[all fields] OR “fMRI”[all fields] OR “Functional MRI”[all fields] OR 
“Functional MRIs”[all fields] OR “Chemical Shift Imaging”[all fields] OR “MRI”[all fields]) 
AND (“Spondylarthritis”[Mesh] OR “spondyloarthritis”[all fields] OR “Spondylarthritides”[all 
fields] OR “Spinal Arthritis”[all fields] OR “Spondylitis, Ankylosing”[Mesh] OR “ankylosing 
spondylitis”[all fields] OR “Bechterew Disease”[all fields] OR “Bechterew’s Disease”[all 
fields] OR “Bechterews Disease”[all fields] OR “Ankylosing Spondyloarthritis”[all fields] 
OR “Rheumatoid Spondylitis”[all fields] OR “Spondylarthritis Ankylopoietica”[all fields] OR 
“Ankylosing Spondylarthritis”[all fields] OR “Ankylosing Spondylarthritides”[all fields] OR 
“Ankylosing Spondylitis”[all fields] OR “Marie-Struempell Disease”[all fields] OR “Marie 
Struempell Disease”[all fields] OR “Spondylarthropathies”[all fields] OR “Marie-Strumpell 
Spondylitis”[all fields] OR “Marie Strumpell Spondylitis”[all fields] OR “Spondyloarthropathy”[all 
fields] OR “Spondyloarthropathies”[all fields] OR “Spondylarthropathy”[all fields] OR 
“Sacroiliitis”[Mesh] OR “sacroiliitis”[all fields] OR “Arthritis, Psoriatic”[Mesh] OR “psoriasis 
arthritis”[all fields] OR “psoriatic arthritis”[all fields] OR “Psoriasis Arthropathica”[all fields] 
OR “Arthritic Psoriasis”[all fields] OR “Arthritis, Reactive”[Mesh] OR “Reactive Arthritides”[all 
fields] OR “Reactive Arthritis”[all fields] OR “Post-Infectious Arthritis”[all fields] OR “Post 
Infectious Arthritis”[all fields] OR “Postinfectious Arthritis”[all fields] OR “Postinfectious 
Arthritides”[all fields] OR “Reiter Syndrome”[all fields] OR “Reiter’s Disease”[all fields] OR 
“Reiters Disease”[all fields] OR “Reiter Disease”[all fields] OR inflammatory back pain OR 
((“Arthritis”[mesh] OR “arthritis”[all fields]) AND (“Inflammatory Bowel Diseases”[Mesh] OR 
“inflammatory bowel disease”[all fields] OR “inflammatory bowel diseases”[all fields] OR 
“ibd”[all fields] OR “crohn disease”[all fields] OR “crohns disease”[all fields] OR “crohn’s 
disease”[all fields] OR “Ulcerative Colitis”[all fields])))
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To review and update the existing definition of a positive MRI for classification of axial 
spondyloarthritis (SpA).
Methods 
The Assessment in SpondyloArthritis International Society (ASAS) MRI working group 
conducted a consensus exercise to review the definition of a positive MRI for inclusion in the 
ASAS classification criteria of axial SpA. Existing definitions and new data relevant to the MRI 
diagnosis and classification of sacroiliitis and spondylitis in axial SpA, published since the 
ASAS definition first appeared in print in 2009, were reviewed and discussed. The precise 
wording of the existing definition was examined in detail and the data and a draft proposal 
were presented to and voted on by the ASAS membership.
Results 
The clear presence of bone marrow oedema on MRI in subchondral bone is still considered 
to be the defining observation that determines the presence of active sacroiliitis. Structural 
damage lesions seen on MRI may contribute to a decision by the observer that inflammatory 
lesions are genuinely due to SpA but are not required to meet the definition. The existing 
definition was clarified adding guidelines and images to assist in the application of the 
definition.
Conclusions
The definition of a positive MRI for classification of axial SpA should continue to primarily 
depend on the imaging features of ‘active sacroiliitis’ until more data are available regarding 
MRI features of structural damage in the sacroiliac joint and MRI features in the spine and 
their utility when used for classification purposes.
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INTRODUCTION
Since the early 1990s MRI has been increasingly used to visualise inflammation in the 
sacroiliac (SI) joints and spine and it has become clear that inflammatory lesions can be 
visible on MRI before structural changes are detectable on radiography or CT.1 In 2009, 
the Assessment in SpondyloArthritis International Society (ASAS) published new criteria for 
axial spondyloarthritis (SpA) based on principles that incorporated demographic, clinical, 
laboratory and imaging components but now added an MRI definition so as to enable the 
identification of patients without evidence of structural change on radiography.2 A ‘positive 
MRI’ was defined in a publication which described and illustrated the variety of lesions that 
may be encountered on MRI of SI joints showing sacroiliitis and its differential diagnoses, 
and also defined the nature and extent of inflammation in the SI joints that would be 
necessary to meet the definition of ‘MRI positive for active sacroiliitis’.3 The definition relied 
on the observation of inflammation seen in subchondral bone and other observations were 
not required as part of the MRI definition.
As only 30%–50% of subjects with axial SpA are positive for active sacroiliitis on MRI4-6 
the question arose as to whether the wording of the current definition for a positive MRI is 
appropriate and whether structural change of the SI joint or findings on spine MRI should 
be incorporated into the ASAS definition of a positive MRI. The purpose of this consensus 
exercise was to examine and discuss whether data published in the last 5 years relevant 
to the diagnosis and classification of axial SpA are sufficient to merit a change in the MRI 
definition of a positive MRI and clarify any misunderstanding of the existing definition that 
may have become apparent since its first publication.
METHODS
This manuscript has been developed on the basis of participation by 16 rheumatologists 
and 4 radiologists and 1 research fellow of the ASAS MRI working group with interest and 
experience in both SpA and MRI in a consensus exercise; presentation and discussion of 
evidence at a meeting on 5 September 2013 in Dusseldorf, Germany by the ASAS MRI 
working group; after refining the scope of the review, presentation during the annual assembly 
of ASAS on 17 January 2014 with voting on proposals open to all members; and consensus 
approval of the final manuscript by the members of the ASAS MRI working group.
Through the above process, the group was tasked with answering four questions related to 
MRI for inclusion in the ASAS classification criteria of axial SpA: (A) How does the current 
ASAS definition for a positive MRI perform? (B) Do we need to update the existing definition? 
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(C) Do we need to add MRI features of structural changes of the SI joint to the definition? (D) 
Do we need to include features of SpA on MRI of the spine in the definition? At the consensus 
meeting, an updated systematic literature review was presented, followed by review of the 
definition of a positive MRI scan of the SI joint and the definition of a positive MRI scan of the 
spine. Next, new data (partly unpublished at that time but published and cited since) related 
to one or more of the study questions were presented by members of the group. Finally, the 
precise wording of the existing definition was examined in detail. During the 2014 annual 
assembly of ASAS a summary of the data and the draft proposal of the group was presented 
followed by voting open to all full ASAS members.
RESULTS
There was consensus that there was no need to change the existing technical requirements 
necessary to reliably detect MRI features of inflammation or structural damage in bone 
marrow. As the presence of inflammation is the principal observation required by the current 
definition, this must be a focus for the MRI scan. The terms ‘bone marrow oedema’ (BMO) and 
‘osteitis’ are considered to be equivalent in this context and the inflammatory and structural 
lesions have been previously described. The description for SI joint BMO is: 
 □ BMO is depicted as a hyperintense signal on short tau inversion recovery (STIR) images 
(or equivalent water-sensitive sequences) and usually as a hypointense signal on T1-
weighted images (Figure 1). The more intense the signal the more likely that it reflects 
active inflammation. A strong hyperintense signal is similar to that of cerebrospinal fluid. 
The sacral interforaminal bone marrow signal forms the reference for assignment of 
normal signal in the bone.
 □ BMO is an indicator of active sacroiliitis but may be found in other diseases (Figure 2) or 
as an incidental finding (Figures 3 and 4).
 □ Affected bone marrow areas are typically located periarticularly (subchondral bone 
marrow).
 □ BMO may be associated with signs of structural damage such as sclerosis or erosion 
(Figure 5).
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Figure 1: MRI sacroiliac (SI) joints—typical inflammatory sacroiliitis in non-radiographic axial 
spondyloarthritis. MRI of SI joints in a 26-year-old male with inflammatory low back pain of more than 3 
months duration. C-reactive protein was 49.3 mg/L and HLA-B27 was positive. Pelvic radiograph was 
suspicious for spondyloarthritis but did not meet the definition for a positive radiograph according to 
the modified New York criteria—right SI joint grade 1 and left SI joint grade 0. The short tau inversion 
recovery (STIR) sequence shows abnormal increased signal (arrows) in the iliac bones bilaterally, 
typical for bone marrow oedema (BMO) due to inflammatory sacroiliitis. All the BMO are subchondral 
in location; the BMO is multifocal; each lesion is of a significant size; their margins are poorly defined; 
the right lower iliac lesion is larger and part of this lesion is intensely bright, similar in signal intensity to 
cerebrospinal fluid (not shown); and there are corresponding areas of diminished signal intensity on the 
T1-weighted sequence (arrows on T1). No erosion or other evidence of structural damage was visible on 
MRI or radiography. All these features are typical for inflammatory sacroiliitis.
Figure 2: MRI sacroiliac (SI) joints—Osteitis Condensans Ilii (OCI). MRI of SI joints in a 28-year-old 
female with persistent low back and buttock pain of 4 years duration was performed 1 year after the 
second pregnancy. C-reactive protein was normal and HLA-B27 was positive. Pelvic radiograph revealed 
bilateral iliac sclerosis with joint space narrowing and minimal irregularity of the joint surface. The short 
tau inversion recovery (STIR) sequence shows abnormal increased signal (arrow) in the left iliac bone, 
with a non-specific appearance. The BMO has an arcuate contour surrounding an area of diminished 
signal intensity on the T1-weighted sequence (arrow on T1) that corresponded to radiographic sclerosis. 
More prominent sclerosis and less intense BMO were seen on multiple slices. The subchondral location 
of the finding may be seen in lesions related to either spondyloarthritis or mechanical causes. The 
very sharp definition of the borders of the abnormality does not help distinguish the etiology. The T1 
sequence did not show evidence of structural damage (erosion, fat metaplasia or ankylosis) except for 
sclerosis, which is a non-specific observation. The patient was followed up for 10 years and a diagnosis 
of OCI was subsequently confirmed.
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Figure 3: MRI sacroiliac (SI) joints—mechanical back pain. MRI of SI joints in a 31-year-old male 
with mechanical low back pain of more than 3 months duration. C-reactive protein was normal. On 
pelvic radiography, the SI joints were normal. The short tau inversion recovery (STIR) sequence 
shows abnormal increased signal (arrow) in the subchondral bone of the left ilium with a non-specific 
appearance. Although a BMO lesion is clearly present, it is small and on the T1-weighted sequence an 
even smaller focus of very low signal is seen in the same location paralleling the articular surface. There 
was no evidence of structural damage in the SI joints. These coronal images also show evidence of disc 
degeneration at L5/S1 with loss of height and signal intensity of the nucleus pulposis, bulging annulus 
and Modic type 1 reactive inflammation (bright on STIR) at the perimeter of the disc. The patient was 
followed up and the final diagnosis for the cause of the mechanical low back pain was disc degeneration. 
The cause of the left SI lesion is unproven but it most likely represents a small fatigue stress reaction in 
association with mild osteoarthritis of the SI joint. These MRI observations are frequently seen in weight-
bearing joints as they degenerate.
Figure 4: MRI sacroiliac (SI) joints—healthy volunteer. MRI of SI joints in a 35-year-old female health 
services worker who was an asymptomatic volunteer enrolled as a control subject into an ethics-
approved research project. There was no history of pregnancy. The subject was fit and healthy and did 
not participate in any endurance activities. Clinical evaluation confirmed the absence of any symptoms, 
signs or risk factors for spondyloarthritis (SpA). The volunteer has been followed for 10 years and 
remains asymptomatic. The short tau inversion recovery (STIR) sequence shows abnormal increased 
signal (arrows) in the subchondral bone of both SI joints. The findings were clearly visible on at least two 
slices bilaterally. The lesions on STIR are small (12 mm on left and 8 mm on right) and are located close 
to the anterior borders of the SI joints. Some brighter signals in the ‘joint space’ seen on these and other 
images are suspicious for cartilage degeneration. Minimal signal change is present on the T1-weighted 
sequence and no structural damage changes are present. The follow-up MRI performed 8 weeks later 
as part of the clinical trial was unchanged.
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New data regarding the classification of patients with early axial SpA were presented from 
several cohorts that are currently under investigation. Using the DESIR cohort of subjects 
with inflammatory back pain (IBP) of less than 3 years duration before the age of 50, the 
reliability of classification of radiographs and MRI was compared between rheumatologists 
and radiologists of 25 local recruiting centres and central readers.5-7 The results indicate that 
the existing MRI definition could be applied across multiple centres with the expectation of 
acceptable reliability and at least with better reliability than the X-ray definition of sacroiliitis 
according to the modified New York criteria.
A detailed analysis of SI joint MRI scans from a pair of Canadian/Swiss inception cohorts of 
157 consecutive subjects ≤50 years old with back pain that included age and sex-matched 
controls suggests that benefit might be gained from adding SI erosion to the definition.8 
Figure 5: MRI sacroiliac (SI) joints—typical findings in non-radiographic axial spondyloarthritis (SpA) 
showing minimal inflammation and structural damage changes. MRI of SI joints in a 20-year-old male with 
inflammatory low back pain of more than 3 months duration. C-reactive protein was normal at the time 
of the MRI scan and HLA-B27 was positive. Pelvic radiograph was suspicious for SpA but did not meet 
the definition for a positive radiograph according to the modified New York criteria—right SI joint grade 
2 and left SI joint grade 0. The short tau inversion recovery (STIR) sequence shows subtle increased 
signal (white arrows) in the subchondral bone of the right and left sacral alae suspicious for bone marrow 
oedema (BMO). However, the lesions are faint and heterogeneous and the right sacral lesion was only 
visible on one slice. If no other findings were present, it would be difficult to decide whether the BMO 
changes alone do or do not meet the criteria for a positive MRI. However, multiple other abnormalities 
are present on the MRI that materially influence the decision. On the T1-weighted sequence, subtle 
articular surface erosion is definitely seen at the caudal end of the right ilium (arrowheads); subtle foci 
of fat metaplasia are seen in all four bones (black arrows); and bilateral iliac subchondral sclerosis 
is present. Additionally, on the STIR sequence, abnormal increased signal overlying the area of 
articular surface erosion is typical for inflammation in the cartilage/joint space (compound arrow). Each 
finding individually is non-specific; however, in combination the appearance and distribution of all the 
findings are typical for inflammatory sacroiliitis. In conclusion, the MRI scan meets the Assessment in 
SpondyloArthritis International Society (ASAS) definition for a positive MRI because (1) BMO on STIR is 
present; (2) the inflammation is located in a typical anatomical area (subchondral bone) and (3) the MRI 
appearance is highly suggestive of SpA—in this case, because the findings of BMO are supported by 
MRI findings of structural damage (erosion, fat metaplasia and sclerosis) that are typical in appearance 
and distribution for SpA.
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This was observed in both non-radiographic axSpA patients with short symptom duration 
(mean 1.3 years) and those with longer duration (mean 10 years). However, the analysis 
did not take into consideration whether these subjects had or had not already met the ASAS 
classification for axial SpA by the clinical arm and so the incremental benefit to classification 
by adding erosion to the definition is not clear.
In the SPACE cohort of subjects with chronic back pain of less than 2 years duration starting 
before age 45, the effect of adding structural change to the definition of a positive SI joint MRI 
was analysed by each feature individually and in combination.9 In this cohort, there was no 
single lesion or combination of lesions that would confer a significant benefit to sensitivity of 
the ASAS MRI definition without a corresponding risk of losing specificity.
With regard to the spine, the Canadian/Swiss inception cohorts examined the incremental 
value of spine MRI and concluded that while sensitivity was enhanced by 16% with combined 
assessment of the spine in addition to the sacroiliac joint (SIJ), false-positive diagnoses of 
SpA were increased by a similar degree.10 Data were also analysed for the spine MRI in the 
SPACE cohort with the effect on classification of the subjects analysed by lesion type and 
also by the number of qualifying lesions present with a range of cut-off thresholds analysed 
for each lesion separately. For each type of lesion, the marginal benefit (sensitivity) for adding 
spine MRI to the definition comes at the price of both diminished specificity and additional 
financial cost.11
In summary, new data were presented indicating that:
 □ For the SI joint, the current definition of a positive MRI (active sacroiliitis) performs 
satisfactorily for the classification of axial SpA according to the ASAS axial SpA criteria, 
and can be interpreted across many centres with substantial reader agreement.
 □ Evaluation of structural features, especially erosions, may enhance confidence in the 
classification of axial SpA emphasizing the importance of simultaneous assessment 
of T1W and fat-suppressed sequences, and the contextual interpretation of MRI. 
However, the effect on classification of the addition of any structural damage feature 
to the definition of a positive SI joint MRI is not yet clear, in part due to variations in MRI 
acquisition protocol and advancing MRI technology that compounded the complexities 
of achieving consensus for definitions for each MRI structural damage lesion and the 
setting of thresholds for any defined lesion or combination of lesions.
 □ There is no consistent beneficial effect of adding features of SpA on spine MRI to the 
definition.
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Following extensive discussion, the consensus opinion of the group was that ‘The definition of 
a positive MRI should not be changed at this time. The utility of the structural damage changes 
of the SI joints and the addition of features on MRI of the spine for classification purposes 
is not yet clear and this continues to be an important research agenda’. The available data 
(not all data from some references were available at the time) were then presented and 
discussed at the annual assembly of ASAS on 17 January 2014. The meeting concluded 
with voting open to all members and a proposal to not change the existing definition was 
unanimously approved.
Definition of sacroiliitis on MRI
After deciding to not change the definition of sacroiliitis on MRI for application in the ASAS 
classification criteria, it was agreed by consensus to provide some clarification of the existing 
definition and guidelines for the application of the definition. The presentation of the existing 
definition was reformatted accordingly (Box 1) and guidelines for the application of the 
definition are now provided (Box 2).
Inflammation of the sacroiliac joints highly suggestive of SpA is required for the fulfilment of the 
imaging criterion ‘active sacroiliitis on MRI’ according to the ASAS classification criteria for axial 
SpA. The requirements are listed below and guidelines for the application of the definition are 
provided in Box 2.
REQUIRED MRI evidence of bone marrow inflammation must be present and the features required 
for the definition of active sacroiliitis on MRI are:
1. Bone marrow oedema (BMO) on a T2-weighted sequence sensitive for free water (such as 
short tau inversion recovery (STIR) or T2FS) or bone marrow contrast enhancement on a T1-
weighted sequence (such as T1FS post-Gd).
2. Inflammation must be clearly present and located in a typical anatomical area (subchondral 
bone).
3. MRI appearance must be highly suggestive of SpA. 
NOT REQUIRED Other findings related to sacroiliitis may be observed on MRI but are not required 
to fulfil the imaging criterion ‘active sacroiliitis on MRI’:
 □ The sole presence of other inflammatory lesions such as synovitis, enthesitis or capsulitis 
without concomitant BMO is not sufficient for the definition of ‘active sacroiliitis on MRI’.
 □ In the absence of MRI signs of BMO, the presence of structural lesions such as fat metaplasia, 
sclerosis, erosion or ankylosis does not meet the definition of ‘active sacroiliitis on MRI’.
Box 1: Definition of a positive MRI (active sacroiliitis) for the classification of axial 
spondyloarthritis (SpA) according to the Assessment in SpondyloArthritis International Society 
(ASAS) axial SpA criteria 
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DISCUSSION
The ASAS/OMERACT MRI working group previously decided by consensus that the presence 
of subchondral BMO (or osteitis) in the SI joints reflecting inflammation highly suggestive of 
SpA should be regarded as essential to meet the definition of ‘active sacroiliitis on MRI’ in 
cases of axial SpA when radiographic changes are absent or doubtful.3 The purpose of this 
consensus exercise was to examine whether new data published in the last 5 years regarding 
axial SpA are sufficient to merit a change in the MRI definition of a positive MRI and clarify 
any misunderstanding of the existing definition that may have become apparent since its 
first publication. After detailed consideration, the unanimous consensus of ASAS members 
was to retain the existing definition with a slight rewording that would help to emphasise the 
critical components of the definition.
The ASAS definition of ‘active sacroiliitis on MRI’ was the first definition of ‘a positive MRI’ to 
be widely used in clinical trials research. The development of the definition was based on 
published data and took other factors into consideration: universal agreement that, above 
all, MRI evidence of inflammation (which is radiographically occult) must be included in a 
MRI interpretation:
 □ Bone marrow oedema (BMO) representing an inflammatory lesion that meets the above 
criterion will usually be easily seen on at least two consecutive slices of an MRI scan. Detection 
of inflammation on a single slice may be sufficient for the criterion ‘highly suggestive of SpA’ if 
there is more than one inflammatory lesion present. However, it is rare for an MRI scan of the 
sacroiliac joints with definite evidence of active sacroiliitis to demonstrate lesions on only a 
single image, and caution should be exercised in the interpretation of small lesions.
 □ It is essential that the reader of the MRI scan simultaneously review sequences designed to 
identify inflammation and sequences that focus on depiction of structural damage.
 □ If an inflammatory bone marrow lesion appears to be present but it is hard to determine whether 
the lesion meets the criterion ‘highly suggestive of SpA’, then the decision may be influenced 
by the presence of concomitant structural damage, especially erosion, and/or other signs of 
inflammation, which in themselves do not suffice to meet the criterion.
Context:
 □ Evaluation of an MRI scan should be performed objectively. However, MRI findings are non-
specific and the determination of the importance of the observations should never be made 
in isolation of the clinical context as demographic, clinical and laboratory information may 
outweigh the importance of the MRI findings.
 □ The definition and guidelines are primarily for the classification of patients with SpA and will not 
be suitable for use in some clinical situations.
Box 2: Guidelines for the application of the definition of a positive MRI (active sacroiliitis) for the 
classification of axial spondyloarthritis (SpA)
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definition of non-radiographic disease; easily applied MRI parameters; ability to apply the 
definition prospectively and retrospectively; and wording and illustration of the definition that 
was simple and intuitive. Ease of application of the criteria internationally is important and the 
minimum MRI technical requirements can be applied on any MRI platform and do not change 
with advancing technology. A wide range of newer sequences such as water excitation or 
chemical shift imaging may be used to detect bone marrow inflammation but do not change 
the principles of image acquisition or the definition of ‘active sacroiliitis’. Most centres use 
either STIR or T2FS as in most cases, T1-weighted contrast-enhanced sequences offer 
no additional benefit in either adults or children and contrast material is expensive and is 
therefore not recommended.12-15
The selection of an MRI definition is influenced by how it performs in a rigorous testing 
environment and by the ability to describe and illustrate the target lesion in terms that facilitate 
widespread application. This is another reason that the ASAS definition remains focused on 
the inflammatory lesion in the SI joint at this time and why structural damage lesions have 
not yet been added to the definition. Erosion of the joint surface may seem to be a logical 
choice for inclusion in a definition of sacroiliitis; however, currently, there is no international 
consensus as to how erosion should be defined on MRI or how it should be quantified. 
For example, it is not yet clear to what extent variation in MRI acquisition parameters, such 
as using a thin-slice high-resolution three-dimensional sequence, would alter the properties 
of a definition that includes structural damage. Features of axial SpA identifiable on spine 
MRI are still not included in the definition of a positive MRI because none of the candidate 
definitions would appear to confer a significant advantage over the current definition. The SI 
joints are involved before the spine in the majority of true axial SpA cases and the matter is 
complicated by the fact that degenerative changes in the spine are frequent and small foci of 
inflammation that are mechanical in origin may be indistinguishable from small inflammatory 
lesions due to SpA.10,16
The European Society of Skeletal Radiology (ESSR) recently reviewed the imaging 
appearances and the radiological features necessary for making a diagnosis of axial SpA 
and recommended that MRI is mandatory to look for early inflammatory lesions if axial SpA 
is suspected and radiographs are negative.17 The burden of disease required to meet a 
diagnosis of sacroiliitis described by the ESSR Arthritis Imaging Subcommittee is consistent 
with the ASAS definition for classification, which requires all lesions to be ‘highly suggestive of 
SpA’. It should be noted that the ESSR publication omits quotation of this critical component of 
the ASAS definition. In the case of minimal inflammatory changes, specific advice regarding 
the exact nature and extent of additional imaging features of SpA that would be required to 
heighten the suspicion of the observer is not provided and this remains an important focus 
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for future research. As noted previously, doubtful cases of BMO should not be considered as 
positive, and this view is supported by data highlighting the prognostic role of more extensive 
BMO for the later development of radiographic sacroiliitis.18
The publication by ASAS of the first ‘definition of active sacroiliitis on magnetic resonance 
imaging (MRI) for classification of axial spondyloarthritis’ was an important step that has 
enabled many subsequent research projects. The existing definition is based on the 
observance of inflammatory lesions in typical locations related to the SI joint and can be 
applied by readers across the world with access to any MRI unit. The ASAS definition was 
reviewed by an expert group of rheumatologists and radiologist with experience in both 
SpA and MRI including systematic analysis of data from different cohorts. The results were 
presented by experts to the ASAS members. By a final vote of all members, the unanimous 
consensus was to retain the existing definition with a slight rewording that would help to 
emphasise the critical components of the definition. The contribution of MRI features of 
structural damage of the SI joint or spinal MRI features of SpA to a refined classification of 
axial SpA remains an important research agenda. However, the existing ASAS definition of a 
positive MRI continues to provide a solid basis for the application of MRI in the ASAS criteria 
for axial SpA.
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Can we use structural lesions seen on MRI 
of the sacroiliac joints reliably for the 
classification of patients according to the 
ASAS axial spondyloarthritis criteria? 
Data from the DESIR cohort
Pauline Bakker







Désirée van der Heijde





Investigating the utility of adding structural lesions seen on MRI of the sacroiliac joints to 
the imaging criterion of the Assessment of SpondyloArthritis (ASAS) axial SpondyloArthritis 
(axSpA) criteria and the utility of replacement of radiographic sacroiliitis by structural lesions 
on MRI.
Methods 
Two well-calibrated readers scored MRI STIR (inflammation, MRI-SI), MRI T1-w images 
(structural lesions, MRI-SI-s) and radiographs of the sacroiliac joints (X-SI) of patients in 
the DEvenir des Spondyloarthrites Indifférenciées Récentes cohort (inflammatory back pain: 
≥3 months, <3 years, age <50). A third reader adjudicated MRI-SI and X-SI discrepancies. 
Previously proposed cut-offs for a positive MRI-SI-s were used (based on <5% prevalence 
among no-SpA patients): erosions (E) ≥3, fatty lesions (FL) ≥3, E/FL ≥5. Patients were 
classified according to the ASAS axSpA criteria using the various definitions of MRI-SI-s.
Results 
Of the 582 patients included in this analysis, 418 fulfilled the ASAS axSpA criteria, of which 
127 patients were modified New York (mNY) positive and 134 and 75 were MRI-SI-s positive 
(E/FL≥5) for readers 1 and 2, respectively. Agreement between mNY and MRI-SI-s (E/FL≥5) 
was moderate (reader 1: κ: 0.39; reader 2: κ: 0.44). Using the E/FL≥5 cut-off instead of mNY 
classification did not change in 478 (82.1%) and 469 (80.6%) patients for readers 1 and 2, 
respectively. Twelve (reader 1) or ten (reader 2) patients would not be classified as axSpA 
if only MRI-SI-s was performed (in the scenario of replacement of mNY), while three (reader 
1) or six (reader 2) patients would be additionally classified as axSpA in both scenarios 
(replacement of mNY and addition of MRI-SI-s). Similar results were seen for the other cut-
offs (E≥3, FL≥3).
Conclusions 
Structural lesions on MRI can be used reliably either as an addition to or as a substitute for 
radiographs in the ASAS axSpA classification of patients in our cohort of patients with short 
symptom duration.
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INTRODUCTION
A commonly used imaging method for the assessment of sacroiliitis is conventional 
radiography. Radiographic sacroiliitis is obligatory in the modified New York (mNY) criteria 
for ankylosing spondylitis (AS).1 However, it has been shown that it is very difficult to reliably 
detect sacroiliitis on conventional radiographs. Substantial observer variation exists for both 
radiologists and rheumatologists, which can lead to substantial misclassification of patients.2 
Moreover, it has been shown that training in the reading of these radiographs does not lead 
to improvement.3
Another downside of conventional radiography is that only structural damage in the sacroiliac 
joints can be detected, frequently appearing after several years of disease, which hampers 
early detection. MRI can reliably detect inflammation of the sacroiliac joints at an early stage 
before damage on radiographs can be detected.4 Sacroiliitis on MRI plays an important role 
in the imaging arm of the Assessment of SpondyloArthritis (ASAS) axial SpondyloArthritis 
(axSpA) criteria.5
Besides inflammatory lesions, structural lesions such as erosions, fatty lesions, sclerosis and 
ankylosis are visible on MRI. Therefore, MRI has great potential for the assessment of both 
active inflammatory lesions and structural damage by means of one single-imaging technique. 
In the recently published European League Against Rheumatism (EULAR) recommendations 
for the use of imaging in the diagnosis and management of axSpA in clinical practice, it was 
advocated to take structural lesions (such as bone erosion, fat infiltration, sclerosis and new 
bone formation) into account in addition to active inflammatory lesions.6 This is augmented 
by accruing worries about radiation exposure coupled with conventional radiographs in 
some parts of the world.
By this study, we aim to further clarify the role of these structural lesions and to investigate their 
usefulness with regard to the ASAS axSpA classification of patients. First, we determine the 
agreement between the presence of sacroiliitis on radiographs (mNY criteria) and structural 
lesions seen on MRI. Subsequently, we evaluate what impact the use of structural lesions 
on MRI-SI could have on the performance of the ASAS axSpA criteria. Two scenarios are 
investigated: the addition of structural lesions seen on MRI to the definition of ‘sacroiliitis on 
imaging’ (scenario 1) and the replacement of radiographic sacroiliitis by structural lesions on 
MRI (scenario 2). For both scenarios, the impact on the classification of patients according 




Baseline data from the DEvenir des Spondyloarthrites Indifférenciées Récentes (DESIR) 
cohort were used for this analysis. The DESIR cohort has been extensively described before.7 
In short, the DESIR cohort is a French prospective longitudinal cohort study following 708 
patients (aged >18 years and <50 years) over time with inflammatory back pain (IBP) for ≥3 
months and <3 years, located in the thoracic spine, lumbar spine and/or buttock area. IBP was 
defined according to either the Calin or Berlin criteria.8,9 Patients were included only in case 
of a suspicion of SpA, according to the rheumatologist defined as a score ≥5 on a 0–10 scale 
(0: not suggestive of axSpA and 10: very suggestive of axSpA). All patients underwent a full 
diagnostic work-up including MRI and conventional radiographs of the sacroiliac joints (MRI-
SI and X-SI, respectively), HLA-B27 testing and the assessment of all other SpA-features, in 
agreement with the descriptions provided by ASAS.5 Inclusion was performed in 25 centres 
across France and took place between December 2007 and April 2010. The database for 
the baseline data used for this analysis was locked on 30 October 2012. The study fulfilled 
Good Clinical Practice Guidelines and was approved by the appropriate medical ethical 
committees. Patients gave informed consent before start of the study.
Imaging and scoring methods
MRI of the sacroiliac joints (MRI-SI) was performed at baseline, in each participating centre, 
on 1.0–1.5 T machines. The acquired sequences were coronal oblique T1-weighted FSE 
and STIR with 12–15 semi-coronal slices of 4 mm thickness, parallel to the long axis of the 
sacrum. Plain radiographs of the pelvis (X-SI) were performed at baseline, in anteroposterior 
view. All available MRI-SIs and X-SIs were read by two well-calibrated readers (MRI: FT and 
RvdB and X-SI: GL and RvdB) independently, in different reading sessions. The reading 
process was completely blinded: readers had no insight in patient characteristics and other 
clinical and imaging data. The training and calibration process of the different readers was 
extensively described before.2 
Sacroiliitis on radiographs was assessed according to the mNY criteria; radiographic 
sacroiliitis was defined as bilateral grade ≥2 or unilateral grade ≥3.1 Regarding the presence 
of inflammatory lesions on MRI-SI, the ASAS definition for a positive MRI-SI was used. An 
MRI-SI was marked positive if one bone marrow oedema (BME) lesion highly suggestive 
of SpA was present on ≥2 consecutive slices or alternatively if several BME lesions highly 
suggestive of SpA were visible on a single slice.4 The presence of structural lesions on MRI-
SI was assessed using different types of lesions: fatty lesions, erosions, sclerosis, (partial) 
ankylosis. 
6
95MRI structural lesions in ASAS axSpA classification (DESIR)
We used a scoring system with similarities to the methodology outlined in the SPARCC online 
training module, as described by Weber et al in 2010, to assess MRI-SI on the presence of 
structural lesions.10 In contrast to the SPARCC method, the scoring method we used is purely 
based on counting the number of structural lesions. Each SI joint is divided into quadrants. 
The presence of structural lesions was assessed (present vs absent) in each quadrant on 
six consecutive slices through the SI joints; starting on the slice on which at least 1 cm of 
vertical height of the cartilage compartment is visible, from anterior to posterior, assessing 
the cartilaginous compartment of the SI joints and the anteroinferior portion of the SI joint. 
Structural lesions were only considered present if seen on at least two consecutive slices, 
resulting in a maximum score of 40 per lesion (5 per quadrant (as a lesion needs to be visible 
on two consecutive slices)× 4 quadrants× 2 sacroiliac joints) except for (partial) ankylosis. It 
was considered sufficient if (partial) ankylosis was seen on a single slice and since ankylosis 
involves always a sacral and an iliac part, the maximum score results in 24. More information 
about the scoring method for structural lesions is given in Supplementary Table 1.
Structural lesions on MRI-SI were assessed by two readers, without the use of an adjudicator. 
Therefore, results were analysed separately per reader. In contrast, regarding the presence 
of sacroiliitis on radiographs (mNY) and inflammation on MRI-SI (ASAS definition) adjudicator 
scores (MR) were available. 
Assessment of structural lesions
Recently, definitions for a positive MRI for structural lesions (MRI-SI-s) using different cut-
offs of various structural lesions were proposed by de Hooge et al.11 This was done in the 
SPondyloArthritis Early Cohort (SPACE): a cohort similar to the DESIR cohort, but slightly 
different since patients with chronic back pain (CBP) were included and not only patients 
with IBP and, more importantly, in SPACE also patients without a high suspicion of SpA were 
included.
The cut-offs were based on ≤5% false positives whereby the false positives were defined as 
structural lesions among patients with a very low likelihood of axSpA.11 These cut-offs are 
as follows: ‘erosions ≥3’, ‘fatty lesions ≥3’, ‘fatty lesions and/or erosions ≥5’. Prevalence of 
sclerosis and ankylosis was so low that there was not a cut-off that could clearly distinguish 
between SpA and no-SpA patients. Therefore, these types of lesions were not taken into 
account any further.
Classification criteria
The ASAS axSpA criteria were used for classification of patients. Patients were grouped 
based on how they fulfilled the criteria: via the imaging arm of the ASAS axSpA criteria (either 
by fulfilling mNY criteria and/or positive MRI); via the clinical arm of the ASAS axSpA criteria; 
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or via both. If patients fulfilled several categories, they were classified as such, resulting in 
seven possible combinations (Tables 3 and 4). Patients not fulfilling the ASAS axSpA criteria 
were grouped into the no-axSpA group. It is important to realise that patients that have 
multiple axSpA features present but formally not fulfil the ASAS axSpA criteria (since they are 
mNY-negative, MRI-negative and HLA-B27-negative) are also included in this group.
Data analysis
Disease characteristics of patients included in the DESIR cohort were presented using 
descriptive statistics. Agreement on the absence or presence of structural lesions using both 
imaging modalities (X-SI and MRI-SI-s) was assessed by cross-tabulation and expressed as 
Cohen’s κ. In order to disregard subjects labelled as negative by both readers, which can 
make agreement look artificially high, percentage agreement on the positive cases (positive 
agreement) was calculated.12 Both measures of agreement were also calculated for the 
concordance between radiographic sacroiliitis on conventional radiographs and a positive 
MRI-SI-s (per individual reader). Radiographic sacroiliitis (present vs absent) was based on 
the mNY criteria and MRI-SI-s for structural lesions was based on the proposed cut-offs for 
a positive MRI-SI-s.
Subsequently, patients were classified according to the ASAS axSpA criteria, using the 
various definitions of MRI-SI-s. First, MRI-SI-s was added to the imaging criterion of the ASAS 
axSpA criteria as an additional possibility to fulfil the imaging arm (scenario 1). Second, the 
mNY criterion was replaced by MRI-SI-s (scenario 2, as if only an MRI was available). For 
patients that newly fulfilled the ASAS axSpA criteria in scenario 1 and whom ASAS axSpA 
classification changed by scenario 2, the probability of having axSpA was calculated by the 
positive likelihood ratio (LR+) product. This was done by multiplying the individual LRs of all 
present SpA features in a patient.13 For example, an LR product of 200 results in a positive 
predictive value of 90% in patients with CBP with an assumed pre-test disease prevalence of 
axSpA of 5%.14 The analyses were performed in STATA V.12.0.
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RESULTS
In total, 582 patients with complete imaging data (both MRI-SI and X-SI present), evaluated 
by two readers, were included in this analysis. Disease characteristics are depicted in Table 
1. The mean age was 31.5 years (SD 7.2 years) and 51% were male. Patients had a mean 
duration of back pain of 18.2 months (SD 10.6 months) and 338 patients (58.1%) were 
HLA-B27 positive. Fulfilment of the ASAS axSpA criteria was seen in 418 (71.8%) patients 
(while using adjudicated scores and based on the original definition of imaging).
As published before, agreement between the two readers regarding the absence/presence 
of radiographic sacroiliitis (mNY) is moderate: κ 0.54.2 Regarding the definition of a positive 
MRI-SI according to the ASAS definition, inter-reader agreement was much better: κ 0.73.15 
Inter-reader agreement between readers 1 and 2 was calculated for the various structural 
lesions definitions. The agreement on the presence of ≥3 erosions was poor: κ 0.19. For 
the presence of fatty lesions and the combination of fatty lesions/erosions, it was somewhat 
better, κ 0.50 and κ 0.44, respectively. Subsequently, agreement between radiographic 
sacroiliitis (mNY criteria) and a positive MRI-SI-s (using the various cut-offs) was assessed. 
Agreement was rather low and varied between κ 0.21 and κ 0.44 (Table 2).
Table 1: Disease characteristics of the patients included in the analyses  
Total number of patients (n=582)
Age (years) at inclusion, mean ±SD 31.5 (7.2)
Male, n (%) 297 (51.0)
Symptom duration (months) at first visit, mean ±SD 18.2 (10.6)
HLA-B27 positive, n (%) 338 (58.1)
Positive family history SpA, n (%) 146 (25.1)
IBP, n (%) 582 (100)
Psoriasis, n (%) 90 (15.5)
Dactylitis, n (%) 74 (12.7)
Enthesitis, n (%) 282 (48.5)
Uveitis, n (%) 40 (6.9)
IBD, n (%) 29 (5.0)
Elevated CRP, n (%) 168 (30.6)
Good response to NSAIDs, n (%) 459 (78.9)
Peripheral arthritis, n (%) 100 (17.2)
Sacroiliitis present on radiograph, n (%) 126 (21.6)
Positive MRI (ASAS definition), n (%) 210 (36.1)
HLA-B27, human leukocyte antigen B27; IBP, inflammatory back pain; IBD, inflammatory bowel disease; 
CRP, C-reactive protein; NSAIDs, non-steroidal anti-inflammatory drugs, MRI, magnetic resonance 
imaging; ASAS, Assessment of SpondyloArthritis international Society.
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Table 2: Agreement between sacroiliitis on conventional radiographs (modified New York 






modified New York criteria                       κ: 0.21
 Positive Negative Total
Positive 22 10 32
Negative 105 444 549




 modified New York criteria                       κ: 0.39
Positive Negative Total
Positive 53 34 87
Negative 74 420 494




modified New York criteria                        κ: 0.39
Positive Negative Total
Positive 49 26 75
Negative 78 428 506







modified New York criteria                        κ: 0.39
Positive Negative Total
Positive 68 63 131
Negative 59 391 450




modified New York criteria                        κ: 0.40
Positive Negative Total
Positive 61 47 108
Negative 66 407 473




modified New York criteria                        κ: 0.44
Positive Negative Total
Positive 74 60 134
Negative 53 394 447
Total 127 454 581
Positive agreement: 39.6%
*Note: in this table 581 patients are included (total number of included patients in the study being 582) 
since the T1-sequence MRI was missing in one patient (STIR-sequence available).
X-SI, conventional radiographs of the sacroiliac joints; MRI-SI, magnetic resonance imaging of the 
sacroiliac joints.  
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First, we investigated the effect of adding MRI-SI-s to the imaging criterion of the ASAS 
axSpA criteria (Table 3) . Using a cut-off value of 5 for the combination of ‘fatty lesions and/
or erosions’, classification did not change in the majority of the patients: 556 patients (95.5%) 
and 522 patients (89.7%) for readers 1 and 2, respectively. Regarding the combination of 
‘fatty lesions and/or erosions’, three or six patients (readers 1 and 2, respectively) would be 
additionally classified as axSpA if structural lesions on MRI were taken into account (two 
patients, identified by both readers). Only two of these in total seven patients presented 
with four SpA features in addition to IBP, which was present in all cases. None of these 
patients was HLA-B27 positive. The LR+ products varied between 3 and 968, respectively, 
corresponding to post-test probabilities of 13% and 98%. A post-test probability of >80% 
was seen in one patient only. Similar results were found when using a cut-off for ‘fatty lesions’ 
only and ‘erosions’ only (both cut-off values of 3) (Supplementary Table 2 and Supplementary 
Table 4).
More patients did not gain an ASAS classification by applying MRI-SI-s, but changed 
subgroups within the ASAS axSpA criteria. Regarding the combination of ‘fatty lesions and/or 
erosions’, 23 (reader 1) and 54 (reader 2) patients would be classified via different arms due 
to the presence of structural lesions on MRI-SI. Also, 16 or 40 patients (reader 1 or reader 
2) were already classified via the imaging arm based on inflammatory lesions on MRI and 
also showed structural lesions on MRI (Table 3) with or without fulfilment of the clinical arm. 
And, 7 or 14 other patients (reader 1 or reader 2) fulfilled the clinical arm only, but fulfilled 
the imaging arm too based on a positive MRI-SI-s. The same trends were seen when using 
a cut-off for ‘fatty lesions’ only and ‘erosions’ only (both cut-off values of 3) (Supplementary 
Table 2 and Supplementary Table 4).
Scenario 2
Second, we assessed whether replacing radiographic sacroiliitis by structural lesions on MRI 
(Table 4)  had an impact on ASAS classification. Using the same cut-off values of 5 for the 
combination of ‘fatty lesions and/or erosions’, classification did not change in the majority of 
the patients (82.1% and 80.6% for readers 1 and 2, respectively). A similar result was seen 
using a cut-off value of 3 for ‘erosions’ and ‘fatty lesions’ only: classification did not change in 
80.2% or 79.0% (readers 1 and 2) and 81.4% or 80.6% of the patients, respectively (Table 5). 
Comparing results of the two readers, differences were seen among them, but these changes 
mainly involve shifts between the different arms within the ASAS axSpA criteria rather than 
changes in ASAS axSpA classification (yes/no) in general (Table 5). Similar results were 
found when using a cut-off for ‘fatty lesions’ only and ‘erosions’ only (both cut-off values of 3) 
(Supplementary Table 3 and Supplementary Table 5). 
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In this scenario, of course, the same patients would be additionally classified as axSpA 
as in scenario 1. But in contrast to scenario 1, now patients can also no longer fulfil the 
ASAS axSpA criteria. Using the combination of ‘fatty lesions and/or erosions’, 12 and 10 
patients (2.1% and 1.7% for readers 1 and 2, respectively) would not be classified axSpA 
anymore if radiographic sacroiliitis was replaced by structural lesions on MRI, for example, 
assuming that only an MRI was available. In total and between brackets for the individual 
readers separately, 89 (66+23) and 97 (43+54) patients changed arms within the criteria 
using the combined cut-off of ‘fatty lesions and/or erosions’ (Table 4: yellow and orange 
boxes). However, all those patients were still classified axSpA.
The clinical phenotype of the patients that are no longer classified by the ASAS axSpA 
criteria was assessed. The same 10 patients were captured by both readers: all HLA-B27 
and the number of present SpA features varied between 1 (only IBP) and 4 (IBP, peripheral 
Table 5: Scenario 2: Changes in ASAS axSpA-classification, using all three combinations of lesions
Reader 1
Erosions ≥3 Fatty lesions ≥3 Erosions and/or 
fatty lesions ≥5
Classification remained the same 467 (80.2%) 474 (81.4%) 478 (82.1%)
mNY+ patients with MRI-SI-s-, but remained 
ASAS+
92 (15.8%) 62 (10.6%) 66 (11.3%)
mNY- patients with structural lesions on MRI, 
within ASAS+
9 (1.5%) 30 (5.2%) 23 (4.0%)
ASAS- patients based on mNY- became 
ASAS+ based on MRI-SI-s+
1 (0.2%) 4 (0.7%) 3 (0.5%)
ASAS+ patients based on mNY+ became 
ASAS- based on MRI-SI-s-
13 (2.2%) 12 (2.1%) 12 (2.1%)
Total 582 582 582 
Reader 2
Erosions ≥3 Fatty lesions ≥3 Erosions and/or 
fatty lesions ≥5
Classification remained the same 460 (79.0%) 469 (80.6%) 469 (80.6%)
mNY+ patients with MRI-SI-s-, but remained 
ASAS+
49 (8.4%) 56 (9.6%) 43 (7.4%)
mNY- patients with structural lesions on MRI, 
within ASAS+
51 (8.8%) 41 (7.0%) 54 (9.3%)
ASAS- patients based on mNY- became 
ASAS+ based on MRI-SI-s+
12 (2.1%) 6 (1.0%) 6 (1.0%)
ASAS+ patients based on mNY+ became 
ASAS- based on MRI-SI-s-
10 (1.7%) 10 (1.7%) 10 (1.7%)
Total 582 582 582
ASAS, Assessment of SpondyloArthritis international Society; axSpA, axial spondyloarthritis; mNY, 
modified New York; MRI-SI, magnetic resonance imaging of the sacroiliac joints; MRI-SI-s, MRI-SI 
assessed for structural lesions. 
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arthritis, enthesitis, dactylitis). The LR+ products varied between 3 and 190, corresponding 
with disease probabilities of 13% and 90%, respectively. A post-test probability of >80% 
was seen in two patients. The two additional patients that no longer fulfilled the ASAS axSpA 
criteria by reader 1 only, showed both a good response to non-steroidal anti-inflammatory 
drugs and one presented with enthesitis as well (corresponding to disease probabilities of 
45% and 74%). Similar results were found when using a cut-off for ‘fatty lesions’ only and 
‘erosions’ only (Supplementary Table 3 and Supplementary Table 5).
DISCUSSION
When sacroiliitis on radiographs was replaced by structural lesions on MRI, only minor 
changes in the classification according to the ASAS axSpA criteria were seen. Most patients 
change from one subcategory to another subcategory, rather than becoming ASAS axSpA 
criteria positive or negative. This adds to the robustness of the ASAS axSpA criteria as a 
whole. 
Based on these data, if a T1-sequence MRI is available, but a pelvic radiograph is lacking, 
this MRI may suffice and there no reason of always obtaining additional radiographs. MRI can 
be therefore a reasonable alternative for radiographs since this prevents radiation exposure. 
More generally, our results are in line with the recent published EULAR recommendations 
for the use of imaging in the diagnosis and management of SpA in clinical practice, stating 
that on MRI both active inflammatory lesions (primarily BME) and structural lesions (such 
as bone erosions, new bone formation, sclerosis and fat infiltration) should be considered.6 
Nevertheless, it is important to stress the difference between that publication and the current 
study: the EULAR recommendations are aimed for diagnosis and in the current study we look 
at the ASAS axSpA classification.
As described earlier, the recognition of radiographic sacroiliitis is challenging. Unfortunately, 
agreement on structural lesions was only fair–moderate as well. However, it is reassuring to 
see that the same conclusions (effects on ASAS axSpA classification) can be drawn while 
comparing the data of the individual readers. This strengthens our findings and adds to 
the validity of the criteria itself since the results seem not too much affected to inter-reader 
variation in this respect. This in contrast to the mNY criteria that immediately change in 
case of discrepant readings. We know from earlier studies that training does not improve 
recognition of radiographic sacroiliitis.3 The question whether training ameliorates recognition 
of structural lesions on MRI was not addressed in this study and could be relevant for future 
studies.
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To our knowledge, the replacement of conventional radiographs by structural lesions on 
MRI in itself, and the effects on the ASAS axSpA classification have never been investigated 
before. However, data on the recognition and reliability of structural lesions visible on MRI-
SI in general are available. In 2009, ASAS experts defined structural damage lesions of 
the sacroiliac joints on MRI. Subsequently, reliability of their detection has been studied. 
Weber et al found that erosions can be reliably detected on MRI to a comparable degree 
of reliability as BME (κ: 0.72).16 Regarding the detection of fatty lesions, lower κ values were 
shown in the same paper (κ: 0.55).16 More recently, the SPARCC SSS score was developed 
by the Canada–Denmark study group.17 Recent data from a collaboration between two 
research groups (from Edmonton, Canada, and Leiden, the Netherlands) have shown 
that the presence and extent of erosions and fat metaplasia can be reliably assessed by 
readers from these different centres (intraclass correlation coefficient (ICC): 0.60 and 0.65, 
respectively), even without calibration.18 Interobserver reliability for status scores was good 
for fat metaplasia (ICC: 0.71–0.78) and moderate to good for erosions (ICC: 0.58–0.62) for 
different reader pairs. In this study, we found a lower agreement compared with data from 
other studies. However, a clear comparison between reliability data of different groups is 
hampered by variability in study design such as inclusion criteria of the cohorts and slightly 
different scoring methods. Hypothesising about this, it could be plausible that patients with a 
short symptom duration, like in our early cohort, usually have less structural damage and that 
recognition of structural lesions is more challenging in a cohort of patients with early disease. 
Therefore, the agreement on positive imaging presented in this study might be slightly worse 
than could be expected in more established disease.
In the current study, we investigated the effect of using different combinations of structural 
lesions (fatty lesions, erosions and a combination of fatty lesions and erosions) on the 
classification of patients with axSpA. We could debate on the choice for the ideal cut-off and 
corresponding structural lesion. In this study, we found worse agreement for erosions alone 
and better agreement for the combination of erosions/fatty lesions and fatty lesions alone. 
Despite similar effects on the ASAS classification of patients, personally we prefer using a 
combination of fatty lesions and/or erosions instead of fatty reasons alone for reasons of face 
validity. But a definition based on erosions only could be a viable option too.
Although our data look promising, we should be cautious with generalising conclusions and 
results should be placed into perspective carefully. Before any decision can be taken on 
eventually leaving conventional radiographs behind, more evidence is needed since this 
is a decision with possibly far-reaching consequences. MRI is an expensive tool and might 
not be available throughout all parts of the world, which can lead to feasibility problems. 
Besides this, rheumatologists and radiologists worldwide are familiar with the mNY criteria. 
We should especially be cautious to generalise results of these data to patients with long-
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standing disease since we only tested this hypothesis in one cohort with early disease. The 
ideal cut-off could be different in patients with longer symptom duration and more structural 
lesions in the sacroiliac joints. Therefore, more data are warranted and confirmation of these 
results is needed first, especially in cohorts of patients with established disease.
Replacement of sacroiliitis on radiographs by structural lesions on MRI is resulting in a loss of 
a small number of patients (scenario 2). And these patients showed a low likelihood of axSpA 
based on the SpA features present. Nevertheless, for the reasons explained above, we favour 
(for the time being) addition of structural lesions on MRI to the ASAS axSpA classification 
(scenario 1) instead of replacement of conventional radiographs.
Strengths of our study are the intensive scoring process by multiple readers, which adds 
to the credibility of our findings and the cohort itself. The DESIR cohort is a cohort of early 
disease, with a substantial number of patients. In general, the urge for sensitive and specific 
imaging tools is an emerging issue in the field of early axSpA. Besides strengths of the study, 
we would like to address some limitations. An important limitation of this study is the lack of 
a gold standard to assess structural changes in the sacroiliac joint by means of CT. Another 
limitation of this study is that only patients with a short disease duration are included in the 
DESIR cohort and that we in general see a limited number of patients with structural lesions. 
Therefore, hesitation is needed in order to prevent drawing definite conclusions about the 
use of MRI-SI-s for the definition of sacroiliitis on imaging in the ASAS axSpA criteria.
To conclude, assessment of structural lesions on MRI instead of or in addition to conventional 
radiographs does not lead to a different ASAS axSpA classification in the large majority 
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SUPPLEMENTARY MATERIAL
Supplementary Table 1: Scoring method for the assessment of structural lesions on MRI-SI (MRI-SI-s)
A. Maximum score that can be obtained for scoring erosions, fatty lesions and sclerosis separately:
Left SI-joint Right SI-joint
Quadrant: Quadrant:





Slice 1 and 2 0-1 0-1 0-1 0-1 0-1 0-1 0-1 0-1
Slice 2 and 3 0-1 0-1 0-1 0-1 0-1 0-1 0-1 0-1
Slice 3 and 4 0-1 0-1 0-1 0-1 0-1 0-1 0-1 0-1
Slice 4 and 5 0-1 0-1 0-1 0-1 0-1 0-1 0-1 0-1
Slice 5 and 6 0-1 0-1 0-1 0-1 0-1 0-1 0-1 0-1
Total score 0-5 0-5 0-5 0-5 0-5 0-5 0-5 0-5
Total score 
per SI-joint 0-20 0-20
Total score 
(both SI-joints) 0-40
B. Maximum score that can be obtained for scoring partial ankylosis and ankylosis:













Slice 1 0-1 0-1 0-1 0-1
Slice 2 0-1 0-1 0-1 0-1
Slice 3 0-1 0-1 0-1 0-1
Slice 4 0-1 0-1 0-1 0-1
Slice 5 0-1 0-1 0-1 0-1
Slice 6 0-1 0-1 0-1 0-1
Total score 0-6 0-6 0-6 0-6
Total score 
per SI-joint 0-12 0-12
Total score 
(both SI-joints) 0-24
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To investigate in patients with chronic back pain of a short duration, the utility of adding 
structural MRI lesions of the SI joints to the imaging criterion of the Assessment of 
SpondyloArthritis International Society (ASAS) axial SpA (axSpA) criteria and the utility of 
replacement of radiographic sacroiliitis by structural MRI lesions.
Methods
MRI STIR (inflammation, MRI-SI), MRI T1-weighted images (structural lesions, MRI-SI-s) and 
radiographs of the SI joints of patients in the SPondyloArthritis Caught Early-cohort (chronic 
back pain: ≥3 months, ≤2 years; onset <45 years) were scored by two well-calibrated readers. 
Previously proposed cut-offs for a positive MRI-SI-s were used (based on <5% prevalence 
in no-SpA patients): erosions ≥3, fatty lesions ≥3, fatty lesions and/or erosions (erosions/fatty 
lesions) ≥5. Using the definitions of MRI-SI-s, patients were classified according to the ASAS 
axSpA criteria.
Results
Twenty-nine of 294 patients were modified New York (mNY) positive and 32 were MRI-SI-s 
positive (erosions/fatty lesions ≥5). Agreement between mNY and MRI-SI-s (erosions/fatty 
lesions ≥5) was moderate (k: 0.58). Using the erosions/fatty lesions ≥5 cut-off, 3/294 additional 
patients were classified as axSpA (adding MRI). Using this cut-off instead of mNY (replacing 
mNY), classification did not change in 286 patients (97.3%), but 5 patients (1.7%) would not 
be classified as axSpA and 3 previously unclassified patients (1.0%) would be classified as 
axSpA. Similar results were seen for the other cut-offs (erosions ≥3 and fatty lesions ≥3).
Conclusion
Assessment of structural lesions (fatty lesions and erosions) on MRI-SI instead of or in addition 
to conventional radiographs does not lead to a different ASAS axSpA classification in most of 
the patients with early disease onset. This suggests that structural lesions (fatty lesions and 
erosions) can be reliably used in the ASAS axSpA classification of patients, as both addition 
and replacement of radiographs of the SI joints.
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INTRODUCTION
Recently, we have demonstrated that in the DEvenir des Spondyloarthrites Indifférenciées 
Récentes (DESIR) cohort of patients with inflammatory back pain with a high suspicion of 
having axial SpA (axSpA), structural lesions on MRI can be used reliably either as an addition 
to or as a substitute for radiographs in the Assessment of SpondyloArthritis International 
Society (ASAS) axSpA classification of patients with spondyloarthritis.1 Since this is a new 
concept with potential consequences for daily clinical practice, replication in other cohorts 
is highly warranted. The current study investigates the same research question in an entirely 
independent cohort, the SPondyloArthritis Caught Early (SPACE) cohort of patients with 
chronic back pain of a short duration.
The rationale behind using structural lesions on MRI instead of conventional radiographs is 
mainly based on the fact that a reliable detection of sacroiliitis on conventional radiographs 
is notoriously difficult. Sacroiliitis is the hallmark of AS and the presence of sacroiliitis on 
conventional radiography is obligatory in the modified New York (mNY) criteria for AS.2 
However, it has been shown that substantial observer variation (interreader, intrareader) 
exists for both radiologists and rheumatologists, and training does not lead to improvement.2 
Recent data from the DESIR cohort have also revealed a poor to moderate agreement 
between different readers leading to substantial misclassification of patients.3 With the help 
of MRI it has become possible to detect active sacroiliitis (bone marrow oedema, BME) in 
early stages of axSpA. The ASAS definition for a positive MRI is solely based on identification 
of BME highly suggestive for SpA, but structural lesions can be seen [fatty lesions, erosions, 
sclerosis and (partial) ankylosis] are visible on MRI as well.4 The 3D (albeit tomographic) 
character of MRI may be an advantage as compared with the 2D projection of conventional 
radiographs.5 Another advantage of MRI above radiography is that patients are not exposed 
to ionizing radiation.
Both the SPACE and the DESIR are cohorts of early disease. Since it often takes 6-8 years from 
the onset of symptoms before radiographic sacroiliitis can be detected on plain radiographs, 
conventional radiography is a suboptimal imaging technique especially in patients with 
complaints of a short duration (in addition to the earlier described reliability issues). The 
DESIR cohort only includes patients with inflammatory back pain (IBP) with up to 3 years of 
symptoms, whereas the SPACE cohort includes patients with chronic back pain (CBP) with 
up to 2 years of symptoms. Different reader pairs were involved in the scoring process of the 
two cohorts, to rule out a reader-dependent effect.
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In this study we aim to evaluate the usefulness of structural lesions with regard to the ASAS 
axSpA classification criteria in the SPACE cohort. First of all, we determine the agreement 
between sacroiliitis seen on radiographs (mNY) and structural lesions seen on MRI. Then 
we aim to evaluate the potential impact of adding structural lesions on MRI to the definition 
of a positive MRI or replacing radiographic sacroiliitis by MRI structural lesions on the ASAS 
axSpA classification of patients.
METHODS
Study population
For this analysis, baseline data from the SPACE cohort were used. An extensive description 
of the SPACE cohort has been given elsewhere.6 In short, SPACE is an inception cohort with 
on-going inclusion and follow-up of patients with CBP of short duration (≥3 months but ≤2 
years, with onset <45 years). Patients were recruited from five participating centres in the 
Netherlands (Leiden, Amsterdam, Gouda), Norway (Oslo) and Italy (Padua). Approval by the 
local medical ethics committees was obtained, as well as written informed consent from all 
patients in accordance with the Declaration of Helsinki.
A full diagnostic work-up was performed in all patients including: HLA-B27 testing, conventional 
radiographs and MRI of the SI joints (X-SI and MRI-SI, respectively), and the assessment of all 
other SpA features, in agreement with the descriptions supplied by the ASAS group.7
Imaging and scoring methods
MRI-SI was performed on a 1.5 Tesla machine (Philips Medical Systems, Best, Netherlands). 
Coronal oblique T1-weighted TSE (TR 550/TE 10) and STIR (TR 2500/TE 60) with a slice 
thickness of 4 mm were the acquired sequences used. All available baseline MRI-SI and 
X-SI were read independently, in different reading sessions, by two trained, well-calibrated 
readers (P.A.B., M.d.H.). Readers were blinded to the score of the other reader and other 
modality as well as the clinical information, throughout the scoring process.
The mNY criteria were used to assess radiographs of the SI joints; radiographic sacroiliitis was 
defined as bilateral grade 52 or unilateral grade 53.8 In consensus with the ASAS definition, 
an MRI-SI was defined positive if one BME lesion highly suggestive of SpA was present on 
two or more consecutive slices, or otherwise if several BME lesions highly suggestive of 
SpA were visible on a single slice.9 A third reader served as adjudicator (R.vd.B.) in case of 
disagreement among the two initial readers regarding a positive MRI (ASAS definition) or the 
presence of sacroiliitis (mNY criteria).
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The presence of structural lesions, namely fatty lesions, erosions, sclerosis and (partial) 
ankylosis, was assessed on MRI T1-weighted images in conjunction with the STIR images. A 
scoring system with similarities to the methodology outlined in the Spondyloarthritis Research 
Consortium of Canada (SPARCC) online training module, as described by Weber et al. was 
used.10 Weber et al. proposed a scoring system to quantify structural lesions called SPARCC 
SI structural lesion score. This method is founded on the assessment of lesions (present vs 
absent) counting them in each quadrant on six consecutive slices through the SI joints. The 
starting point is the slice on which at least 1 cm of vertical height of the cartilage compartment 
can be seen, from anterior to posterior evaluating the cartilaginous compartment of the SI 
joints and the antero-inferior portion of the SI joint. Each SI joint is split into four quadrants. 
Structural lesions were taken into account only if present on at least two consecutive slices. 
This is reflected by a maximum score of 40 per lesion (5 lesions per quadrant 4 quadrants 2 
SI joints) except for (partial) ankylosis. As an exception, (partial) ankylosis was considered 
sufficient when seen on a single slice reflected by a maximum score of 24 per patient.
As shown earlier by our group, an MRI positive for structural lesions (MRI-SI-s) was determined 
by the use of different cut-offs.11 These chosen cut-offs were anchored on 45% false positives 
whereby the false positives were specified as structural lesions among patients not having 
axSpA according to the ASAS axSpA criteria. The described cut-offs have pointed out to 
be: erosions ≥3, fatty lesions ≥3, fatty lesions and/or erosions ≥5. In this early cohort, the 
prevalence of sclerosis and (partial) ankylosis was so low that there was no cut-off that could 
clearly differentiate between SpA and no-SpA patients. As a consequence, these types of 
lesions were not further considered.
Classification criteria
Patients were classified according to the ASAS axSpA criteria. Subsequently, patients were 
grouped based on the way they met the criteria: through the imaging arm of the ASAS axSpA 
criteria alone (either by mNY criteria and/or by positive MRI); through the clinical arm of the 
ASAS axSpA criteria alone; or through both. If patients fulfilled more than one category, they 
were classified in that way, reflected by seven possible combinations (Table 3 and 4). The 
no-axSpA group is made up of patients not fulfilling the ASAS axSpA criteria.
Data analysis
Descriptive statistics were used to calculate disease characteristics of the included patients. 
In the analysis, regarding structural lesions the mean score of the two readers in agreement 
of a positive MRI (ASAS definition) was used. In case of disagreement, the mean of the scores 
of the adjudicator and the reader in agreement with the adjudicator’s judgement regarding a 
positive MRI for that particular case were used.
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Agreement about the absence or presence of structural lesions using both imaging 
modalities (X-SI and MRI-SI-s) was assessed by cross-tabulation and expressed as Cohen’s 
k. Percentage positive agreement was calculated in order to leave out patients labelled as 
negative by the two readers, which could lead to an artificially high agreement.
Subsequently, using the various definitions of MRI-SI-s, patients were classified by the ASAS 
axSpA criteria. MRI-SI-s was added to the imaging criterion of the ASAS axSpA criteria in the 
first place, resulting in an additional possibility to fulfil the imaging arm (scenario 1). Second, 
replacement of the mNY criterion by MRI-SI-s (scenario 2) was applied as if only an MRI was 
performed.
Disease probabilities were calculated by the positive likelihood ratio (LR) product, for those 
patients changing ASAS axSpA classification in scenario 2. This was done by multiplying the 
individual LRs of all identified SpA features.12 In patients with CBP with an assumed disease 
prevalence of axSpA of 5%, an LR product of 200 results in a positive predictive value of 90%. 
These patients were further described by their clinical phenotype: gender, age and whether a 
patient was diagnosed as axSpA according to the treating rheumatologist. The analyses were 
performed in STATA 12.0 (StataCorp LP, College Station, Texas, USA).
RESULTS
Included in the analysis are 294 patients with complete imaging data at baseline (both MRI-SI 
and X-SI present). Table 1 describes patient characteristics. Patients had a mean (S.D.) age 
of 31.6 years of age (10.7 years) and a mean (S.D.) duration of back pain of 13.1 months (7.3 
months). Of these patients, 34.6% were men and 34.6% were HLA-B27 positive.
One hundred and three out of 294 patients (35.0%) fulfilled the ASAS axSpA criteria using the 
standard definition. Of these 103 patients, 50 patients fulfilled the imaging arm (48.5%) and 
53 patients fulfilled the clinical arm only (51.5%). The most prevalent SpA features were IBP 
(62.6%), a positive family history for SpA (38.1%) and a good response to NSAIDs (31.6%).
Regarding the prevalence of structural lesions, 20/294 patients (6.8%) showed three or more 
fatty lesions; 16 of these 20 patients (80%) already formally fulfilled the ASAS axSpA criteria. 
Thirty-four patients (11.6%) had three or more erosions, and 27 of these 34 (79.4%) already 
formally fulfilled the ASAS axSpA criteria. Thirty-one patients (10.5%) had 5 or more fatty and/
or erosive lesions (combination), of which 26 patients (83.9%) already formally fulfilled the 
ASAS axSpA criteria.
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The agreement regarding the presence/absence of radiographic sacroiliitis and the presence/
absence of structural lesions on MRI was moderate (Table 2). Subtle differences were seen 
between the various definitions used: k: 0.51 (erosions ≥3); k: 0.45 (fatty lesions ≥3); and k: 0.58 
(combination of fatty lesions and erosions ≥5).
Table 1: Baseline characteristics of the SPACE cohort
Total number (n=294)
Age at inclusion, mean (SD), years 31.6 (10.7)
Male, n (%) 102 (34.6)
Symptom duration at first visit, mean (SD), months 13.1 (7.3)
Good response to NSAIDs, n (%) 92 (31.6)
IBP, n (%) 184 (62.6)
Positive family history SpA, n (%) 112 (38.1)
Peripheral arthritis, n (%) 37 (12.6)
Dactylitis, n (%) 10 (3.4)
Enthesitis, n (%) 43 (14.6)
Uveitis, n (%) 21 (7.1)
IBD, n (%) 26 (8.8)
Psoriasis, n (%) 29 (9.7)
Elevated CRP, n (%) 54 (18.8)
HLA-B27 positive, n (%) 100 (34.6)
Sacroiliitis present on radiograph, n (%) 29 (9.8)
Positive MRI (ASAS definition), n (%) 37 (12.5)
SPACE, Spondyloarthritis Caught Early; NSAIDs, non-steroidal anti-inflammatory drugs; IBP, 
inflammatory back pain; SpA, spondyloarthritis; IBD, inflammatory bowel disease; CRP: C-reactive 
protein; HLA-B27, human leukocyte antigen B27; MRI, magnetic resonance imaging; ASAS, Assessment 
of SpondyloArthritis international Society.
Table 2: Agreement between sacroiliitis on conventional radiographs (mNY criteria) and a 
positive MRI-SI based on structural lesions (MRI-SI-s)
Erosions: cut-off ≥3; 
mean 2 out of 3 readers
mNY (adjudicated)                       κ: 0.51
Positive Negative Total
Positive 18 17 35
Negative 11 248 259
Total 29 265 294
Fatty lesions: cut-off ≥3; 
mean 2 out of 3 readers
 mNY (adjudicated)                       κ: 0.45
Positive Negative Total
Positive 12 8 20
Negative 17 257 274
Total 29 265 294
Erosions/fatty lesions: cut-off ≥5; 
mean 2 out of 3 readers
 mNY (adjudicated)                       κ: 0.58
Positive Negative Total
Positive 19 13 32
Negative 10 252 262
Total 29 265 294
Agreement based on MRI-SI structural lesions (MRI-SI-s) using the three different definitions. 
mNY, modified New York criteria; MRI-SI-s, MRI of the sacroiliac joints assessed for structural lesions.
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Scenario 1
The addition of MRI-SI-s to the imaging criterion of the ASAS axSpA criteria was investigated 
first (Table 3). Classification did not change in the majority of the patients (96.3%) using a cut-off 
value of 5 for the combination of fatty lesions and/or erosions. If a cut-off value of 3 for erosions or 
fatty lesions only was used, comparable results were seen: classification did not change in 94.9 
and 97.6% of the patients, respectively. Considering the combination of five fatty lesions and/or 
erosions, three patients would be classified additionally axSpA if structural lesions on MRI were 
taken into consideration. The positive LR products of the three additionally classified patients 
were 15.8, 5.1 and 2.5, corresponding to post-test probabilities of 44, 20 and 11%, respectively. 
The rheumatologist diagnosed only one of these three patients (all female and HLA-B27 negative) 
with axSpA. Regarding the definition based on erosions, five patients would be additionally 
classified (all female and HLA-B27 negative). Only two of them were diagnosed as axSpA by 
the rheumatologist. Regarding the definition based on fatty lesions, three patients would be 
additionally classified as axSpA (one was described above, the other two were male patients, 
HLA-B27 negative, of whom one was diagnosed as having axSpA by the rheumatologist).
Some patients changed subgroups within the ASAS classification, without a change in ASAS 
axSpA positivity or negativity. Eight patients would be classified via different arms due to the 
presence of structural lesions, using the combination of fatty lesions and/or erosions. Five 
patients also showed structural lesions on MRI (Table 3) but were already classified via the 
imaging arm based on inflammatory lesions on MRI. Three other patients fulfilled the clinical 
arm only, but fulfilled the imaging arm as well based on a positive MRI-SI-s. Using the cut-offs 
for fatty lesions or erosions only (both cut-off values were 3), the same trends were seen (data 
not shown).
Scenario 2
Second, the replacement of radiographic sacroiliitis by structural lesions on MRI (Table 4) 
and its impact on the ASAS axSpA classification was assessed. Using the same cut-off 
values of 5 for the combination of fatty lesions and/or erosions, classification did not change 
in the large majority of the patients (93.5%). A similar result was seen at a cut-off value of 
3 for erosions and fatty lesions only: classification did not change in 91.8 and 92.9% of the 
patients, respectively. The same patients would be additionally classified as axSpA as in 
scenario 1. But assuming that only an MRI was performed, five patients (1.7%) would not be 
classified axSpA anymore if radiographic sacroiliitis was replaced by structural lesions on 
MRI using the combination of fatty lesions and/or erosions. The SpA-features of the patients 
that are newly classified by the ASAS axSpA criteria are described in Table 5, and the SpA-
features of the patients that are no longer classified by the ASAS axSpA criteria are described 
in Table 6.          
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One of these patients had four axSpA features, leading to a positive LR product of 192.4 
and a corresponding high disease probability of 91%. One other patient had a disease 
probability of 75%. The disease probabilities of the other three patients turned out to be much 
lower: between 14 and 32%. Three of these five patients were female and two of the five 
patients were HLA-B27 positive (one male, one female). Of the five patients who would not 
be classified as axSpA anymore in this scenario, three patients were diagnosed axSpA by 
the rheumatologist. Regarding the definition based on erosions only, one additional patient 
would not be classified as ASAS axSpA anymore. This female patient was HLA-B27 negative, 
and was not diagnosed axSpA by the treating rheumatologist. Regarding the combination of 
fatty lesions and/or erosions, 11 patients changed arms within the criteria under this scenario 
but all stayed ASAS axSpA positive. Similar results were found when using a cut-off for fatty 
lesions only and erosions only (both cut-off values of 3) (data not shown).
DISCUSSION
In this cohort of patients with CBP of short duration we have shown that adding structural lesions 
to the imaging criterion of the ASAS axSpA criteria has a limited effect on the classification 
of patients. Also, when sacroiliitis on radiographs was replaced by structural lesions on MRI, 
only minor changes in the ASAS axSpA classification of patients were seen. In patients with 
CBP suspicious for axSpA, structural lesions are associated with other SpA features and the 
majority of patients with structural lesions in our study fulfil the ASAS axSpA criteria anyway.
If conventional radiographs were replaced by MRI-SI-s, using a combination of fatty lesions 
and erosions, only 3/294 (1.0%) patients would be additionally classified as ASAS axSpA. 
On the other hand, only 5/294 (1.7%) patients would lose their ASAS axSpA classification. 
Three out of these five patients with a state change had relatively low ratio products and 
corresponding probabilities of axSpA, suggesting that they did not have classic disease 
presentations. However, the two other patients have high disease probabilities and therefore 
could be missed erroneously. Most changes that are seen are a change in a subcategory 
between the various ASAS axSpA criteria rather than a change in classification per se. In 
other words, patients do not lose their ASAS classification solely by changing the content of 
the criteria. This characteristic adds to the credibility of the ASAS criteria.
Only a few patients lose ASAS axSpA classification in scenario 2, which may justify 
replacement of conventional radiographs by MRI. However, it is important to realize that this 
is purely data-driven and feasibility issues should not be overlooked. MRI is an expensive 
imaging technique, especially in certain areas of the world. Furthermore, rheumatologists and 
radiologists are worldwide familiar with the mNY criteria, and evaluation of structural lesions 
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on an MRI of the SI joints is a new concept. Education and time is needed in order to become 
familiarized with it. At this point in time, we therefore favour the addition of structural lesions to 
the imaging criterion of the ASAS axSpA criteria above replacement.
These results are in line with recent data from the DESIR cohort, investigating the same 
research question in another cohort. In the SPACE cohort, even more patients do not 
change classification while replacing radiographic sacroiliitis by structural lesions seen on 
MRI compared with DESIR (SPACE: 95.3% vs DESIR: 80%). In general, a notable difference 
between the two cohorts is that in DESIR only patients with IBP are included, whereas in 
SPACE 62.6% of the patients have IBP. Other SpA features are also more common in the 
DESIR cohort, among which HLA-B27 positivity and radiographic sacroiliitis on conventional 
radiography and inflammation on MRI are highlighted. This is reflected in the fact that in the 
DESIR cohort, 71.8% fulfil the ASAS axSpA classification criteria, compared with 35.0% in the 
SPACE cohort. In DESIR all patients included are of French origin, whereas the SPACE cohort 
recruits patients from three European countries (The Netherlands, Italy, Norway). Though there 
might not be a big disparity between the prevalence of axSpA and CBP in general between 
these countries, it is important to observe these results in two populations of a different origin.
Reliability of structural lesions remains a difficult issue and in a research setting often two 
or more well-calibrated readers are involved, which may cause difficulties translating this to 
clinical practice. So we should also be informed on the agreement between evaluation of MRI-
SI-s in clinical practice before this can be advocated for use in a clinical setting. A limitation 
of the study is the absence of a gold standard to assess structural changes in the SI joint, by 
means of CT.
Although the agreement regarding the presence/absence of radiographic sacroiliitis and the 
presence/absence of structural lesions on MRI in this study is only moderate, it is slightly 
better compared with the similar study in the DESIR cohort.1 In general, it is reassuring to 
see consistent findings in two independent cohorts with different (though well-trained) reader 
pairs. This increases confidence regarding the generalizability.
Although the research question has now been investigated in two cohorts, both cohorts include 
patients with short-standing back pain complaints and it would be very interesting to see 
replication of these findings in cohorts with advanced disease before possible far-reaching 
conclusions can be drawn on potentially changing ASAS axSpA classification criteria. The 
ideal cut-off could potentially be different in patients with longer symptom duration and more 
structural lesions in the SI joints. In general, more data are warranted on the prevalence of 
structural lesions in advanced disease, and it is beyond the scope of this study how lesions 
develop over time.
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Although the focus of this study is the impact of structural lesions on the ASAS axSpA 
classification criteria, we could speculate about possible implications for the diagnostic 
process. The modified Berlin algorithm advises that all patients suspected of axSpA should 
have a plain radiograph of the pelvis to check for sacroiliitis as a first step.13 In patients 
without evidence of radiological sacroiliitis in whom axSpA still is suspected, an MRI of the 
SI joints (assessed for inflammation only) may support a diagnosis of non-radiographic 
axial spondyloarthritis when inflammation is present. Our data suggest that there is no solid 
indication to change the strategy of first asking a pelvic radiograph, since the classification 
remains very similar when replacing pelvic X-rays by MRI-s. However, in young patients 
MRI can be obtained as an alternative to plain radiography. This is in line with the recently 
published EULAR recommendations.14 Similarly, if an MRI (STIR and T1 sequence) is present 
in a clinical setting, but there is no pelvic radiograph, this MRI may suffice and there is no 
reason to obtain radiographs.
A strength of the study is the intensive scoring process by two well-calibrated readers with an 
adjudication process in place, which adds to the reliability of our findings. Another strength of 
this study is the SPACE cohort itself. The SPACE cohort is one of early disease, and comprises 
a control group of (chronic) back pain patients, just as in daily practice where a distinction 
between axSpA and no-axSpA should be made in every patient presenting with a suspicion 
of axSpA.
In conclusion, our study has confirmed the earlier promising finding that the assessment of 
structural lesions on MRI instead of or in addition to conventional radiographs does not lead 
to a different ASAS axSpA classification in most of these patients with symptoms of an early 
disease onset.
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To investigate the value of repeating MRI of the sacroiliac joints (MRI-SI) in the diagnostic 
process of early chronic back pain patients (CBP) suspected of axial SpondyloArthritis 
(axSpA) and study determinants of MRI-SI-positivity. 
Methods 
Patients with CBP (duration: ≥3 months, ≤2 year, onset <45 years) with ≥1 SpA-feature 
included in the SPondyloArthritis Caught Early cohort underwent baseline, three months and 
one year visits with evaluation of all SpA-features and repeated MRI-SI. MRI-SI-positivity 
according to ASAS was assessed by two (or three) well-trained readers, blinded for clinical 
information. Factors determining MRI-SI-positivity over follow-up were calculated by GEE 
analysis. 
Results
Of the 188 patients (38.3% male, mean (SD) age 31.0 (8.2) years, symptom duration 13.2 (7.1) 
months), 31 (16.5%) were MRI-SI-positive at baseline. After three months and one year 3/27 
(11.1%) and 11/29 (37.9%) patients changed from MRI-SI positive to negative, respectively 
which was partly induced by the start of anti-TNF therapy. Changes from negative to positive 
were seen in 5/116 (4.3%) and 10/138 (7.2%) patients, respectively. HLA-B27-positivity and 
male gender independently determined the likelihood of a positive MRI at any time point 
(42% in HLA-B27+ men and 6% in HLA-B27- females). If the baseline MRI is negative, the 
likelihood of a positive MRI during follow-up is very low (max 7%).
Conclusions
MRI-SI ASAS status changes are seen in a minority of the patients. Both male gender and 
HLA-B27-positivity are important predictors of MRI-positivity. Repeating MRI after three 
months or one year in the diagnostic work-up in early disease is not useful.
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INTRODUCTION
In the diagnostic process of axial spondyloarthritis (axSpA), sacroiliac joint imaging plays a 
pivotal role.1 Conventional radiography has always been and still is the most commonly used 
method to detect sacroiliitis. However, it is known that radiographic abnormalities evolve 
over several years of time, which contributes to a reported delay of 8-9 years in diagnosis.2,3 
This substantial delay in diagnosis is problematic since effective treatments are available for 
patients with axSpA.4-6 Over the last decade, Magnetic Resonance Imaging (MRI) rapidly 
gained ground and proved to be an important imaging technique in the diagnostic process 
of (non-radiographic) axial spondyloarthritis.7 It has been shown that MRI can detect the early 
inflammatory stages of sacroiliitis, months to years before structural damage can be detected 
on a conventional radiograph.8,9 Besides the fact that MRI has substantial advantages in 
terms of sensitivity, MRI has the benefit of providing information on activity and structural 
damage by one imaging modality.10-12
Axial spondyloarthritis (axSpA) should be considered in patients with chronic back pain 
(CBP) with an onset before 45 years of age. Regrettably, no formal diagnostic criteria exist 
and there is no single SpA-feature with sufficient specificity to establish the diagnosis. The 
modified Berlin algorithm is a helpful tool for rheumatologists in establishing an early diagnosis 
of axSpA with greater confidence.1 According to this algorithm, MRI of the sacroiliac joints 
(MRI-SI) should be performed in a certain group of patients after obtaining conventional 
radiographs and HLA-B27 testing.13 The more recently published EULAR recommendations 
on imaging in SpA even state that in certain cases, such as young patients and those with 
short symptom duration, MRI of the SI-joints is an alternative first imaging method.14
Although inflammation on MRI is now widely considered as an important manifestation in 
early axSpA, not much evidence is available on how inflammatory lesions develop over time 
(outside clinical trials).15,16 Though, with the augmented interest of MRI in the early diagnosis 
of axSpA this is important. We do know that inflammatory lesions (bone marrow edema, 
BME) can change over relatively short periods of time in patients diagnosed with SpA. But in 
patients with CBP and with a suspicion of axSpA, it is unclear if BME-lesions newly develop 
or fluctuate over time. For example, a relevant clinical question is if an MRI is completely 
normal and there is still a clinical suspicion of axSpA, should the MRI be repeated? And if 
so, after what period of follow-up? Or does this not contribute to the diagnostic process? The 
SPondyloArthritis Caught Early (SPACE) cohort is an ideal cohort to investigate this research 
question since it includes a population of patients with back pain of short duration referred 
to rheumatologists with a suspicion of SpA (but without the mandatory presence of a single 
or multiple SpA-features). With this study, we aim to investigate the evolution of MRI-lesions 
over a 3-month and 1-year time frame in the SPACE-cohort. 
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METHODS
Study design and patient population
SPACE is a multi-national ongoing cohort study, started in January 2009. Across five 
participating centres in Europe, patients with chronic back pain (≥3 months, ≤2 years, onset 
<45 years; aged 16 years and older) are included. Before start of the study, approval was 
obtained by the local medical ethics committees. Before inclusion, written informed consent 
was obtained from all patients in accordance with the Declaration of Helsinki. A detailed 
description of the SPACE cohort has been given elsewhere.17 All patients underwent a 
diagnostic work-up at baseline. This includes a physical examination, MRI and radiographs 
of the SI-joints (MRI-SI, X-SI respectively), HLA-B27 testing and examination of all other 
SpA-features.13,18 Patients fulfilling the Assessment of SpondyloArthritis international Society 
(ASAS) axSpA-criteria at baseline or patients with possible axSpA (i.e. the presence of SpA-
features though not sufficient to be classified as axSpA, defined as the presence of ≥1 SpA-
feature) were included for follow-up visits. At three months and 1-year follow-up, clinical and 
laboratory data were again collected and another MRI-SI was performed. It was considered 
arbitrarily that three month MRI data of about 150 patients was sufficient to answer the 
question about the change over three months and therefore decided to leave out the three 
month MRI in the patients included in the cohort after July 2012. 
Imaging and scoring methodology 
MRI-SIs were performed on a 1.5 Tesla MRI-scanner at baseline and follow-up. Coronal 
oblique MRI images were obtained, with a slice thickness of 4 millimetres. Both short tau 
inversion recovery (STIR) and T1 weighted turbo spin echo (T1TSE) sequences were 
acquired and evaluated in the scoring process. At baseline, conventional radiographs of 
the pelvis (sacroiliac joints) in anterior-posterior view (X-SI) were performed. MRI-SIs and 
X-SIs were scored independently by two trained and well-calibrated readers, blinded for 
patient characteristics, clinical data, time sequence and the other imaging modality. In case 
of discrepancy on dichotomous scores a third reader scored the images (see below for 
details).
A radiograph was marked positive for sacroiliitis according to the fulfilment of the modified 
New York (mNY) criteria: at least bilateral grade 2 sacroiliitis or at least unilateral grade 3 
sacroiliitis was mandatory.19 According to the ASAS definition for a positive MRI, an MRI-SI 
was marked positive if ≥1 bone marrow edema (BME) lesion highly suggestive of SpA was 
present on ≥2 consecutive slices or if several BME lesions highly suggestive of SpA are visible 
on a single slice.7,18 MRIs were also scored according to the SPondyloArthritis Research 
Consortium of Canada (SPARCC) score which measures inflammation on a continuous 
8
133Repeating MRI in the diagnostic process 
scale (range: 0-72).20 According to the SPARCC score, the presence of increased signal 
corresponding to BME lesions is marked on 6 consecutive slices of an MRI-SI. The maximum 
score for two SI-joints on each slice is 8. In addition to these 8 points per slice, a score for 
intensity (adding 1 point) may be assigned to each SI-joint if a so-called intense signal is 
seen in any quadrant on each slice. The signal from pre-sacral blood vessels defined a 
lesion that is scored as intense. Further, a score for depth (adding 1 point) may be assigned 
to each SI-joint if a homogeneous and unequivocal increase in signal is extending over a 
depth of at least 1 cm from the articular surface on each slice, resulting in a maximum score 
of 12 points per slice. For assessment of both the ASAS definition and the SPARCC score 
on the STIR sequence, the readers took into account the findings on the T1TSE sequences, 
looking at both sequences simultaneously.  
In case of disagreement on the presence of radiographic sacroiliitis (mNY) or a positive MRI 
(ASAS-definition) amongst the two initial readers, a third reader served as adjudicator (final 
score: two out of three agreeing readers). The SPARCC scores of the two agreeing readers 
on a positive MRI were used for further analysis.
Statistical methods
Disease characteristics of patients were presented using descriptive statistics. Then, we 
described the MRI-SI ASAS-status over time in different ways. First, by depicting the course 
of MRI-SI ASAS status at the (two or three) available time points and second, by means of a 
two-by-tow table reflecting changes in MRI ASAS-status (positive-negative). Agreement on 
the absence or presence of MRI-SI ASAS inflammation was assessed by cross-tabulation and 
expressed as Cohen’s kappa. Cumulative probability plots were used to visualize baseline 
and 1 year-SPARCC-scores in which patients were grouped according to either positivity or 
negativity according to the ASAS-definition. Subsequently, patients of special interest, i.e. in 
which the MRI changed from positive to negative or vice versa after three months and one-
year follow-up, were described phenotypically: according to the presence of SpA-features 
and other disease characteristics. Thereafter, we investigated the likelihood of having a 
positive MRI at any time point during follow-up and identified which factors determine MRI-SI 
ASAS-positivity. After the analysis for the whole group of patients, we repeated this analysis 
in the subset of patients that have IBP according to the ASAS definition. Subsequently, we 
looked at the likelihood of having a positive MRI in the follow-up time points (3 months or 
1 year), taking into account the baseline MRI (positive vs negative), first in all patients and 
secondly in the subgroup of patients with IBP. This was done by using generalised estimated 
equation (GEE) analysis for binomial outcome variables: MRI ASAS status was defined as 
the dependent variable, HLA-B27 and gender being independent explanatory variables. 
CRP was added to the model as a covariate, in order to assess the contribution of CRP 
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in explaining a positive MRI. The likelihood of finding a positive MRI if the baseline MRI is 
either positive or negative was calculated, taking into account HLA-B27 status and gender. 
Odds ratios from the model were converted into probabilities (likelihood).21 Data analysis was 
performed using Stata SE v. 14 software (StataCorp LP, College Station), TX, USA).
RESULTS
Patient characteristics 
In total, 188 patients were included in the current study. Baseline characteristics were 
described in Table 1. The mean age of the included patients was 31.0 years (SD 8.2 years) 
and 38.3% were male. The mean symptom duration of back pain was 13.2 months (SD 
7.1 months) and 139 patients (74.3%) had inflammatory back pain according to the ASAS 
criteria definition. Almost half of the patients (48.4 %) were HLA-B27 positive. 
Table 1: Baseline characteristics
 Total number (n=188)
Age (years) at inclusion, mean (SD) 31.0 (8.2)
Male, n (%) 72 (38.3%)
Symptom duration (months) at first visit, mean (SD) 13.2 (7.1)
Good response to NSAIDs, n (%) 76 (41.3%)
IBP, n (%) 139 (74.3%)
Positive family history SpA, n (%) 96 (51.3%)
Peripheral arthritis, n (%) 34 (18.2%)
Dactylitis, n (%) 15 (8.0%)
Enthesitis, n (%) 41 (21.9%)
Uveitis, n (%) 16 (8.6%)
IBD, n (%) 17 (9.1%)
Psoriasis, n (%) 25 (13.4%)
Elevated CRP, n (%) 35 (18.9%)
HLA-B27 positive, n (%) 91 (48.4%)
Sacroiliitis present on radiograph, n (%) 19 (11.1%)
Positive MRI (ASAS definition), n (%) 31 (16.5%)
Diagnosis axSpA according to rheumatologist, n (%)* 74 (39.6%)
ASAS, Assessment of SpondyloArthritis; axSpA, axial spondyloarthritis; CRP, C-reactive protein; 
HLA-B27, human leukocyte antigen-B27; IBD, inflammatory bowel disease; IBP, inflammatory back pain; 
MRI, magnetic resonance imaging; NSAIDs, non-steroidal anti-inflammatory drugs.
*Confidence level ≥7 (NRS 0-10). 
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MRI findings
Agreement between the two readers regarding the definition of a positive MRI-SI according 
to the ASAS definition was good: kappa 0.85. In 8 of the 188 cases (4.3%) adjudication was 
needed since reader 1 and reader 2 were in disagreement on the MRI-SI ASAS status. 
The course of MRI-SI ASAS positivity over time is visualised in Table 2. In 122 out of 188 
patients, all three time points were available: baseline, three months and one-year follow-
up. In 66 out of 188 patients, MRI was performed at two time points: in 21/66 patients at 
baseline and three months’ follow-up and in 45/66 patients at baseline and one-year follow-
up. In all three scenarios mentioned above, the vast majority of patients 77.1% (145/188) 
had a negative MRI according to the ASAS definition at baseline which did not change at the 
follow-up time point(s) (triple/double-negative). In patients with all three time points available, 
persistence of a positive MRI was seen in (15/122) 12.3% of the patients (triple-positive) and 
(21/122) 17.2% of the patients showed MRI fluctuations over time (for instance: 0-0-1; 1-1-0; 
0-1-1 etcetera). 
Table 2: Course of MRI-SI ASAS positivity over one-year time
MRI-SI ASAS definition over time Number of patients
Patients with MRI-SI available 










Patients with MRI-SI available





Patients with MRI-SI available





*0=MRI ASAS negative; 1 = MRI ASAS positive; cases with all three time points available (a), cases with 
baseline & 3 months available (b) and cases with 3 months & 1 year available (c).
MRI-SI, magnetic resonance imaging of the sacroiliac joints; ASAS, Assessment of SpondyloArthritis 
international Society.
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Changes in MRI-SI ASAS-status over time are depicted in another way by means of a two-
by-two table (Table 3). In contrast to Table 2, data are clustered, shown independently of 
the availability of the third time point. The upper part of the table reflects changes over three 
months and changes over one-year time are shown in the lower part of the table. In 8 out of 
143 patients (5.6%) a change in MRI-SI ASAS status was seen after three months’ follow-up. 
After a year follow-up, the percentage with a change in MRI-SI status was slightly higher: 
12.6% (21/167). The MRI of 10 of 138 patients (7.2%) turned from negative to positive after 
one year follow-up (compared to 5/116 (4.3%) patients after three months) and on the other 
hand, 11 out of 29 (37.9%) patients with a positive MRI-SI ASAS at baseline were negative 
after one year of follow-up (compared to 3/27 (11.1%) patients after three months). Thus, 
relatively more patients become negative in comparison to patients that develop a positive 
MRI. To visualise the amount of BME, cumulative probability plots for each of the readers, 
of baseline and 1 year-SPARCC-scores in which patients were grouped according to either 
positivity or negativity according to the ASAS-definition are given in Supplementary Figure 
1a and b.
Table 3: Changes in MRI-SI ASAS positivity over three months and one-year time
MRI 3 months ASAS positive MRI 3 months ASAS negative Total
MRI baseline positive 24  3 27
MRI baseline negative 5 111 116
Total 29 114 143
MRI 1 year ASAS positive MRI 1 year ASAS negative Total
MRI baseline positive 18 11 29
MRI baseline negative 10 128 138
Total 28 139 167
MRI, magnetic resonance imaging; ASAS, Assessment of SpondyloArthritis international Society.
With special interest, we reviewed the patients with a change in MRI-SI-ASAS status; their 
disease characteristics are depicted in Table 4. Three of the five patients that turned ASAS 
MRI-positive after three months (Table 4, orange cells) were male (60%) and three patients 
(60%) were HLA-B27 positive. One patient had sacroiliitis on radiographs (mNY-criteria) 
at baseline. After three months, two patients developed a new SpA-feature, namely good 
response on NSAIDs. One patient used NSAIDs on baseline, whilst three (60%) after three 
months. All three patients with an initial positive MRI according to the ASAS definition that 
turned negative (Table 4, blue cells) were on NSAID treatment from baseline, were men and 
HLA-B27 positive. 
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Of the 10 newly MRI-SI positive patients at one-year follow-up (Table 4, green cells) 5 
patients were male (50%) and the majority (n=8, 80%) was HLA-B27 positive. Sacroiliitis 
on radiographs (mNY criteria at baseline) was present in 30% of the patients (3/10). Two 
patients developed new SpA-feature(s) over one-year time, which were not yet present at 
baseline (patient 10: good response on NSAIDs, patient 16: good response on NSAIDs, 
inflammatory back pain and dactylitis). All 10 patients used NSAIDs after one-year follow-up 
(50% at baseline) and there were no patients on anti-TNF treatment in this group. Of the 11 
patients that started with a positive baseline MRI, which became negative at one year (Table 
4, red cells), the majority was male (n=7, 64%) and HLA-B27 (n=8, 73%) and developed new 
SpA features (n=6, 55%). Four patients had started anti-TNF therapy and one patient started 
an NSAID. 
SPARCC scores are depicted in the last column of Table 4. Overall, when comparing SPARCC 
scores between the two different readers, only modest differences are seen, which implies 
a high level of agreement. Reviewing patients becoming newly ASAS positive (after three 
months or one year: Table 4, orange and green cells), half of the patients become marginally 
positive in terms of SPARCC scores whilst other patients become evidently positive with a 
marked raise in SPARCC scores up to 18. After one year, patients that were initially ASAS 
positive but became negative over time (Table 4, red cells) had mostly low SPARCC scores 
except those that have been treated (patients were treated according to clinical practice). 
Four patients were on anti-TNF therapy which showed an important decrease in SPARCC-
scores at one-year follow-up. 
Factors determining a positive MRI 
According to the GEE analysis, both HLA-B27 positivity (OR: 2.36, 95% CI: 1.09-5.12, p=0.029) 
and male gender (OR: 5.63, 95% CI: 2.58-12.27, p<0.001) independently determined the 
likelihood of a positive MRI at any time point. 
Figure 1 displays the effects of HLA-B27 and sex in an absolute manner. The likelihood 
of a positive MRI in HLA-B27 negative women with CBP is only 7%, whereas in HLA-B27 
positive men this is 43.0% (HLA-B27 positive women: 6%, HLA-B27 negative men: 14%). In 
men, HLA-B27 positivity or -negativity has a significant effect on the likelihood of having a 
positive MRI at any time point (OR: 4.54, 95% CI: 1.50-13.79, p=0.008) whereas this effect 
was not present in women (OR: 0.84, 95% CI: 0.23-3.12, p=0.800). Influences of CRP were 
investigated in all models, but correcting for CRP had only very minor influence. Therefore, 
data uncorrected for CRP are shown. Only minor differences were seen between patients 
with CBP and IBP according to the ASAS definition (data not shown). 
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Likelihood of a positive MRI during follow-up 
The likelihood of finding a positive MRI at 3 months or 1 year according to the baseline MRI 
status (either positive or negative) was considered. Both HLA-B27 status (OR: 2.41, 95% CI: 
0.94-6.18, p=0.067) and MRI baseline status (OR: 43.89, 95% CI: 17.59-109.52, p<0.001) 
were independently contributory to a positive MRI at follow-up. This analysis was repeated 
with sex instead of HLA-B27 status: both sex (OR: 2.54, 95% CI: 1.01-6.39, p=0.048) and MRI 
baseline status (OR: 36.04, 95% CI: 14.42-90.08, p<0.001) appeared to be independently 
contributory to a positive MRI over time. Again, only minor changes were seen between CBP 
and IBP patients, not reaching significance (data not shown). 
In Figure 2, the likelihood of a positive MRI in relation to baseline MRI and HLA-B27 status (a) 
and sex (b) is visualized. In an HLA-B27 negative patient with a negative baseline MRI, the 
likelihood of a positive MRI at follow-up is negligible (1.5%). On the contrary, in an HLA-B27 
positive patient with a positive baseline MRI-SI, the likelihood is rather high: 73%. In patients 
with a positive MRI on baseline, HLA-B27 status does not influence the likelihood of a positive 
MRI at any follow-up time point (OR: 0.65, 95% CI: 0.14-2.96, p=0.582). However, in MRI 
baseline negative patients, HLA-B27 positivity or negativity has a significant effect on the 
likelihood of a positive MRI at follow-up (OR: 8.12, 95% CI: 1.65-40.11, p=0.010). 
Figure 1: Likelihood of a positive MRI at any time point in CBP patients investigated at baseline, 
3 months and 1-year follow-up in the subgroups of patients according to HLA-B27 status and 
gender
HLA-B27, human leukocyte antigen B27.
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For sex, in a male or female patient with a positive baseline MRI the likelihood of having a 
positive MRI at 3 months or 1 year follow-up is 75%, whereas it is only 2.8% in a female patient 
with a negative baseline MRI and 12% in a male patient with a negative MRI at baseline. In 
patients with a negative baseline MRI, there is a significant effect of sex (OR: 4.67, 95% CI: 
1.41-15.44, p=0.01) while this is absent in patients with a positive MRI on baseline (OR: 0.96, 
95% CI: 0.20-4.54, p=0.959). 
As an example, MRI-SIs of patients with an ASAS status change over 1 year time are 
depicted in Supplementary Figure 2: two patients being MRI-SI ASAS positive at baseline, 
but negative after 1 year (a) and two patients being MRI-SI ASAS negative at baseline, but 
positive after 1 year (b).
Figure 2: Likelihood of a positive MRI at three months or 1-year follow-up in CBP patients, in 
the subgroups of patients according to the result of the baseline MRI (negative or positive) and 
HLA-B27 status (a) or sex (b)
HLA-B27, human leukocyte antigen B27; BL, baseline.
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DISCUSSION
In this study of patients with chronic back pain suspicious for axial SpA, 83.5% of the patients 
(157/188) had a negative MRI at baseline. Of these patients, only (12/157) 7.6 % had a 
positive MRI at any follow-up time point. Twelve of the 31 patients (38.7% ) with a positive MRI 
at baseline had a negative MRI at any follow-up time point. Although changes are visible in 
both directions, relatively more patients become negative (4.3% after three months and 7.2% 
after one year) than positive (11.1% after 3 months and 37.9% after one year). Nevertheless, 
it is important to realise that 36% of the patients that became negative after one year started 
anti-TNF therapy, which is known to decrease inflammation in the sacroiliac joints visible on 
MRI.16
This study showed that MRI status at baseline appeared to be strongly influencing the chance 
of having a positive MRI of the sacroiliac joints at follow-up. If the baseline MRI is positive, the 
likelihood that the MRI will be positive again at three months or one year is very high (75%). 
The usefulness of repeating a negative MRI in terms of diagnostic yield is low, but there are 
different risks related to sex and HLA-B27 status.
In baseline MRI negative patients, HLA-B27 status has a significant effect on the likelihood 
of a positive MRI at follow-up. In HLA-B27 negative patients with a negative MRI at baseline, 
sacroiliitis at follow-up can be excluded with a high level of confidence. The likelihood of 
a positive MRI at follow-up is only 1.5%. In HLA-B27 positive patients with a negative MRI 
at baseline, the likelihood of a positive MRI at three months or one year is still low, though 
somewhat higher (namely 11%). Of course, we can debate on the clinical relevance of this 
small difference in terms of percentage and, in general, chances of MRI positivity at follow-up 
are very low when the baseline MRI is negative. But, if a clinical suspicion about the diagnosis 
axial spondyloarthritis remains (for example a patient develops other SpA features) it might 
be worthwhile to consider re-doing an MRI in HLA-B27 positive patients. Likewise, there is a 
statistically significant difference between male and female patients with a negative baseline 
MRI, namely that in male patients more often a positive MRI at follow-up is seen (difference: 
12% in men, 3% in women). Of course, interpretation of MRI findings should always be 
determined in the context of all clinical, laboratory and other imaging parameters available, 
for example other SpA-features that enhance diagnostic confidence. Also, other findings 
on MRI (for example the presence of structural lesions) can be supportive in the diagnostic 
process. However, in this group of patients with short symptom duration, the frequency of 
structural changes in SI-joints is relatively low and only discriminates between patients with 
and without axial SpA if at least 5 structural lesions (especially erosions and fatty lesions) are 
present.11 This indicates that at this phase of the disease, BME is the most important feature. 
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Van Onna et al. performed a two-year follow-up study, which observed MRI status changes 
in 15% of the patients with recent-onset inflammatory back pain (IBP) that can be seen as 
relatively similar to our data, although follow-up time is considerably shorter in our study.22 
On the other hand, in our study substantially more patients are included and two validated 
scoring methods are used. Like in our study, in the study by van Onna et al. relatively more 
patients became negative in comparison to patients that developed a positive MRI over time: 
30% became negative (while positive at baseline) and 15% became positive (while negative 
at baseline) at one or two years follow-up. They also found that male gender and HLA-B27 
positivity were predictive of a positive MRI-SI at follow up. In our study too, male gender and 
HLA-B27 positivity determined independently the likelihood of a positive MRI at any time point. 
HLA-B27 positive male patients with chronic back pain, have the highest chance of a positive 
MRI at any time. Other studies have investigated the natural history of MRI-determined BME in 
individuals with suspected axSpA as well. Sengupta et al. concluded that in patients fulfilling 
the ASAS IBP criteria repeat MRI scans within a 12-week period should only be considered 
in HLA-B27 positive males; since there were no HLA-B27-negative patients changed from 
MRI-negative to –positive in this study. Although this was a considerably smaller group of 
patients, data are in line with our findings that HLA-B27 positivity determines the likelihood of 
a positive MRI.23 Marzo-Ortega et al. also reported a higher chance of a positive MRI at one 
year in early, untreated IBP patients being HLA-B27 positive.24 
Regarding sex differences, historically ankylosing spondylitis (AS) was considered as a 
predominantly male disease, but it has been reported that 46% of the patients diagnosed since 
1990 were female compared to 10% in 1960.25 This suggests that the male predominance 
in AS and axSpA may be (at least in part) induced by missing the diagnosis of AS among 
women in earlier times and more data become available that the percentage female patients 
with non-radiographic axial SpA and AS is substantial. Another reason for the higher male/
female ratio in AS may be that men develop more often radiographic sacroiliitis compared 
to females. This is also in line with our findings that male patients are more likely to have a 
positive MRI at any time point, as a positive MRI is a predictor of development of radiographic 
sacroiliitis.9
Another issue is timing: when to re-do an MRI in case of persistent axSpA suspicion and 
after what period of follow-up. With this study, we looked at both three months and one-
year follow-up, and at both time points the additional value is very limited. Given the low 
diagnostic yield, taking costs and feasibility into account, repeating an MRI after 3 months or 
1 year should not be performed routinely. Two-year data on the SPACE cohort will become 
available in the future, which will provide information on a longer interval. 
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In general, MRI has become an important tool in the evaluation of patients with axSpA 
and relevant improvements in the field have taken place: such as the standardization of 
imaging protocols, and the development and validation of standardized descriptions of 
lesions. These lesions include not only inflammatory lesions, but also structural lesions: by 
means of fatty lesions, erosions, sclerosis and ankylosis. MRI has the unique potential of 
visualizing both inflammatory and structural lesions by means of one imaging technique and 
it is hypothesized that structural lesions could enhance sensitivity and/or specificity which 
could be helpful when in diagnostic doubts. Research on the incremental value of structural 
lesions is ongoing. 
Looking at methodological aspects, the fact that we have repeated MRI in all patients 
irrespective of the diagnosis is an important strength of our study compared to studies 
doing this in a selected population of patients. Moreover, the follow-up is quite complete 
avoiding unintentional bias in leaving out patients with a low likelihood of axial SpA. Another 
strength of our study is our scoring process with two readers with adjudication in case of 
discrepancy, which adds to the credibility of the findings. Moreover, the fact that we used 
two well-validated scoring methods (ASAS and SPARCC) provides additional insight. On the 
other hand, limitations of the current study are the limited duration of follow-up and the fact 
that we could not compare these findings with an external standard. Diagnosis is influenced 
by MRI findings and would lead to circular reasoning. Moreover, we lack another imaging 
technique like low-dose CT or histology. Prospective evaluation over a sufficient time frame 
with a longer follow-up should enhance confidence in the diagnosis of this sometimes slowly 
evolving disease. 
In conclusion, MRI-SI ASAS status changes are seen in a minority of the patients of the 
SPACE cohort and both changes from negative to positive and from positive to negative 
occur. Especially a very small percentage of patients become positive (4.3% and 7.2% after 
three months and one year, respectively), which indicates that the usefulness of repeating 
an MRI-SI in the diagnostic process after three months or one year is very limited. Relatively 
more patients become negative (37.9% after one year) and one should realize that resolution 
of inflammation is partly induced by the use of anti-TNF therapy. Male gender and HLA-B27 
positivity determine independently the likelihood of a positive MRI at any time point, while 
MRI-SI status at baseline strongly predicts MRI-SI status at follow-up. 
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Supplementary Figure 1a: Cumulative probability plot of baseline and 1 year-SPARCC-scores in 
which patients were grouped according to either positivity or negativity according to the ASAS-
definition – reader 1
ASAS, Assessment of SpondyloArthritis; axSpA, axial spondyloarthritis; BL, baseline; SPARCC, 
SPondyloArthritis Research Consortium of Canada.
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Supplementary Figure 1b: Cumulative probability plot of baseline and 1 year-SPARCC-scores in 
which patients were grouped according to either positivity or negativity according to the ASAS-
definition – reader 2
ASAS, Assessment of SpondyloArthritis; axSpA, axial spondyloarthritis; BL, baseline; SPARCC, 































































































































































































































































































































































The HLA-B27+/HLA-B*4001+ high risk 
ankylosing spondylitis genotype in 
early back pain patients suspected of 
axial spondyloarthritis: prevalence 








Désirée van der Heijde






HLA-B27 accounts for only a small part of the genetic risk for axSpA. Earlier studies have 
shown that the HLA-B27+/HLA-B*4001+ genotype has a high specificity for AS. Prevalence 
of this genotype was assessed in two cohorts of patients with chronic back pain suspected 
of axSpA. 
Methods
Patients from the DESIR- (inflammatory back pain: ≥3 months, ≤3 years, age<50 years) and 
SPACE-cohort (back pain: ≥3months, ≤2 years, onset<45 years) were included as cases. 
Randomly selected healthy blood-bank donors from the Netherlands and France were used 
as controls. After DNA isolation from whole blood samples, a total of 854 patients (DESIR: 
582; SPACE: 272) and 15761 controls (France: 10177; Netherlands: 5584) were genotyped 
for the presence of HLA-B27 and HLA-B*4001. 
Results
The HLA-B27+/HLA-B*4001+ genotype was significantly more common in early back pain 
patients (DESIR 3.3% and SPACE 4.8%) than in controls (0.4% in both cohorts, p<0.001). 
HLA-B27+/HLA-B*4001+ patients showed a high percentage of radiographic sacroiliitis 
(DESIR 42% and SPACE 15% but were relatively similar to HLA-B27+/HLA-B*4001- back pain 
patients in terms of radiographic sacroiliitis (DESIR 27.6% and 16.5%) and to a lesser extent 
sacroiliitis on MRI. While comparing the mean number of SpA-features (surrogate for an 
increased likelihood of axSpA) no differences were seen between HLA-B27+/HLA-B*4001+ 
(DESIR: 2.6, SPACE: 3) and HLA-B27+/HLA-B*4001- (DESIR: 2.7, SPACE: 3.2) patients.
Conclusions
The HLA-B27/HLA-B*4001 high risk genotype was common in early back pain patients 
suspected of axSpA but as HLA-B27+/HLA-B*4001+ patients were similar to HLA-B27+/
HLA-B*4001- patients our results suggest that combined testing for HLA-B27 and HLA-B*4001 
has no added value in the early detection of axSpA.
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INTRODUCTION
Susceptibility to ankylosing spondylitis (AS) is largely due to genetic factors. More than 
fifty years ago, the tendency of AS to recur within families was documented.1 By means of 
family aggregation studies, it is estimated that genetic risk factors contribute to 80-90% of 
the susceptibility to AS. This is supported by studies, which have shown that concordance 
rates in monozygotic (50-75%) twins and dizygotic twins (15%) are markedly higher than the 
disease risk in the population at large.2,3
HLA-B27 (a major histocompatibility class (MHC) I molecule) is known to be the major genetic 
risk factor for AS. The association with the HLA-B27 gene was recognized 40 years ago and 
since then HLA-B27 is the strongest known risk factor for the disease.4-6 However, only 5-6% 
of the HLA-B27 positive people in the general population will develop spondyloarthritis7  and 
the overall contribution of HLA-B27 to AS heritability is estimated at 23.3%.8 This suggests 
that HLA-B27 by itself is not sufficient for development of the disease, supporting the 
contribution of additional genes. In recent history, several large genome-wide association 
studies (GWAS) have been carried out, leading to the discovery of many new genetic risk 
factors.  
Currently, over 30 genetic loci (both inside and outside the MHC) have been described 
to be operative in AS susceptibility. Within the MHC complex HLA-B*4001 (an allele that 
corresponds to HLA-B60 at the serological or protein level) is identified to be another genetic 
risk factor for AS. HLA-B60 was shown to be increased in HLA-B27 positive AS patients in 
five independent data sets in 1989.9 More recently, this association was confirmed in the UK, 
the Netherlands and in Taiwan.10-12 In 2013, epistasis between HLA-B27 and HLA-B*4001 
has been reported to associate with increased risk of AS in Caucasians, with a very high 
relative excess risk. 11 The epistatic interaction is not reproduced in all studies, but the high 
specificity of the combined genotype was found in all three previously mentioned studies 
(sensitivity:  10.1%, 18.2%, 18.7%, specificity: 99.7%, 99.6%, 98.7%).10-12
Axial SpondyloArthritis (axSpA) is an umbrella term for a group of rheumatic diseases 
characterised by inflammation of the axial skeleton: sacroiliac (SI) joints and vertebral 
column. An important differentiation is made between radiographic axSpA (r-axSpA) 
and non-radiographic axSpA (nr-axSpA). In r-axSpA, sacroiliitis is visible on x-rays of the 
sacroiliac (SI) joints and the corresponding modified New York (mNY) criteria for AS are 
often used in studies and drug trials. But, axSpA can also be present in patients without 
radiographic changes but with active sacroiliitis being present on MRI (nr-axSpA). Axial SpA 
is a relatively uncommon disease (r-axSpA has an estimated pooled prevalence between 
0.02%-0.35%, variation in reported prevalence estimates around the world)13 presenting 
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with a very common complaint: 60-80% of the general population report back pain at some 
point in their lives.14 As the clinical presentation of axSpA is heterogeneous and no single 
unique feature exists to identify axSpA from patients with back pain due to other causes, 
early diagnosis of axSpA is challenging.15 In recent cohort studies of back pain patients at 
increased risk of axSpA have been set up to follow these patients prospectively over time. 
There is a potential role for biomarkers to assist in the diagnostic process of axial SpA, 
including genetic diagnostic tests. As previously mentioned, the combined HLA-B27+/
HLA-B*4001+ genotype has been shown to be very specific for AS. However, this has only 
been investigated in late stage AS patients. The aim of this study is to assess the added 
value of HLA-B27/HLA-B*4001 in the detection of early axSpA. Therefore, we study the 
prevalence of the HLA-B27+/HLA-B*4001+ in two unique cohorts of patients with early back 
pain suspected of axSpA and studied the correlation of the genotype with other SpA-features. 
METHODS
Patients and controls
Patients from the DEvenir des Spondyloarthrites Indifférenciées Récentes (DESIR) cohort 
and SPondyloArthritis Caught Early (SPACE) cohort were included as cases. Both cohorts 
are described extensively elsewhere.16,17 DESIR is a longitudinal cohort study, with patients 
included from 25 participating centres in France. Patients (aged >18 years and <50 years) 
with inflammatory back pain (IBP) with a duration of ≥3 months but <3 years are included in 
the study. IBP was defined according to either the Calin or the Berlin criteria.18,19 Patients were 
only included in the cohort if the treating rheumatologist had a suspicion of axSpA defined as 
a score of ≥5 on a 0-10 scale (0: not suggestive of axSpA and 10: very suggestive of axSpA). 
The database for the baseline data used for this analysis was locked on 30 October 2012. 
In contrast to the DESIR-cohort that includes only patients with IBP, the SPACE-cohort 
includes patients with chronic back pain (of a short duration (≥3 months but ≤ 2 years, onset 
<45 years). SPACE is an on-going inception cohort and patients are recruited in several 
centres across Europe and data from the following four participating centres were included 
in the current analysis: the Netherlands (Leiden, Gouda), Norway (Oslo) and Italy (Padua). 
Both studies fulfilled Good Clinical Practice (GCP) Guidelines and were approved by local 
medical ethical committees in all participating centres. Before inclusion, written informed 
consent was obtained from all patients. 
Two control groups were used as a comparison. HLA-B typing from randomly selected, 
unrelated, healthy blood bank donors from the Netherlands11 were used as controls for the 
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SPACE cohort and blood bank donors from France were used as controls for the DESIR 
cohort.
Diagnostic work-up
Patients in the SPACE and DESIR cohort underwent a full diagnostic work-up at baseline 
including MRI and conventional radiographs of the sacroiliac joints, and the assessment 
of all other SpA-features, in agreement with descriptions provided by the Assessment of 
SpondyloArthritis international Society (ASAS).20 To define a patient as having ankylosing 
spondylitis, fulfilment of the modified mNY criteria is mandatory.21 Radiographic sacroiliitis 
according to the mNY criteria was defined as bilateral grade ≥2 or unilateral ≥3. MRIs of 
the sacroiliac joints (MRI-SI) were considered positive according to the ASAS definition for 
a positive MRI.22,23 Both radiographs and MRIs were reviewed by two experienced central 
readers per cohort, blinded for clinical data and the other imaging modality. In case of 
disagreement on mNY- or MRI-SI ASAS-positivity between the two initial readers, a third 
reader served as adjudicator. Images were marked positive if two out of three readers agreed.
DNA isolation and genotyping
HLA-B27 and HLA-B*4001 genotype data were collected from both patients and healthy 
controls. HLA-B27 typing was performed with sequence-specific primers on genomic DNA 
with real-time polymerase chain reaction using SYBR Green. In a total volume of 5 µl 10 ng, 
gDNA was mixed with 2.5 µL of SYBR Select Master Mix (ThermoFisher Scientific, Breda, The 
Netherlands),  and 0.05 µL of a 100 nM primer solution mix was added. Primermix consists of 
both forward primer (5′-GCT ACG TGG ACG ACA CGC T) and reverse primer (5′-GCG CCC 
GCG GCT CCT CT). All reactions take place in a 384-well micro-plate and was measured 
by a CFX-384 ThermoCycler (Biorad Laboratories) with the following protocol: 95.0°C for 3 
min followed by 40 amplification cycles (95.0°C for 0:05; 66.8°C for 0:10); standard melting 
curves.24 Fluorescence data were analysed by CFX Manager Software Version 3.1 (Bio-Rad). 
For HLA-B*4001 two separate PCRs are used with the same PCR reaction mix as HLA-B27. 
PCR1: forward primer (5’-AGA TCT CCC AGC GCA AGT T) and reverse primer (5’- TCA GCG 
CGC TCC AGC TTG) with the following protocol: 95.0°C for 3 min followed by 40 amplification 
cycles (95.0°C for 0:05; 60.7°C for 0:10); standard melting curves.PCR2: forward primer 
(5’- GGG AGC CCC GCT TCA TCA CC) and reverse primer (5’-GGC TCC TTC CTC GGA 
CTC GT) with the following protocol: 95.0°C for 3 min followed by 40 amplification cycles 
(95.0°C for 0:05; 61.3°C for 0:10); standard melting curves. In blood donors who served as 
controls, HLA-AB typing was performed using PCR with sequence specific primers (SSP) 
using commercially available kits.25
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Statistical analysis
Associations with the high-risk genotype were calculated for patients in both cohorts versus 
controls. Therefore, patients and controls were categorised into four strata based on both 
HLA-B27 and HLA-B*4001 positivity or negativity in a 4 by 2 table. With the disease risk in the 
HLA-B27-/HLA-B*4001- stratum in patients and controls as a reference (1), odds ratios for 
the risk of disease were calculated for the three remaining strata: HLA-B27+/HLA-B*4001+, 
HLA-B27+/HLA-B*4001-, HLA-B27-/HLA-B*4001+. For patients stratified by HLA-B typing, 
disease characteristics were calculated using descriptive statistics. Thereafter, the clinical 
phenotype of the non-AS patients with the HLA-B27+/HLA-B*4001+ genotype present was 
described, mainly evaluating the SpA-features present. The analyses were performed in 
STATA 12.0. 
RESULTS
A total of 16615 subjects were analysed: 854 patients with chronic back pain suspected of 
having axSpA (DESIR: 582, SPACE: 272) and 15761 controls (living in France: 10177, living 
in the Netherlands: 5584). 
First, we investigated the presence of the HLA-B27+/HLA-B*4001+ genotype in the two 
cohorts (results are depicted in Table 1). In DESIR, the HLA-B27+/HLA-B*4001+ genotype 
was present in 3.3% (n=19) of the patients and in 0.4% of the controls (odds ratio (OR) 
9.5; 95% confidence interval (CI) 5.4-16.7; p<0.0001). In SPACE, the high-risk genotype 
was found in 4.8% of patients (n=13) and in 0.4% of controls (OR 12.7; 95% CI 6.3-25.5; 
p<0.0001). Nearly all of the patients with the HLA-B27+/HLA-B*4001+ genotype (94.7% 
(DESIR) and 100% (SPACE)) were Caucasoid (not shown).
Table 1: Presence of the HLA-B27+/HLA-B*4001+ genotype in two cohorts of chronic back pain 
(CBP) patients and controls
DESIR Controls
HLAB27+/HLA-B*4001+ 19 (3.3%) 36 (0.4%)
HLAB27+/ HLA-B*4001- 319 (54.8%) 832 (8.2%)
HLAB27-/ HLA-B*4001+ 11 (1.9%) 936 (9.2%)
HLAB27-/ HLA-B*4001- 233 (40.0%) 8373 (82.3%)
Total 582 (100%) 10177 (100%)
SPACE Controls
HLAB27+/HLA-B*4001+ 13 (4.8%) 22 (0.4%)
HLAB27+/ HLA-B*4001- 85 (31.3%) 381 (6.8%)
HLAB27-/ HLA-B*4001+ 25 (9.2%) 654 (11.7%)
HLAB27-/ HLA-B*4001- 149 (54.8%) 4527 (81.1%)
Total 272 (100%) 5584 (100%)
DESIR: OR 9.5 (95% CI: 5.4-16.7; p<0.0001).
SPACE: OR 12.7 (95% CI: 6.3-25.5; p<0.0001).
HLA-B27, human leukocyte antigen B27; HLA-B*4001, human leukocyte antigen B*4001; DESIR, DEvenir 
des Spondyloarthrites Indifférenciées Récentes; SPACE, SPondyloArthritis Caught Early. 
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Disease characteristics of the two cohorts are depicted in Table 2. The data shown are 
stratified according to the presence of HLA-B27 and HLA-B*4001. In Table 2: data from 
the four strata taken together, patients had a mean age of 31.5 (DESIR) and 31.3 (SPACE) 
years. Mean symptom duration was 18.2 months in DESIR and 13.0 months in SPACE. Of 
the 19 patients in the DESIR cohort with the high-risk genotype, 8 (42.1%) had radiographic 
sacroiliitis (mNY). In the SPACE cohort, radiographic sacroiliitis according to the mNY-criteria 
was seen in 2/13 (15.4%) patients with the high risk HLA-B27+/HLA-B*4001+ genotype 
(Table 2). 
Of the HLA-B27+/HLA-B*4001+ and HLA-B27+/HLA-B*4001- patients in both cohorts 
the majority was male, whereas in the two other strata females were overrepresented. A 
positive family history of SpA was more frequent in HLA-B27+/HLA-B*4001+ and HLA-B27+/
HLA-B*4001- patients, compared to patients in the two other strata.
Recently published data of the SPACE cohort have pointed out that an increasing number of 
SpA-features is associated with an increased likelihood of axSpA although this association was 
not absolute.26  Comparing the mean total number of SpA features (SD) between HLA-B27+/
HLA-B*4001+ with HLA-B27+/HLA-B4001- patients revealed no notable differences: being 
3 (1) in the HLA-B27+/HLA-B*4001+ patients and 3.2 (1.1) in the HLA-B27+/HLA-B4001- 
patients of the DESIR cohort (SPACE: 2.6 (1.7) and 2.7 (1.6) respectively). Overall, while 
comparing disease characteristics of patients amongst the four strata, differences in disease 
characteristics were seen. But, differences turned out to be marginal when comparing 
HLA-B27+/HLA-B*4001+ with HLA-B27+/HLA-B4001- patients.    
Likewise, comparing the percentage of patients with any positive imaging (defined as 
minimally one positive imaging modality: sacroiliitis on radiographs according to the mNY 
definition and/or a positive MRI according to the ASAS definition) revealed differences 
between the HLA-B27 positive versus negative group, with more patients having positive 
imaging in the HLA-B27 positive patients. (DESIR odds ratio (OR) 1.9; 95% confidence 
interval (CI) 1.3 to 2.7; p<0.001 and SPACE OR 4.0; 95% CI 2.1 to 7.5; p<0.001.). However, 
positive imaging was not significantly different in HLA-B27+/HLA-B*4001+ and HLA-B27+/
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In both cohorts, 11 patients have the high-risk genotype but did not fulfil the mNY-criteria for 
AS. The characteristics and SpA-features of these patients are shown in Tables 3 and 4. The 
number of other present SpA-features which influences the likelihood of axSpA (in absence 
of one single distinguishing feature and diagnostic criteria) varied between patients (Tables 
3 and 4). For example, patient number 5 in DESIR has five additional SpA-features: a history 
of uveitis, enthesitis, elevated CRP or ESR and a good response to NSAIDs. Likewise, patient 
11 in SPACE is highly suspicious to have axSpA being HLA-B27 positive and having 6 other 
SpA-features. On the contrary, patient 6 (SPACE) has no single other SpA-feature which 
makes axSpA unlikely.  Equally, a positive family history as the only single SpA-feature in 
HLA-B27 positive patients (DESIR: 10, SPACE: 5) is not very suggestive for axSpA. 
DISCUSSION
In these two cohorts of early inflammatory and chronic back pain patients, the high risk AS 
genotype (HLA-B27+/HLA-B*4001+) was found to be increased compared to controls. To our 
knowledge high-risk or complex SpA genotypes have never been studied in early back pain 
patients suspected of axSpA. Studies that have been earlier performed, were all performed 
in ankylosing spondylitis patients only: i.e. a much more homogeneous group than patients 
with axSpA. This is of course pivotal for the identification of novel genetic associations. 
However, the ‘real-life’ situation at the outpatient clinic is different and confirmation in more 
heterogeneous cohorts is needed to investigate its possible diagnostic value. A strength of 
this current study is that we assessed the prevalence of the HLA-B27+/HLA-B*4001+) high-
risk genotype in two independent cohorts of patients with chronic back pain, suspected for 
axSpA. The fact that images in each cohort were scored by two well-trained readers, blinded 
for clinical data and genotype status, also adds to the credibility of the findings. 
Of the patients with the high-risk genotype, even with a short symptom duration, a considerable 
proportion already had radiographic sacroiliitis. Moreover, objective measures for 
inflammation (elevated CRP, positive MRI-SI) were also common in HLA-B27+/HLA-B*4001+ 
patients. However, all these observations were also true for patients with HLA-B27 but without 
HLA-B*4001. In general, differences in disease characteristics were seen while comparing 
the four strata, but differences were insignificant while comparing HLA-B27+/HLA-B*4001+ 
with HLA-B27+/HLA-B4001- patients. Therefore, these data indicate that there is no added 
value of HLA-B*4001 testing compared to testing for HLA-B27 alone in this population of 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Despite the lack of diagnostic potential, it will be interesting to investigate if the high-risk 
genotype is associated with disease progression such as radiographic damage progression 
in the two cohorts. Relatively little is known about long term radiographic progression in early 
axial spondyloarthritis (both in the spine and sacroiliac joints). 
It is important to realise that patients in both cohorts were already referred to a rheumatologist. 
This pre-selection of patients is in itself not a problem, though certain symptoms or ‘red flags’ 
might have led to referral and therefore pre-test probabilities will be higher which could 
underestimate the effect of testing for the combined high risk genotype in a population of 
unselected back pain patients. A next step could be to investigate if the high-risk genotype 
could help identifying patients at risk of axSpA. This could be useful in population studies 
with high a prevalence of chronic back pain not caused by SpA where a high specificity is 
a needed. 
In the current study, we only looked at the presence of HLA-B*4001 but other AS high risk 
genotypes are known. It has been previously shown that HLA-B27 homozygosity is associated 
with an increased risk of AS.27 Unfortunately, our current PCR technique is not suited to 
test for HLA-B27 homozygosity in patients. Gene-gene interactions between HLA-B27 and 
ERAP1 have also been studied and a high specificity is suggested.28 Regrettably, for the 
current study we did not have controls available to investigate the prevalence of a combined 
HLA-B27/ERAP genotype or combinations of HLA-B27, HLA-B*4001 and ERAP1 SNPs. 
In summary, although AS was common in HLA-B27+/HLA-B*4001+ chronic back pain 
patients, our results show that HLA-B27+/HLA-B*4001+ testing has no incremental value in 
the diagnostic process of axSpA by a rheumatologist above HLA-B27+ testing alone. High-
risk genotypes might have value in screening back pain patients in the population, but this 
needs to be investigated further. 
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The studies described in this thesis were all centred around the same aim: the early recognition 
of axial spondyloarthritis (axSpA) and a minimization of the diagnostic delay. An important 
step in tackling these issues was that experts in the field have designed prospective cohort 
studies in which consecutive patients with either chronic or inflammatory back pain (the 
latter being the most common first symptom) of short duration are included and followed up 
in a standardized manner with imaging performed at certain pre-set times. This allows us to 
obtain information on who will develop axSpA and who will not. Those cohort studies provide 
valuable information on the early detection and disease course of axSpA and form the basis 
of the research presented in this thesis.
The first part of this thesis covered two studies on the performance of different classification 
criteria sets in a worldwide clinical setting and the necessity of performing additional 
investigations (HLA- B27 testing; sacroiliac joint imaging) in a subgroup of patients with 
only one or even zero SpA  features (i.e. a low pre-test probability of having axSpA). 
Subsequently, the focus shifted to the role of imaging in the early detection of the disease. 
First, the literature on recent advances in sacroiliac joint imaging (both conventional x-rays 
and MRI) was reviewed; this formed partly the starting point for a consensus exercise by 
ASAS which resulted in an update of the existing definition for a positive MRI for classification 
of axSpA. Then, the additional value of using structural lesions on MRI in the ASAS axSpA 
classification criteria was assessed. Thereafter, we zoomed in on the diagnostic process 
again; the usefulness of repeating an MRI of the sacroiliac joints (after three months or one 
year) with regards to diagnosis of patients with chronic back pain suspected of axSpA was 
assessed. In the last part of this thesis, the prevalence of the HLA-B27+/HLA-B*4001+ 
genotype was assessed in two early axSpA cohorts; and its potential role in the diagnostic 
process was discussed.
The studies presented in this thesis were conducted in two prospective cohort studies and one 
study with a cross-sectional design. The two cohort studies are the SPondyloArthritis Caught 
Early (SPACE) cohort and the DEvenir des Spondyloarthropathies Indifférenciées Récentes 
(DESIR) cohort. The cross-sectional study mentioned is the Assessment of SpondyloArthritis 
international Society COMOrbidities in SPondyloArthritis (ASAS-COMOSPA) study. SPACE 
is an ongoing observational cohort study in which patients aged ≥16 years with short-term 
chronic back pain (CBP of ≥3 months, ≤2 years and an onset of <45 years) referred to a 
rheumatologist are included.1 Patients are recruited from several participating centres in four 
European countries: the Netherlands, Norway, Italy and Sweden. Follow-up is performed 
in a standardised manner with the collection of clinical and imaging data at pre-set times 
(baseline, three months, one year, two years, thereafter every two years). Baseline and one-
year follow-up data were used for this thesis. DESIR is a longitudinal cohort study in which 
patients aged 18-50 years with inflammatory back pain (IBP) are included from 25 regional 
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centres in France.2 The presence of IBP (according to the Calin or Berlin criteria)3,4 and 
a back pain duration of ≥ 3 months and <3 years was required for inclusion. Besides the 
mandatory presence of IBP, a patient was only included if the rheumatologist responsible for 
enrolment had a level of confidence about the diagnosis of SpA of at least 5 (0-10 scale: 0 
is not confident and 10 means very confident). The cohort is aiming for a 10-year follow-up, 
but for this thesis only baseline data were used. The SPACE cohort has important similarities 
to DESIR, though an important difference is that in DESIR patients with IBP are included, 
whereas SPACE includes patients with chronic back pain, not necessarily inflammatory 
back pain. Furthermore, in DESIR the presence of an axSpA diagnosis is at least probable 
whereas this is not the case in SPACE. A practical  difference is that SPACE is an ongoing 
cohort study; whereas inclusion in DESIR is currently closed and was performed between 
December 2007 and April 2010. The ASAS-COMOSPA study is a study initiated by ASAS 
aimed to evaluate the prevalence of comorbidities and risk factors in SpA patients (both axial 
and peripheral) in different countries worldwide and to evaluate the gap between available 
recommendations and daily practice for management of these comorbidities. It is an 
international, observational study with a cross-sectional design in which patients diagnosed 
with SpA (according to the treating rheumatologist) were included.5 Inclusion took place in 
22 countries from five different regions across the world: Asia, North Africa, Latin America, 
North America, Central Europe and Western Europe. The multi-nationality of the study; the 
high number of included patients raised the opportunity for ancillary studies like the one 
described in this thesis.
In this final chapter, we summarize the main findings of the studies presented in this thesis 
and we will place them in a broader perspective. We will also discuss future perspectives 
and formulate research questions that could be relevant to assess in the years ahead of us.
PART I: EARLY RECOGNITION AND CLASSIFICATION 
CRITERIA
Classification criteria are frequently evaluated in restricted patient populations; very often 
cohort studies with strict inclusion criteria in specialised clinics, which leads automatically to 
fairly homogeneous groups of patients.6-9 This is of course essential for the proof-of-concept 
of evaluating the performance of those criteria, but at the same time it poses the question 
how these classification criteria would perform in a setting which closely resembles the 
situation of daily clinical practice: a situation where a heterogeneous assembly of patients 
with chronic back pain presents to rheumatologists worldwide.
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Classification criteria have all been developed using ‘expert opinion’ as the external standard 
in the absence of an indisputable gold standard. Pattern recognition forms the basis of this 
expert opinion: rheumatologists combine individual patient characteristics and presenting 
symptoms with their own knowledge about the pattern of disease (the so-called ‘Gestalt’). 
It is therefore not difficult to understand that ‘expert opinion’ is not an unequivocal and 
homogeneous construct. It may potentially integrate different pictures of the disease which 
is even more comprehensible from a global perspective (diversity of patient populations and 
rheumatology training programmes).
In chapter 2, the performance of several classification criteria sets was tested in a worldwide 
population of patients. Patients were recruited from routine clinical practice in a large number 
of rheumatology clinics around the world. We investigated if rheumatologists worldwide 
diagnose a similar type of patients as having SpA by testing if patients fulfil similar criteria 
sets in the ASAS- COMOSPA study. This was done under the assumption that the more 
criteria sets a patients fulfils the higher the likelihood is that a patient with diagnosis of SpA 
truly has SpA. It was concluded that most patients with a clinical diagnosis of SpA fulfil several 
classification criteria sets and substantial overlap between criteria sets was seen which adds 
to the credibility and validity of the different criteria sets. In this case it is important to mention 
that this cohort is not a cohort of early disease, reflected by 65% modified New York criteria 
positivity. But despite the overlap of the various criteria sets, a substantial number of patients 
was being picked up by only one criteria set; namely the ASAS axSpA criteria.
Earlier studies already revealed that the ASAS criteria10,11 which were released in 2009, 
outperformed other classification criteria such as the Amor12 and ESSG13 criteria in terms 
of a better sensitivity due to the presence of MRI in the imaging arm compared to other 
criteria sets developed in the pre-MRI era. When tested against experts’ diagnosis the ASAS 
criteria represent the current ‘Gestalt’ better than the ESSG and AMOR criteria, that were 
designed decades ago before the introduction of MRI. Besides the fact that MRI findings 
are incorporated in the imaging arm of the ASAS axSpA-criteria which is not the case in 
any other criteria set; the ASAS criteria in general differentiate between axial and peripheral 
SpA. Although the ESSG and Amor criteria cover the whole spectrum of SpA and include a 
broader range of manifestations compared to the modified New York criteria (which will be 
discussed later), these criteria do not distinguish between axial and peripheral SpA. This 
differentiation is important though, for example when testing treatment strategies. Recently, a 
systematic literature review and meta-analysis was performed to summarise the evidence on 
the performance of the ASAS classification criteria.14 The entire set of the ASAS SpA criteria 
yielded a high pooled sensitivity (73%) and specificity (88%). Similarly, good results were 
found for the axSpA criteria (sensitivity: 82%, specificity: 88%).
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Nonetheless, rheumatologists and healthcare systems around the world have raised 
concerns regarding the criterion validity of the ASAS criteria and have posed the question if 
a modification of the criteria is needed. More explicitly, the specificity of the criteria is being 
questioned: it has been advocated that the clinical arm adds sensitivity to the axSpA criteria, 
while compromising on specificity. In other words, that patients fulfilling only the clinical arm 
should not be considered as having ‘true axSpA’ (mislabelling).15,16 This contrasts sharply 
with the imaging arm, which had been broadly recognized and well-accepted. Therefore, 
in chapter 2 we have also compared disease characteristics of patients fulfilling the clinical 
and imaging arm. It was found that patients fulfilling the clinical arm were remarkably similar 
to patients fulfilling the imaging arm with respect to the presence of most SpA features. This 
finding is in line with earlier observations in the SPACE and DESIR cohort.1,17 Also, in the 
ABILITY-1 trial (a randomized controlled trial performed in patients with non-radiographic 
axSpA to evaluate the efficacy and safety of adalimumab) there were no striking differences 
between patients who fulfilled the imaging arm and those who fulfilled the clinical arm of the 
ASAS axSpA criteria.18 In these studies, it was also noted that patients in the different arms 
were not only remarkably similar with respect to the presence of SpA features, but also with 
respect to levels of disease activity (BASDAI and ASDAS). In the current ASAS-COMOSPA 
study, the relevance of the clinical arm was demonstrated once again.
Many patients in this study did not undergo MRI. This situation is (highly) compatible with 
daily clinical practice since MRI is relatively expensive and the availability can be limited. 
When MRI is not available, a substantial proportion of patients will remain unrecognized and 
the sensitivity of the criteria decreases. If the problem will be more prominent in women, 
who seem to be at a lower risk of radiographic progression (male gender was found to be 
a risk factor for developing radiographic sacroiliitis and therefore, for evolution from non-
radiographic axSpA to radiographic axSpA) needs to be evaluated19 as we observed that a 
positive MRI was less frequent in females in SPACE (see below). Another important issue is 
the fact that sacroiliac joint imaging (both conventional radiographs and MRI) is difficult to 
interpret, especially in clinical practice.20-22 In the DESIR cohort, it was shown that both trained 
readers and local rheumatologists/radiologists agreed only moderately on the recognition of 
radiographic sacroiliitis. A significant proportion of patients that were labelled as having 
radiographic sacroiliitis by local readers was not confirmed by central readers (false 
positive).21 In another study, disagreement amongst local and central readers on positive 
sacroiliac joint imaging (MRI and/or x-rays) was present in 28% of the patients.20 Since 
imaging was marked positive more often by local readers, the specificity of the imaging arm 
is jeopardized (false-positivity). As was demonstrated by our study, many patients fulfil both 
the imaging and the clinical arm. Therefore, the risk of the above described ‘misinterpretation’ 
becomes less prominent in presence of the clinical arm.
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Until recently, the validity of the ASAS criteria had only been studied in a cross-sectional 
setting in different cohorts1,22,23 which means that the fulfilment of the criteria and the 
diagnosis of the rheumatologist (external standard) are assessed at the same time. In a 
sense, the metrics sensitivity and specificity are somewhat static, leaving aside predictive 
characteristics such as the probability of having SpA once the criteria are applied (post-test 
probability). It is essential to know if patients that were initially classified as axSpA will still 
be considered as having a SpA diagnosis after years of follow-up). Recently, data on the 
predictive validity of the ASAS criteria have been published14 patients from the ASAS cohort 
were followed over 3-5 years and rheumatologists carefully reviewed their cases again. 
93.3% of the patients that initially fulfilled the criteria would still be diagnosed as axSpA 
by the rheumatologist which leads to an excellent predictive validity and likewise suggests 
consistency of the criteria over time. Comparable results were found for the imaging arm 
(range: 94.5-96.5%) and clinical arm (range: 96.4-98.2%) and also considering those fulfilling 
the ‘imaging arm’ only (range: 85.1-86.7%) and clinical arm only (range: 87.9-92.9%). The 
negative predictive value was somewhat lower. However, since it is known that SpA features 
can change over time this might just reflect the natural disease course rather than revealing 
a negative test characteristic. These data on the predictive validity adds up to the robustness 
of the ASAS criteria. Since similar PPVs for both arms of the axSpA criteria were found, these 
data also support the view that the clinical arm comprises a group of patients who belong to 
the SpA spectrum as much as those fulfilling the imaging arm.
Due to the lack of diagnostic criteria, physicians may be tempted to use classification criteria 
as such. The same clinical, laboratory and imaging indices are used for classification and 
diagnosis, but clear differences exist in their application. Caution should be raised on using 
classification criteria as a check box to be ticked in order to make a diagnosis.24,25 An essential 
step that is missed by simply counting SpA features, is the exclusion of other likely diagnoses 
(differential diagnostic thinking) and also negative findings not pointing in the direction of 
axSpA. As earlier explained classification criteria are designed for classification instead of 
diagnostic purposes and furthermore, should only be applied in patients diagnosed with SpA 
(not vice versa).Honesty demands the admission that in our studies classification was not 
applied only in diagnosed patients and with progressive insight we would have approached 
this differently. The problem of using classification criteria to make a diagnosis is especially 
problematic in case of ticking boxes, patients not seen by a rheumatologist and especially 
if the pre-test probability is low. In patients with a relatively high pre- test probability, such 
as in the studies described in this thesis where the pre-test probability is around 30%, the 
misdiagnosis is much less. Furthermore, in SPACE, exclusion of other likely diagnoses was 
done by the rheumatologist even before patients were presented to and thereafter included 
in SPACE. Plus, the fact that evaluation of SpA features was done by experts only. However, 
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this can still be seen as a relative weakness of the studies. Classification criteria are 
developed to get a clear yes/no answer, to create a rather homogeneous group of patients, 
usually for inclusion into a cohort or clinical trial. They ensure comparability across these 
studies, but it is difficult to capture the full range of disease presentations by any single set 
of criteria. As explained above, knowledge of the pre-test probability of having the disease 
is essential in diagnosis. In a cohort of patients with chronic back pain in a primary care 
physician setting, SpA was diagnosed in 5% of the cases and this is frequently used as the 
assumed pre-test probability of this disease. In the studies described in this thesis, we used 
the 5% pre-test probability to calculate disease probabilities. But, we performed our studies 
in a secondary (or even tertiary) care setting were the pre-test probability is expected to be 
higher compared to the primary care setting. Unfortunately, an estimation of the pre-test 
probability in this setting was unknown when the cohort was started, after a few years we 
investigated that it is around 30%. So, the pre-test probability of 5%, which we used, resulted 
in an underestimation of the post-test disease probability.
The diagnostic work-up of axSpA is a challenge; some of the arguments why this is the case 
did already come across earlier in this chapter. In general, the disease should be suspected 
in patients with chronic back pain (CBP) with onset before 45 years of age and a history 
of CBP that has been almost continuous for three months or more (sub-acute onset). This 
should prompt further evaluation to establish whether other SpA features are present.
The modified Berlin algorithm serves as a helpful tool to assist rheumatologists in the diagnosis 
of axSpA; and it should be applied in patients with CBP with age of onset <45 years.26 The 
algorithm suggests that radiographs of the sacroiliac joints are advised in all referred patients 
with back pain with the features described above, regardless of the presence of other SpA 
features, and if negative all patients are assessed for the presence of other SpA features and 
tested for HLA-B27. In the study described in chapter 3, we aimed to investigate if HLA-B27 
testing and imaging of the sacroiliac joints (by means of conventional radiographs and MRI) 
is necessary in a subgroup of patients with a low likelihood of axSpA: patients with zero or 
only one SpA feature after clinical examination and measurement of acute phase reactants. 
Surprisingly, a diagnosis of SpA was made in 18.4% (zero SpA features) and 17.9% (one 
SpA feature) of the patients. We were surprised of these relatively high percentages. Even 
in patients without a single SpA feature after clinical examination and acute phase reactants 
measurement, it was not possible to entirely rule out axSpA. It is relevant to keep in mind the 
population of patients in which the research question is investigated, which influences the 
pre-test probability. Patients included in the SPACE cohort are referred to a rheumatologist 
and certain red flags or other findings have precluded referral. In fact, more likely diagnoses 
are already excluded. Therefore, the results of this study should be restricted to patients 
with a higher pre-test probability; and therefore, cannot be automatically extrapolated or 
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generalized to for example the general practitioners’ practice.
However, these nuances set aside, it is surprising that in these groups of patients with a 
low likelihood of the disease before testing, diagnosis is not that uncommon as expected 
beforehand. It can be questioned how realistic the majority of these diagnoses are. Imaging 
plays a pivotal role and is often decisive in whether or not making a diagnosis. This is well 
understandable since radiologic abnormalities feel as an objective sign of disease. But as 
an example, it feels like overshooting that in a female patient with back pain but zero other 
SpA features, a sole finding of sacroiliitis on radiographs is sufficient to establish a diagnosis. 
On the other hand, a diagnosis may still be justifiable because of features or symptoms 
that are outside the SpA features we examined, for example buttock pain, presence of 
structural lesions on MRI-SI or spinal inflammatory lesions. It might also have been the case 
that the modified Berlin algorithm is followed to stringently especially by less experienced 
rheumatologists (in training) in the field of axSpA. It should be stressed again that the ASAS 
modified Berlin algorithm is only a tool in aiding rheumatologists in diagnosing axSpA and 
can and should not replace a differential diagnostic procedure in patients with CBP. For 
example, the dominance of conventional radiographs in the modified Berlin algorithm is 
under debate. In general, discussion is on-going to what extent additional investigations 
should be performed in order to approve or disapprove a diagnosis and worries have been 
expressed if the current diagnostic work-up is not too extensive, mainly in patients with a low 
pre-test probability. Ideally we would aspire a tailored diagnostic process in which doctors 
should only perform specific investigations under certain motivations and be more resilient 
in specific patient groups with a low pre-test probability. Moreover, only follow-up of these 
patients will confirm if the diagnosis was correct and if imaging was interpreted correctly.
Sequential testing is also advocated in the modified Berlin algorithm. Although we have not 
tested the algorithm in the study described in chapter 3, we think that the role for MRI-SI may 
be a bit too confined. MRI-SI should only be performed in a very specific situation, which 
sharply contrasts to conventional radiography which is the broadly recognized first step in 
the algorithm. In a group of patients with short-standing complaints like the SPACE cohort it 
is however very likely that radiographic abnormalities have not yet developed which could 
possibly lead to a false-negative diagnosis if no other tests are performed. The recently 
published EULAR recommendations are a bit less conservative and recommend MRI-SI 
as an alternative first imaging method in for example young patients with a short symptom 
duration. In the later described chapter 8 we will assess the course of MRI-SI activity over 
one year and the identification of predicting factors for a positive MRI.
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Future perspectives
The early diagnosis of axSpA by a rheumatologist is important and a main objective of this 
thesis. But one step back, identification of patients at an increased risk of axSpA which 
precedes this process is also essential. It is obvious that a late referral of patients to a 
rheumatologist contributes to the diagnostic delay. CBP is highly prevalent in the general 
population and axSpA is responsible for only 5% of the cases in the primary care setting. 
Effective referral strategies are highly warranted.
Therefore, increased disease awareness is also of critical importance both on doctor and 
patient level. Education is important to reach the goal of early referral and diagnosis. This 
includes also in secondary setting the appropriate use of imaging for making a diagnosis 
and the correct interpretation. Education about not using classification criteria for making 
a diagnosis is essential. The Berlin algorithm needs to be reviewed carefully, especially 
the dominant place of conventional radiographs can be challenged. Although MRI has also 
drawbacks; it can be discussed if in patients with chronic back pain (early phases of disease) 
that MRI might be more appropriate than conventional radiographs. Cost-effectiveness of 
both radiographs and MRI would be also an interesting topic to investigate.
PART II: THE USE OF IMAGING (MRI) IN EARLY AXIAL 
SPONDYLOARTHRITIS
Sacroiliitis is the hallmark of axSpA. Radiography is the most commonly used method to 
detect sacroiliitis, though patients may have symptoms years before abnormalities can be 
seen on radiography and it is therefore not very adequate in the detection of early disease. 
In addition, not all patients will develop structural bone damage in the axial skeleton. With the 
help of MRI, it became possible to visualize inflammatory changes., which usually become 
apparent much earlier in the disease course. As a consequence, non-radiographic axSpA is 
now a well-respected part of the disease spectrum.
In chapter 4 results of a systematic literature review (SLR) are described which summarizes 
recent advances in both imaging modalities of sacroiliac joint imaging. It was concluded 
that substantial observer variation heavily influences reliability of conventional radiographs 
which leads to the fact that sacroiliitis is often missed or incorrectly diagnosed. This reader 
variability cannot be improved by training.27 The poor reliability of evaluating conventional 
radiographs was established in post- hoc analyses on the data of the ABILITY-1 and RAPID-
axSpA trials. More recent data from the DESIR cohort revealed that in recent onset IBP-
patients, both trained readers and local rheumatologists/radiologists agree moderately in 
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recognizing radiographic sacroiliitis (kappa: 0.55- 0.54). A significant proportion of locally 
recognized AS patients was not confirmed by central reading (41.5% false-positives) while 
only a minority is false-negative (7.5%).21
In recent years, studies on MRI have been performed. ASAS developed useful 
recommendations how to perform an optimal MRI of the sacroiliac joints and developed a 
definition for a positive MRI.28,29 MRI proved to be a more sensitive tool in the early detection of 
axSpA. In contrast to the moderate agreement regarding radiographic sacroiliitis, agreement 
regarding sacroiliitis on MRI was substantially better: as well between the two central readers 
in the DESIR cohort as between the local and central reader in this cohort (kappa: 0.73; 
kappa: 0.70 respectively).20 In chapter 8 of this thesis, agreement on a positive MRI between 
the two readers was even better (kappa: 0.84).
With great interest; the effect of discrepant imaging reading was investigated on fulfilment of 
the ASAS axSpA classification criteria. Of the patients with discrepant MRI and/or radiograph 
reading; 28% could have been classified differently (sec looking at imaging) but only 7.9% 
were actually classified differently. This is mainly due to the presence of the clinical arm. In 
general; rheumatologists need to be aware of discrepant imaging data and this underlines 
the importance of reviewing a patient as a whole in the diagnostic process rather than to fully 
rely on imaging.
Due to the expanding literature, the question was raised whether the wording of the ASAS 
definition of a positive MRI was still appropriate. An often heard critical note in the field is that 
while reading an MRI one is tempted to simply count the visible white spots which will result 
in a low specificity.
Low specificity of the MRI finding of sacroiliac joint bone marrow edema may lead to 
misclassification, especially in populations with a low axSpA prevalence. In chapter 5 a 
consensus exercise among experts in the field was undertaken. It was decided that the 
clear presence of bone marrow edema (BME) on MRI in subchondral bone is still considered 
to be the defining observation that determines the presence of active sacroiliitis though 
the presentation of the definition was reformatted and guidelines are provided essential to 
clinicians. It was emphasized that the definition is primarily for the classification of patients 
with SpA. In general, caution should be exercised in the interpretation of small lesions. 
Though detection of inflammation on a single slice may be sufficient for the criterion ‘highly 
suggestive of SpA’ it should be realised that it is rare for an MRI-SI with definite evidence of 
active sacroiliitis to demonstrate lesions on only a single image. MRI sequences (STIR, T1) 
should be simultaneously reviewed. If an inflammatory bone marrow lesion appears to be 
present, but it is hard to determine whether the lesion meets the criterion ‘highly suggestive 
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of SpA’ then the decision may be influenced by the presence of concomitant structural 
damage, especially erosion and/or other signs of inflammation, which in themselves do not 
suffice to meet the criterion.
As earlier mentioned, besides inflammatory lesions, structural lesions such as: erosions, fatty 
lesions, sclerosis and ankylosis are visible on MRI. Therefore, MRI has great potential for 
the assessment of both active inflammatory lesions and structural damage by means of 
one single-imaging technique. The ASAS group that developed the ASAS axSpA criteria 
abstained from including other lesions than bone marrow edema due to lack of evidence 
on the utility of structural lesions in the classification of axSpA. An important first step was to 
investigate the extent and performance of structural MRI-SI lesions in patients with suspected 
axSpA. Several studies have been performed on this topic, but since a control group was 
lacking it was impossible to assess the specificity of these lesions.30-33 The study by de 
Hooge et al. did include a control group of CBP patients due to other causes than axSpA 
since these patients are included in the SPACE cohort. This made it possible to quantify 
MRI lesions in patients with and without axSpA. On purpose a high specificity (>95%) was 
selected to reduce misclassification of patients as the imaging arm is fulfilled in case of 
positive imaging plus only one additional SpA feature. This study revealed that the presence 
of at least five (≥5) fatty lesions and/or erosions as well as ≥3 fatty lesions and ≥3 erosions 
allowed an acceptable discrimination of axSpA and no SpA, while assuring >95% specificity.
These cut-offs were applied in two studies described in this thesis: chapters 6 and 7. In these 
studies, we wanted to further clarify the role of these structural lesions and to investigate 
their usefulness with regard to the ASAS axSpA classification of patients. Two scenarios 
were tested: the addition of structural lesions seen on MRI to the definition of ‘sacroiliitis on 
imaging’ (1) and the replacement of radiographic sacroiliitis by structural lesions on MRI 
(2). For both scenarios the impact on the classification of patients according to the ASAS 
axSpA criteria was assessed. It was investigated that while applying both scenarios; only 
minor changes in the ASAS axSpA classification took place. Most patients changed from 
one subcategory to another, rather than becoming ASAS axSpA positive or negative. Again, 
the clinical arm demonstrated its importance here. It was concluded that structural lesions 
on MRI can be used reliability either as an addition to or as a substitute for radiographs in 
the ASAS axSpA classification. This adds to the robustness of the ASAS axSpA criteria as a 
whole. Despite the fact that both replacement and addition had more or less the same effect 
(replacement was resulting in a loss of a small number of patients with a low likelihood of 
axSpA) for feasibility reasons we favour the scenario of addition.
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We investigated the use of structural lesions with regard to classification. Though for diagnostic 
purposes; if a T1-sequence MRI is available in absence of a pelvic radiograph, this MRI may 
sometimes suffice if there are obvious abnormalities and in those circumstances there is 
no reason of obtaining additional radiographs. In the recently published European League 
Against Rheumatism (EULAR) recommendations for the use of imaging in the diagnosis and 
management of axSpA in clinical practice, it was also advocated to take structural lesions 
(such as bone erosion, fat infiltration, sclerosis and new bone formation) into account in 
addition to active inflammatory lesions and these data are in line with that.
As described earlier, the recognition of radiographic sacroiliitis is challenging. Unfortunately, 
agreement on structural lesions on MRI was only fair to moderate as well. It is however 
reassuring to see that the same conclusions (effects on ASAS axSpA classification) can be 
drawn while comparing the data of the individual readers. This strengthens our findings and 
adds to the validity of the criteria itself since the results seem not too much affected to inter-
reader variation in this respect. This in contrast to the mNY criteria that immediately change 
in case of discrepant readings, as described earlier in this chapter.21
Because axSpA usually starts in the sacroiliac joints, active inflammatory (or structural) 
lesions of the spine were not incorporated in the ASAS axSpA classification criteria. However, 
we do know that inflammatory lesions in the spine occur in axial SpA,34,35 sometimes even in 
the absence of sacroiliitis in MRI.36 These studies raised interest to investigate the yield of a 
positive MRI-spine as imaging criterion in the ASAS axSpA classification of patients. On the 
basis of a literature review and expert consensus, the ASAS-OMERACT working group defined 
a positive (for active inflammation) MRI-spine in axSpA as the presence of ≥3 inflammatory 
lesions in the vertebrae; and the presence of each lesion on ≥2 consecutive slices.33 Weber 
et al. advocated that the presence of ≥5 inflammatory lesions might discriminate even better 
from control groups37 and the earlier described study by de Hooge et al. showed that a cut-
off value of ≥5 inflammatory lesions defined a positive MRI-spine with a higher specificity of 
≥95% (i.e. <5% patients without axSpA with a positive MRI-spine).
In SPACE and DESIR, the presence of a positive MRI-spine (using the cut-off of ≥5 
inflammatory lesions) was investigated by Ez-Zaitouni et. al.38 A positive MRI-spine was rarely 
seen in patients without sacroiliitis on MRI-SI and X-SI in both cohorts (SPACE: 1%, DESIR: 
2% of the patients). Adding a positive MRI-spine as imaging criterion to the ASAS axSpA 
criteria, led to new classification in only one patient in each cohort as the other patients 
already fulfilled the clinical arm. Therefore, it was concluded that addition of MRI-spine as 
imaging criterion to the ASAS axSpA criteria had a low yield of newly classified patients and 
is therefore not recommended. However, involvement of the spine without sacroiliac joints 
can occur in a small percentage of patients and could be carefully considered during the 
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diagnostic process, especially in patients with longer symptom duration.
Although inflammation on MRI is now considered as an important manifestation in early 
axSpA, not much evidence was available on how inflammatory lesions develop over time 
(outside clinical trials). In chapter 8 we investigated if it is useful to repeat an MRI of the 
sacroiliac joints after three months or one year in the diagnostic process of patients with 
chronic back pain suspected of axSpA in the SPACE cohort. Changes in MRI-SI status were 
seen in a minority of the patients of the SPACE cohort. Although changes were visible in both 
directions, more patients become negative than positive. And part of this becoming negative 
was associated with the start of TNF-blocking treatment. Repeating MRI after three months 
or one year in the diagnostic work-up in early disease is not useful. Both male gender and 
HLA-B27 positivity independently determine the likelihood of a positive MRI at any time point. 
This is in line with earlier studies.39 Not unexpectedly, MRI status at baseline appeared to be 
strongly influencing the chance of having positive MRI of the sacroiliac joints at follow-up. If 
the baseline MRI is positive, the likelihood that the MRI will be positive again at three months 
or one year is very high (84%).
Future perspectives
A major unresolved challenge in imaging studies in axSpA is the selection of the external 
standard with which to compare MRI evaluation. Comparisons between different imaging 
modalities; for example linking structural lesions on MRI to low-dose CT will give us more 
insight. The availability of low-dose CT scans may help to increase the sensitivity of the 
imaging methods to detect the presence and progression of structural damage. Interesting 
future questions are how to incorporate MRI in future clinical trials and whether new drugs such 
as targeting the IL-23/IL-17 axis will have different effects on inflammation, fat deposition and 
other structural damage. Methodology is important here; because when we do not observe 
an effect of for example a biologic agent on radiographic progression this can be due to 
absence of effect; but also due to the fact we have not used the right measurement method. 
In general, prospective evaluation of both inflammatory and structural lesions over a sufficient 
timeframe is needed to further understand the development of axSpA lesions. Longitudinal 
data from the SPACE and DESIR cohort are awaited; but replication of our findings in cohorts 
of more advanced disease is also highly warranted. Ideally, in the near future a clinician can 
determine the risk of progression in an individual patient, using baseline parameters such as 
HLA-B27 positivity, radiographic structural damage, MRI-SIJ inflammation and elevated CRP 
and can fine-tune the treatment accordingly. Overall, regarding imaging in axSpA: optimal 
collaboration between rheumatologists and radiologists will be beneficial. The radiologist 
is the experienced imaging expert and the rheumatologist involved in the care of a given 
patient can place imaging findings in the context of clinical and laboratory data etc. Ideally, 
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clinical practice is a synergy between these two specialisms. Also, automated techniques for 
the evaluation of the volume, signal intensity, and extent of the relevant lesions are presently 
under development.
Although these approaches need to prove their ability to differentiate between pathologic 
lesions and local anatomic tissue abnormalities or artefacts to avoid false-positive or false-
negative scoring results.
PART III: GENETIC ASPECTS IN EARLY AXIAL 
SPONDYLOARTHRITIS
Since the 1960s, it is known that susceptibility to AS is largely due to genetic factors.40 
HLA-B27 (a major histocompatibility class (MHC) class I molecule) is known to be the major 
genetic risk factor for AS.41-43 The strong association with HLA-B27 was recognized over 
40 years ago and since then it has undisputedly remained the strongest known risk factor. 
However, only 5-6% of the HLA-B27 positive people in the general population will develop 
spondyloarthritis44 and the overall contribution of HLA-B27 to AS heritability is estimated at 
23.3%.45 This suggests that HLA-B27 by itself is not sufficient for development of the disease, 
supporting the contribution of additional genes. In other words, despite its strong association, 
HLA-B27 accounts for only a small part of the genetic risk of AS.
Within the MHC complex, HLA-B*4001 (an allele that corresponds to HLA-B60 at the 
serological or protein level) is identified to be another genetic risk factor for AS. HLA-B60 
was shown to be increased in HLA-B27 positive AS patients in five independent data sets 
in 1989.46 More recently, this association was confirmed in the UK, the Netherlands and 
in Taiwan.47-49 In 2013, epistasis between HLA-B27 and HLA-B*4001 has been reported to 
associate with increased risk of AS in Caucasians, with a very high relative excess risk.48 The 
epistatic interaction is not reproduced in all studies, but the high specificity of the combined 
genotype was found in all three previously mentioned studies (sensitivity: 10.1%, 18.2%, 
18.7%, specificity: 99.7%, 99.6%, 98.7%).48,49 In the study by van Gaalen et al. the combination 
of both HLA-B27 and HLA-B60 positivity was very rare in controls with a prevalence of just 
0.4% while it was found in 18.2% of patients with AS.
The combined HLA-B27+/HLA-B*4001+ genotype has only been studied in advanced stage 
AS patients. The aim of this study is to assess the added value of HLA-B27/HLA-B*4001 
in the detection of early axSpA. To our knowledge, no genetic studies have been earlier 
performed in early axSpA patients. For a disease where the genetic background is important, 
genetic testing could play a more prominent role in (early) diagnosis.
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In chapter 9 we assessed the prevalence of the HLA-B27+/HLA-B*4001+ genotype in two 
cohorts of patients with chronic or inflammatory back pain suspected of axSpA (SPACE 
and DESIR) and controls matched by country for both cohorts. The latter is relevant since 
the prevalence of HLA-B27 and HLA-B*4001 may differ by geographical location.50 It was 
found that the high risk AS genotype (HLA-B27+/HLA-B*4001+) was significantly more 
common in both cohorts compared to controls (DESIR: 3.3%, SPACE: 4.8%, versus 0.4% 
in controls). Then we stratified patients by HLA-B typing (1. HLA-B27+/HLA-B*4001+; 2. 
HLA-B27+/HLA-B*4001-; 3. HLA-B27-/HLA-B*4001+; 4. HLA-B27-/HLA- B*4001-) and 
compared the disease characteristics among the different strata. HLA-B27+/HLA- B*4001+ 
patients showed a high percentage of radiographic sacroiliitis (DESIR 42% and SPACE 
15% but were relatively similar to HLA-B27+/HLA-B*4001- back pain patients in terms of 
radiographic sacroiliitis (DESIR 27.6% and 16.5%) and to a lesser extent sacroiliitis on MRI. 
While comparing the mean number of SpA features (surrogate for an increased likelihood of 
axSpA) no differences were seen between HLA-B27+/HLA-B*4001+ (DESIR: 2.6, SPACE: 
3) and HLA-B27+/HLA-B*4001- (DESIR: 2.7, SPACE: 3.2) patients. We concluded that the 
HLA-B27+/HLA-B*4001 high risk genotype was more common in early back pain patients 
suspected of axSpA. However, because HLA- B27+/HLA-B*4001+ patients were similar to 
HLA-B27+/HLA-B*4001- patients with regard to SpA features, combined testing for HLA-B27 
and HLA-B*4001 has no added value in the early detection of axSpA.
Over the past decades, genetic technology in the field of AS has rapidly evolved. Several 
large genome-wide association studies (GWAS) have been carried out, leading to the 
discovery of many other genetic risk factors than HLA-B27 and HLA-B*4001.51-54 With GWAS, 
a plethora of data is generated which may seem promising. However, many associations 
found account only for a small fraction of the risk of AS. Sample size is absolutely critical for 
the power of GWAS to detect associations reliably.
Another issue is the difficulty in identifying the effect on expression or function of a specific 
gene. Recently, two genetic loci have been associated with AS which might be of functional 
relevance: endoplasmic reticulum aminopeptidase (ERAP) and the interleukin (IL) 23 
receptor.52 ERAP encrypts an aminopeptidase expressed in the endoplasmic reticulum and 
is involved in preparing peptides for MHC class 1 presentation to immune effector cells. The 
IL-23 receptor activates T- helper cells secreting the cytokine interleukin (IL) 17, but as well 
other pro-inflammatory cells. The ERAP-1 association (not -2) is limited to HLA-B27 positive 
cases, expressing that peptides presented by HLA-B27 might be of importance.55
As described earlier in this thesis (Introduction) axSpA is clinically associated with inflammatory 
bowel disease (IBD), psoriasis or reactive arthritis in part of the patients. It has been shown 
that these diseases can be clinically silent,56,57 therefore, the association with extra- articular 
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manifestations might be underestimated. Hence, barrier damage of dermal (psoriasis) and 
mucosal (IBD) surfaces (human host’s barrier functions) and the subsequent exposure 
of the immune system to microbes seem to be an important aspect for the pathogenesis. 
Substantial overlap between AS susceptibility loci and IBD loci has been found. An altered 
microbiome has been found in IBD patients58 and is thought to also play an important role 
in SpA.59,60 Evidence that the gut microbiome is important in AS includes findings in several 
animal models of SpA.61 In patients with microscopic bowel lesions, the disease probably 
starts in the gut, where IL-23 receptor- positive IL-17 and IL-22 producing innate lymphoid 
cells (ILCs) are activated perhaps through the gut microbiome. IL-17 is a pro-inflammatory 
cytokine, released by T-helper-17 cells on stimulation with IL-23. ILCs activated in the gut 
migrate to the entheses and joints, causing an inflammatory process in which TNF-a also 
participates. Recently, a metagenomics analysis was performed, comparing stool samples 
between adult SpA and control groups (both healthy controls and rheumatoid arthritis (RA)).62 
The results suggest that distinctive altered microbiomes characterise both SpA and RA. 
Furthermore, a reproducible increase in R. gnavus (an aerobic, Gram-positive gut microbe in 
the class of Clostridia) appears specific for SpA. This observation is consistent with the pro-
inflammatory role of this bacteria and its association with IBD. It remains to be determined 
whether HLA-B27 influences the gut microbiome, but this has been suggested.
Future perspectives
Despite the progress that has been made, there is still a clear lack of understanding of 
pathogenesis in axSpA. The functional mechanisms of HLA-B27 and other genetic 
associations should be studied more thoroughly. Another topic for future research is the 
relation between cytokines, inflammation and bone formation. As described earlier, the 
interest in the role of the microbiome is expanding. This can be helpful to better understand 
the interaction between genetic predisposition and environment (exposure to microbes, 
bacterial triggers). Attention should also go to the possible influence of HLA-B27 on the gut 
microbiome. In general, improved animal models are warranted (TNF-dependent; ankylosing 
mouse models). Ideally we would link tissue samples to imaging to better understand the 
pathologies visualized by various imaging techniques although invasive techniques for 
obtaining tissue samples are undesirable. Furthermore, we are interested in the follow-up 
of axSpA patients from SPACE and DESIR in order to assess whether HLA-B*4001 and 
ERAP-1 are possible risk factors for disease progression (for example radiographic spinal 
progression; but also the progression of nr-axSpA to AS).
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CONCLUDING REMARKS
To wrap-up at the end of this chapter; we stress the urge that the pathogenesis of axSpA 
needs to be unravelled to a larger extent in order to comprehend the exact mechanism 
and to investigate more possibilities to modify this (Part III). Likewise, the debate needs 
to continue as to whether and how classification and diagnosis can be improved; centred 
around the urge for early identification (Part I). The role of MRI in this process needs to be 
further specified (Part II); the course of both active and structural lesions over substantial 
follow-up periods will provide us with useful information and also the concordance with other 
imaging modalities (such as low-dose CT).
The studies in this thesis were all centred around the early recognition of axSpA. But of 
course, once the diagnosis has been made optimal treatment strategies are essential. Non-
steroidal anti- inflammatory drugs and TNF blockers are effective therapies. But blockade of 
interleukin-17 is a relatively new and relevant treatment option and studies in nr-axSpA with 
anti-IL-17 therapy are awaited. Additional studies are still needed to evaluate TNF inhibitors 
plus NSAIDs with the aim to inhibit bone proliferation, as well as comparing biologics head-to-
head in both biologic-naïve patients and those that fail to response to their first TNFi. Finally, 
a treatment that can stop radiographic progression remains an important unmet need.
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Spondyloartritis (SpA) is een chronische reumatische aandoening waarbij zowel gewrichten 
van de extremiteiten als de wervelkolom en het bekken betrokken kunnen zijn. Wanneer de 
ontstekingen met name gelokaliseerd zijn in de gewrichten die het bekken verbinden met de 
wervelkolom (de sacro-iliacale gewrichten) en/of de wervelkolom zelf spreekt men van axiale 
spondyloartritis (axSpA). Deze ontstekingen veroorzaken rugpijn en stijfheid en kunnen op 
termijn leiden tot ernstige verbening van de wervelkolom. Bij perifere spondyloartritis (pSpA) 
zijn juist de perifere gewrichten (bijvoorbeeld knieën en polsen) en pezen aangedaan. Het 
onderscheid tussen axSpA en pSpA is relatief nieuw in het veld. De voordelen van het 
kunnen maken van dit onderscheid voor het karakteriseren van patiënten met SpA zijn: een 
betere beschrijving van de gepresenteerde ziekte en een betere behandeling van de patiënt 
(aangezien de therapeutische strategieën anders zijn). De focus van dit proefschrift ligt 
vooral op axSpA. 
De symptomen van axSpA zijn erg uiteenlopend. Er is helaas niet een eenduidig symptoom 
dat bij alle patiënten voorkomt. Wel zijn er symptomen die veel vaker voorkomen bij 
patiënten met axSpA dan bij patiënten met andere aandoeningen. Dit noemt men SpA 
kenmerken (SpA features). Een veelvoorkomend SpA kenmerk is inflammatoire rugpijn wat 
wordt vastgesteld aan de hand van de volgende symptomen: rugpijn die aanwezig is in 
rust, vermindering van rugpijn bij beweging, stijfheid van de rug in de ochtend gedurende 
meer dan 30 minuten, nachtelijke rugpijn en een alternerende pijn in de bilstreek. Naast 
ontstekingen van de perifere gewrichten (perifere artritis) kunnen peesaanhechtingen 
(entheses) ontstoken raken. Dit wordt gekenmerkt door een pijnlijke zwelling bijvoorbeeld 
ter plaatse van de aanhechting van de achillespees op het hielbeen. Ook kan een dactylitis 
optreden: hierbij is de gehele vinger of teen rood en ontstoken. Ontstekingen kunnen ook 
op andere plaatsen in het lichaam dan de gewrichten voorkomen: de zogenoemde extra-
articulaire manifestaties. Hiermee worden bedoeld: ontstekingen aan de ogen (in de vorm 
van uveitis anterior), ontstekingen aan de huid (in de vorm van de huidaandoening psoriasis) 
en ontstekingen aan de darmen (in de vorm van inflammatoire darmziekten (IBD) zoals de 
ziekte van Crohn). Twee andere SpA kenmerken zijn het substantieel afnemen van pijn en 
stijfheid bij het gebruik van non-steroïdale anti-inflammatoire geneesmiddelen (NSAIDs) en 
een positieve familie anamnese welke is gedefinieerd als het voorkomen van de ziekte bij 
eerste-of tweedegraads bloedverwanten. Patiënten met axSpA hebben vaak verhoogde 
ontstekingswaarden in het bloed zoals een hoog CRP en/of een verhoogde bezinking. 
Aanwezigheid van het gen HLA-B27 (humaan leukocyten antigeen B27) wordt veel vaker 
gevonden in patiënten met axSpA. 
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De kenmerkende ontsteking van de sacro-iliacale (SI) gewrichten kan worden afgebeeld 
met röntgenonderzoek of magnetic resonance imaging (MRI). Sacroiliitis is het centrale 
kenmerk van axSpA. Een conventionele röntgenfoto is de meest gebruikte methode om 
sacroiliitis te detecteren. Het duurt echter vaak 6-8 jaar vanaf het begin van de symptomen 
voordat sacroiliitis op een conventionele röntgenfoto’s kan worden vastgesteld. De gedachte 
is dat radiografische veranderingen (erosies, sclerose, vernauwing/verbreding van de 
gewrichtsspleet (ankylose) de latere gevolgen van de ontsteking weerspiegelen in plaats 
van de ontsteking zelf. Daarom is het niet erg geschikt voor de detectie van de ziekte in 
een vroeg stadium. Bovendien zullen niet alle patiënten uiteindelijk structurele laesies in het 
axiale skelet ontwikkelen. 
Met behulp van MRI werd het mogelijk om inflammatoire veranderingen te visualiseren, 
die meestal veel eerder in het ziektebeloop zichtbaar worden. Als gevolg hiervan is niet-
radiografische axSpA nu een gerespecteerd onderdeel van het ziektespectrum. Patiënten 
met axSpA kunnen dus worden geclassificeerd als één van de twee subtypes van axSpA: 
ankyloserende spondylitis (AS) of niet-radiografische axSpA (nr-axSpA). Patiënten met AS 
vertonen radiografische sacroiliitis. Dergelijke bevindingen zijn niet evident bij conventionele 
röntgenfoto’s in nr-axSpA. In plaats daarvan is een bewijs van actieve ontsteking van de 
sacro-iliacale gewrichten op MRI essentieel.  
Of en welke van de hierboven genoemde SpA kenmerken een patiënt heeft stelt een 
reumatoloog vast via anamnese, lichamelijk onderzoek, laboratoriumonderzoek en 
beeldvorming. Zo wordt een gedetailleerd klinisch beeld verkregen met als doel een 
passende diagnose te stellen. De waarschijnlijkheid van de diagnose varieert afhankelijk 
van de specifieke bevindingen die aanwezig zijn. De geschatte prevalentie van SpA in de 
algemene populatie is 1-1.4%, hoewel cijfers over de incidentie en prevalentie variëren en 
sterk afhankelijk zijn van methodologische verschillen tussen studies. Ongeveer 80% van 
de patiënten ontwikkelt de eerste symptomen op een leeftijd jonger dan 30 jaar (minder dan 
5% van de patiënten is ten tijde van de eerste symptomen ouder dan 45 jaar). Lange tijd 
is gedacht dat axSpA vooral een ziekte was van (jongvolwassen) mannen. De aandoening 
komt echter ook bij vrouwen in ongeveer dezelfde frequentie voor. 
AxSpA wordt geassocieerd met een aanzienlijke ziektelast. De uitkomsten van de 
ziekte in termen van verminderde mobiliteit, arbeidsproductiviteit en een slechtere 
gezondheidsgerelateerde kwaliteit van leven kunnen van grote invloed zijn op het leven van 
jonge patiënten. Het is daarom belangrijk om patiënten tijdig te identificeren om vroegtijdig 
te kunnen starten met behandeling en zo mogelijk het beloop van de ziekte te beïnvloeden. 
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Terwijl de behandeling van axSpA vroeger vooral bestond uit fysiotherapie en 
ontstekingsremmende pijnstillers (NSAIDs) is het therapeutische arsenaal in de afgelopen 
jaren snel uitgebreid. NSAID’s zijn nog steeds de aanbevolen eerstelijns medicamenteuze 
behandeling voor patiënten met axSpA met pijn en stijfheid. Maar het tijdperk van TNF-
blokkerende medicijnen en andere zogenaamde biologicals hebben een revolutie 
teweeg gebracht in de behandeling van axSpA patiënten die ongevoelig zijn voor 
eerstelijnsbehandeling en de resultaten zijn indrukwekkend. 
Tijdige identificatie van patiënten heeft klinische consequenties en is dus relevant, maar 
helaas ook moeilijk. Het interval tussen het begin van de symptomen en de stellen van de 
diagnose bedraagt gemiddeld 8-10 jaar. AxSpA blijft een relatief ongebruikelijke oorzaak 
van een veel voorkomend eerste symptoom: 60-80% van de algemene bevolking rapporteert 
op enig moment in zijn/haar leven rugpijn. Ook speelt bijvoorbeeld de late schade op de 
röntgenfoto een rol. In het algemeen vormt de noodzaak tot een vroege herkenning van 
axSpA en het verkorten van de diagnostische vertraging  de belangrijkste basis achter de 
verschillende onderdelen van dit proefschrift. 
OPZET VAN DIT PROEFSCHRIFT 
De studies beschreven in dit proefschrift zijn allemaal gecentreerd rondom hetzelfde doel: 
de vroege herkenning van axSpA en een verkorting van de vertraging in het diagnostische 
proces. Een belangrijke stap in het aanpakken van dit probleem was dat experts in het 
veld prospectieve cohort studies hebben ontworpen waarin opeenvolgende patiënten met 
chronische of inflammatoire rugpijn van korte duur worden geïncludeerd en vervolgd  op een 
gestandaardiseerde manier met onder andere beeldvorming op gezette tijden. Dit stelt ons 
in staat om informatie te verkrijgen over wie axSpA zal ontwikkelen en wie niet. Deze cohort 
studies bieden waardevolle informatie over de vroege detectie en het ziektebeloop van 
axSpA en vormen de basis van het onderzoek gepresenteerd in dit proefschrift. Ook is een 
groot internationaal netwerk gericht op onderzoek naar axSpA opgericht; de Assessment of 
SpondyloArthritis international Society (ASAS).
Het eerste deel van dit proefschrift heeft betrekking op twee studies naar de prestaties van 
verschillende classificatiecriteria in een wereldwijde klinische setting en de noodzaak om 
aanvullend onderzoek uit te voeren (HLA-B27-testen; beeldvorming van de sacro-iliacale 
gewrichten) in een subgroep van patiënten met slechts één of zelfs nul SpA kenmerken: 
dat wil zeggen een lage voorafkans op axSpA. Vervolgens verschoof de focus naar 
de rol van beeldvorming in de vroege detectie van de ziekte. Eerst werd de literatuur 
over de recente vooruitgang in beeldvorming van de sacro-iliacale gewrichten (zowel 
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conventionele röntgenfoto’s als MRI) besproken. Dit vormde gedeeltelijk het startpunt voor 
een consensusoefening die resulteerde in een update van de bestaande definitie voor een 
positieve MRI voor de classificatie van axSpA. Vervolgens werd de toegevoegde waarde 
van het gebruik van structurele laesies op MRI in de ASAS axSpA classificatiecriteria 
beoordeeld. Daarna zoomden we opnieuw in op het diagnostische proces; waarbij het nut 
van het herhalen van een MRI van de sacro-iliacale gewrichten (na drie maanden of een jaar) 
in patiënten met chronische rugpijn verdacht van axSpA werd geëvalueerd. In het laatste 
deel van dit proefschrift werd de prevalentie van het HLA-B27+/HLA-B*4001+ genotype 
beoordeeld in twee vroege axSpA cohorten; en de potentiële rol van dit genotype in de 
vroege opsporing van de ziekte. 
De studies in dit proefschrift zijn uitgevoerd in twee prospectieve cohort studies en één studie 
met een cross-sectionele opzet (dwarsdoorsnede onderzoek). De twee cohort studies zijn het 
SPondyloArthritis Caught Early (SPACE) cohort and het DEvenir des Spondylarthropathies 
Indifférenciées Récentes (DESIR) cohort. SPACE is een doorlopend observationeel cohort 
onderzoek waarbij patiënten van 16 jaar en ouder met chronische rugpijn (≥3 maanden, 
≤ 2 jaar en aanvang <45 jaar) verwezen naar een reumatoloog worden geïncludeerd en 
vervolgd. Patiënten worden gerekruteerd in verschillende centra in vier Europese landen: 
Nederland, Noorwegen, Italië en Zweden. De follow-up wordt op gestandaardiseerde wijze 
uitgevoerd:  verzameling van klinische gegevens en beeldvorming op gezette tijdstippen 
(baseline, drie maanden, een jaar, twee jaar, daarna elke twee jaar). Basis- en één jaar 
follow-up gegevens werden gebruikt voor dit proefschrift. DESIR is een longitudinale cohort 
studie waarbij patiënten van 18-50 jaar met inflammatoire rugpijn (IBP) zijn opgenomen in 
25 regionale centra in Frankrijk.  De aanwezigheid van IBP en een duur van de rugpijn van 
≥3 maanden en <3 jaar was vereist voor inclusie. Naast de verplichte aanwezigheid van 
IBP, werd een patiënt alleen opgenomen als de reumatoloog betrokken bij de inclusie van 
de patiënt van mening was dat de waarschijnlijkheid dat deze patiënt de diagnose axSpA 
heeft ten minste 50% was. Het cohort streeft naar een follow-up van 10 jaar, maar voor dit 
proefschrift werden alleen baseline gegevens gebruikt. Het SPACE cohort heeft belangrijke 
gelijkenissen met DESIR, hoewel een belangrijk verschil is dat bij DESIR alleen patiënten met 
IBP worden geïncludeerd, terwijl in SPACE de rugpijn niet noodzakelijkerwijs een inflammatoir 
karakter heeft. Bovendien is in DESIR de aanwezigheid van een axSpA-diagnose op zijn 
minst waarschijnlijk, terwijl dit niet het geval hoeft te zijn in SPACE. Een praktisch verschil is 
dat SPACE een doorlopend cohort onderzoek is; en DESIR een gesloten cohort studie (met 
inclusie tussen december 2007 en april 2010). De studie met het cross-sectionele ontwerp 
is de ASAS-COMOSPA studie. Dit is een door ASAS geïnitieerd onderzoek gericht op het 
evalueren van de prevalentie van comorbiditeiten en risicofactoren daarvoor bij patiënten 
met SpA (zowel axiaal als perifeer) in verschillende landen over de hele wereld. Het doel was 
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om brug te slaan tussen beschikbare aanbevelingen en de dagelijkse praktijk van de wijze 
waarop men met deze comorbiditeiten omgaat. Het is een internationaal, observationeel 
onderzoek waarin patiënten met de diagnose SpA (volgens de behandelende reumatoloog) 
werden opgenomen. Inclusie vond plaats in 22 landen uit vijf verschillende regio’s over de 
hele wereld: Azië, Noord-Afrika, Latijns-Amerika, Noord-Amerika, Midden-Europa en West-
Europa. De multi-nationaliteit en het grote aantal geïncludeerde patiënten, maakt het cohort 
ideaal voor het verrichten van aanvullende studies, zoals die beschreven in dit proefschrift.  
DEEL I: VROEGE HERKENNING EN 
CLASSIFICATIECRITERIA 
Aan de hand van de hierboven beschreven SpA kenmerken vormt de reumatoloog een 
zo gedetailleerd mogelijk klinisch beeld van de patiënt met als doel om tot een passende 
diagnose en behandeling te komen. Er bestaan geen strikte criteria voor het stellen van 
een diagnose en het diagnostische proces resulteert zodoende in heterogene groepen van 
patiënten. Om gedegen wetenschappelijk onderzoek te kunnen doen is het echter belangrijk 
om goed gedefinieerde homogene groepen te creëren voor patiënten die de diagnose 
axSpA hebben. Om dit te bereiken zijn verschillende sets van classificatiecriteria ontwikkeld. 
Hierbij worden aan de hand van overeenkomstige kenmerken patiënten in categorieën 
ondergebracht. 
Eén van de meest bekende classificatiecriteria in het veld van axSpA zijn de in 1984 
ontwikkelde modified New York (mNY) criteria. Deze criteria classificeren patiënten met 
ankyloserende spondylitis (AS) wat ook bekend staat als de ziekte van Bechterew. AS is 
de meest uitgesproken variant van axSpA en het wordt gekenmerkt door radiografische 
sacroiliitis. Radiografische sacroiliitis betreft structurele schade aan het bot, veroorzaakt door 
een ontsteking, vast te stellen middels röntgenfoto’s van de sacro-iliacale (SI) gewrichten. 
Deze structurele schade wordt gegradeerd in ernst van graad 0 tot 4 per SI-gewricht. 
Radiografische sacroiliitis is in de mNY criteria gedefinieerd als graad ≥2 aan beide SI-
gewrichten of graad 3-4 aan één van beide gewrichten. Echter, om aan de mNY-criteria te 
voldoen dient de patiënt naast radiografische sacroiliitis ook minimaal één van de volgende 
klinische kenmerken hebben: 1. lage rugpijn gedurende ten minste 3 maanden, die verbetert 
door beweging en niet door rust, 2. verminderde beweeglijkheid van de onderrug bij het 
zijwaarts buigen en bij naar voren en naar achteren buigen, 3. verminderd vermogen om 




De mNY-criteria behelzen axiale kenmerken van de ziekte en daarnaast een zeer beperkt 
aantal SpA kenmerken. Daarnaast geldt de eerder genoemde beperking van mogelijk 
absente röntgenologische afwijkingen bij vroege ziekte.  Al met al hebben de beperkingen 
van de mNY-criteria geleid tot de ontwikkeling van de Amor-criteria en ESSG-criteria begin 
jaren negentig. In deze twee criteria sets zijn meer SpA kenmerken vertegenwoordigd en ze 
omvatten derhalve het hele SpA-spectrum.
De Amor-criteria bestaan uit een lijst met symptomen, die geen van alle noodzakelijk zijn 
om een patiënt als SpA te classificeren. Punten (1-3) worden toegewezen aan verschillende 
symptomen en in totaal zijn ten minste 6 punten nodig voor classificatie. In tegenstelling 
tot de Amor-criteria, worden voor de ESSG-criteria ingangscriteria gehanteerd door middel 
van verplichte aanwezigheid van inflammatoire rugpijn (IBP) of perifere artritis. Volgens de 
ESSG-criteria worden patiënten met ten minste één van de ingangscriteria in combinatie met 
één aanvullend criterium geclassificeerd als SpA.
De Amor- en ESSG-criteria omvatten het hele spectrum van SpA, maar ze kunnen axiale 
en perifere ziekte niet van elkaar onderscheiden. Daarnaast is de MRI niet opgenomen 
in deze criteria sets. In 2009 heeft een groep experts (verenigd in ASAS) twee nieuwe 
classificatiecriteria sets ontwikkeld: één voor axiale SpA (axSpA) en één voor perifere 
SpA (pSpA). Volgens de ASAS-classificatiecriteria voor axiale SpA (ASAS axSpA) kunnen 
de criteria worden toegepast wanneer een patiënt minimaal drie maanden chronische 
rugpijn heeft, met een aanvang voor het 45e levensjaar. Een patiënt kan voldoen aan de 
ASAS axSpA criteria via (minimaal) één van de twee armen: de imaging arm (met de 
nadruk op beeldvorming) en/of de klinische arm (met de nadruk op HLA-B27 positiviteit). 
Patiënten voldoen aan classificatie via de imaging arm als één SpA kenmerk aanwezig is 
naast radiografische sacroiliitis (mNY-criteria) of actieve ontsteking op MRI suggestief voor 
sacroiliitis. Om te voldoen aan de klinische arm, moet de patiënt HLA-B27-positief zijn en 
ten minste twee andere SpA kenmerken hebben. De classificatiecriteria voor perifere SpA 
kunnen alleen worden toegepast bij patiënten met op dat moment perifere manifestaties. 
Om aan deze criteria te voldoen, moet een patiënt artritis, dactylitis of enthesitis hebben in 
combinatie met minstens één andere SpA kenmerk.
Classificatiecriteria worden vaak geëvalueerd in beperkte patiënten populaties, zoals cohort 
studies met strikte inclusiecriteria die patiënten includeren in gespecialiseerde klinieken. Dit 
leidt automatisch tot tamelijk homogene groepen patiënten en is essentieel voor het evalueren 
van de prestaties van die criteria en de proof-of-concept. Echter, het stelt tegelijkertijd de 
vraag hoe deze classificatiecriteria zouden presteren in een omgeving die sterk lijkt op de 
situatie in de dagelijkse klinische praktijk: een situatie waar een heterogene groep patiënten 
zich presenteert aan reumatologen in wereldwijde context.
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Classificatiecriteria zijn allemaal ontwikkeld met behulp van ‘expert opinion’ als de externe 
standaard in de afwezigheid van een onbetwiste gouden standaard. Patroonherkenning vormt 
de basis van deze expert opinion: reumatologen combineren individuele patiëntkenmerken 
en symptomen met hun eigen kennis over het ziektepatroon (het zogenaamde ‘Gestalt’). 
Het is daarom niet moeilijk te begrijpen dat ‘expert opinion’ geen eenduidig  en homogeen 
concept is. Het kan mogelijk verschillende beelden van de ziekte integreren die nog beter 
te begrijpen zijn vanuit een mondiaal perspectief (diversiteit van patiënten populaties en 
reumatologie opleidingsprogramma’s).
In hoofdstuk 2 werden de prestaties van verschillende classificatiecriteria sets getest in 
een wereldwijde populatie van patiënten. Patiënten werden gerekruteerd uit de klinische 
praktijk van een groot aantal reumatologische centra over de hele wereld. We onderzochten 
of reumatologen wereldwijd een eenzelfde soort patiënten diagnosticeren met SpA, door 
te testen of patiënten aan dezelfde classificatie criteria voldeden. Dit werd gedaan in de 
veronderstelling dat aan hoe meer criteria een patiënt voldoet, des te groter de kans is 
dat een patiënt met de diagnose SpA ook echt SpA heeft. Geconcludeerd werd dat de 
meeste patiënten met een klinische diagnose van SpA aan verschillende classificatiecriteria 
voldeden en er een substantiële overlap was tussen de criteria, wat bijdraagt  aan de 
geloofwaardigheid en validiteit van de criteria. In dit geval is het belangrijk om te vermelden 
dat dit cohort geen cohort is van vroege ziekte: 65% van de patiënten voldeed aan de mNY-
criteria. Echter, ondanks de overlap tussen de criteria sets, werd een substantieel deel van 
de patiënten opgepikt door slechts één criteria set: namelijk de ASAS axiale SpA criteria.  
De ASAS-criteria bleken beter te presteren dan classificatiecriteria sets zoals de Amor- 
en ESSG-criteria. De ASAS-criteria hebben met name een betere sensitiviteit door de 
aanwezigheid van MRI in de imaging arm. Wanneer getest tegenover de diagnose van 
experts, vertegenwoordigen de ASAS-criteria het huidige ‘Gestalt’ beter dan de ESSG- en 
AMOR-criteria, die tientallen jaren geleden zijn ontworpen vóór de introductie van MRI. 
Naast het feit dat MRI-bevindingen zijn opgenomen in de criteria, maken de ASAS-criteria 
onderscheid tussen axiale en perifere SpA. Hoewel de ESSG- en Amor-criteria het hele 
spectrum van SpA beslaan en een breder scala aan kenmerken bevatten in vergelijking 
met de modified New York-criteria, maken deze criteria géén onderscheid tussen axiale 
en perifere SpA. Deze differentiatie is echter wel belangrijk, bijvoorbeeld bij het testen van 
behandelstrategieën. Onlangs is een systematisch literatuuronderzoek en meta-analyse 
uitgevoerd om het bewijsmateriaal voor de prestaties van de ASAS-classificatiecriteria samen 
te vatten. De volledige set ASAS SpA-criteria leverden een hoge gepoolde sensitiviteit (73%) 
en specificiteit (88%) op. Evenzo werden goede resultaten gevonden voor de axSpA-criteria 
(sensitiviteit: 82%, specificiteit: 88%). Voor de andere criteria liggen deze getallen lager. 
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Niettemin hebben diverse reumatologen wereldwijd hun bezorgdheid geuit over de 
validiteit van de ASAS-criteria. Met name de specificiteit van de criteria staat ter discussie: 
de aanwezigheid van de klinische arm zou leiden tot een hogere sensitiviteit terwijl dit ten 
koste gaat van de specificiteit. Met andere woorden, patiënten die alleen voldoen aan de 
klinische arm, moeten niet worden beschouwd als ‘echte’ axSpA (mislabeling). Dit staat in 
schril contrast tot de imaging arm die breed erkend en geaccepteerd wordt. Daarom hebben 
we in hoofdstuk 2 de patiëntkarakteristieken vergeleken van patiënten die voldeden aan 
de klinische arm en de imaging arm. Er werd geconcludeerd dat patiënten die voldeden 
aan de klinische arm opvallend veel gelijkenissen hadden met patiënten die voldeden aan 
de imaging arm met betrekking tot de aanwezigheid van SpA kenmerken. Deze bevinding 
komt overeen met eerdere observaties in het SPACE cohort en het DESIR cohort. In de 
ABILITY-1-studie (een gerandomiseerde gecontroleerde studie die werd uitgevoerd om 
de werkzaamheid en veiligheid van adalimumab te beoordelen bij patiënten met non-
radiografische axSpA) waren er ook geen opvallende verschillen tussen patiënten die aan de 
imaging arm en klinische arm voldeden. In deze studies werd ook opgemerkt dat patiënten 
in de verschillende armen niet alleen opvallend vergelijkbaar waren met betrekking tot de 
aanwezigheid van SpA kenmerken, maar ook met betrekking tot ziekteactiviteit (BASDAI en 
ASDAS). In de huidige ASAS-COMOSPA-studie werd de relevantie van de klinische arm 
opnieuw bevestigd.
Veel patiënten in dit onderzoek ondergingen geen MRI. Deze situatie is compatibel 
met de dagelijkse klinische praktijk aangezien MRI een relatief duur onderzoek is en de 
beschikbaarheid ervan soms beperkt. Als MRI niet beschikbaar is, blijft een aanzienlijk deel 
van de patiënten niet herkend en zal de sensitiviteit van de criteria afnemen. Mogelijk zal dit 
probleem groter zijn bij vrouwen, die een lager risico hebben op radiografische progressie 
(mannelijk geslacht was een risicofactor voor het ontwikkelen van radiografische sacroiliitis 
en dus voor de evolutie van nr-axSpA naar r-axSpA). Een ander belangrijk punt is het feit dat 
beeldvorming (zowel conventionele röntgenfoto’s als MRI) moeilijk te interpreteren kan zijn 
in de klinische praktijk. In het DESIR cohort werd aangetoond dat zowel getrainde lezers als 
lokale reumatologen en radiologen slechts matig overeenkwamen voor de herkenning van 
sacroiliitis op röntgenfoto’s. Een aanzienlijk deel van de patiënten die werden gelabeld als 
zijnde radiografische sacroiliitis door lokale lezers, werd niet bevestigd door centrale lezers 
(vals positief). In een ander onderzoek was onenigheid tussen lokale en centrale lezers over 
positieve radiografische sacroiliitis aanwezig bij 28% van de patiënten. Omdat beeldvorming 
vaker door lokale lezers als positief werd gemarkeerd, komt de specificiteit van de imaging 
arm in gevaar (fout-positiviteit). Zoals door onze studie werd aangetoond, voldoen veel 
patiënten aan zowel de imaging arm als de klinische arm. Daarom wordt het risico van de 
hierboven beschreven ‘verkeerde interpretatie’ minder prominent in de aanwezigheid van de 
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klinische arm. Ook dit onderstreept weer de relevantie van de klinische arm van de ASAS 
axSpA-criteria. 
Tot voor kort was de validiteit van de ASAS-criteria alleen bestudeerd in een cross-sectionele 
setting: of iemand voldoet aan de classificatiecriteria, en of iemand de diagnose heeft volgens 
de reumatoloog (externe standaard) wordt op hetzelfde moment bekeken. In zekere zin zijn 
de begrippen sensitiviteit en specificiteit statische begrippen, die los staan van predictieve 
eigenschappen. Het is van essentieel belang om te weten of patiënten die aanvankelijk 
werden geclassificeerd als axSpA nog steeds worden beschouwd als patiënten met een SpA-
diagnose na jarenlange follow-up. Onlangs zijn er gegevens over de voorspellende validiteit 
van de ASAS-criteria gepubliceerd: patiënten uit het ASAS cohort werden gedurende 3-5 
jaar gevolgd en reumatologen hebben de patiënten daarna opnieuw bekeken. 93.3% van de 
patiënten die aanvankelijk aan de criteria voldeden, zou nog steeds worden gediagnosticeerd 
als axSpA door de reumatoloog. Dit leidt tot een uitstekende voorspellende waarde en 
suggereert eveneens consistentie van de criteria over de tijd. Vergelijkbare resultaten werden 
gevonden voor de imaging arm (range: 94.5-96.5%) en klinische arm (range: 96.4-98.2%) en 
ook voor patiënten die alleen aan de imaging arm voldeden (bereik: 85.1-86.7%) ofwel alleen 
aan de klinische arm (bereik: 87.9-92.9%). De negatief voorspellende waarde was iets lager. 
Echter, omdat het bekend is dat SpA kenmerken in de loop van de tijd kunnen veranderen 
zou dit wellicht het natuurlijke ziektebeloop kunnen reflecteren in plaats van een negatieve 
test karakteristiek. Omdat vergelijkbare positief voorspellende waardes voor beide armen van 
de axSpA-criteria werden gevonden, ondersteunen deze gegevens ook de opvatting dat de 
klinische arm een  groep patiënten omvat die evenzeer tot het SpA-spectrum behoort als de 
patiënten die aan de imaging arm voldoen. 
Door het ontbreken van diagnostische criteria kunnen artsen in de verleiding komen 
om classificatiecriteria als zodanig te gebruiken. Dezelfde klinische- laboratorium- en 
beeldvorming-gegevens worden gebruikt voor classificatie en diagnose, maar er bestaan 
duidelijke verschillen in de toepassing ervan. Voorzichtigheid is geboden bij het gebruik van 
classificatiecriteria als lijstjes met kenmerken die kunnen worden aangevinkt om een  diagnose 
te stellen. Een essentiële stap die gemist wordt door eenvoudig SpA kenmerken te tellen, 
is de uitsluiting van andere waarschijnlijke diagnoses (differentiaal diagnostisch denken) en 
negatieve bevindingen die niet in de richting van axSpA wijzen. Zoals eerder uitgelegd, zijn 
de criteria ontworpen voor classificatie in plaats van diagnostische doeleinden en moeten 
ze alleen worden toegepast bij patiënten met de diagnose SpA (en niet omgekeerd). Het 
probleem van het gebruik van classificatiecriteria om een  diagnose te stellen, is met name 
problematisch bij patiënten die niet worden gezien door een reumatoloog en vooral als de pre-
testkans laag is. Bij patiënten met een relatief hoge pre-test probabiliteit zoals in de studies uit 
dit proefschrift, waar de pre-test waarschijnlijkheid rond de 30% is, is dit risico minder groot.
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Bovendien werd in SPACE uitsluiting van andere waarschijnlijke diagnoses door de 
reumatoloog uitgevoerd nog voordat patiënten werden geïncludeerd in SPACE (formeel 
exclusie criterium). Daarnaast werd de evaluatie van SpA kenmerken alleen door experts 
gedaan. Classificatiecriteria zijn ontwikkeld om een  duidelijk ja/nee-antwoord te krijgen, 
waarmee een  vrij homogene groep patiënten wordt gecreëerd, meestal voor opname in 
een cohort studie of klinische trial. Ze zorgen voor vergelijkbaarheid tussen deze studies, 
maar het is moeilijk om het volledige scala van ziektebeelden te vangen aan de hand van 
een reeks criteria. Zoals hierboven uitgelegd, is kennis van de pre-test probabiliteit van het 
hebben van de ziekte essentieel in de diagnose. In een cohort van patiënten met chronische 
rugpijn bij een huisarts in de eerstelijns gezondheidszorg, werd SpA gediagnosticeerd in 
5% van de gevallen en dit wordt vaak gebruikt als de veronderstelde pre-test probabiliteit 
van deze ziekte. In de studies beschreven in dit proefschrift hebben we de 5% pre-test 
waarschijnlijkheid gebruikt om bijvoorbeeld likelihood ratios te berekenen. Maar gezien 
onze studies zijn uitgevoerd in een secundaire dan wel tertiaire setting, waarbij de vooraf 
kans dat patiënten axSpA hebben groter is dan in de eerstelijnszorg is dit waarschijnlijk een 
conservatieve schatting. Helaas was een schatting van de pre-test probabiliteit in deze setting 
onbekend toen het cohort werd gestart, maar na een paar jaar hebben we geconstateerd dat 
het ongeveer 30% is. De pre-test waarschijnlijkheid van 5%, die we gebruikten, resulteerde 
dus in een onderschatting van de waarschijnlijkheid van post-test ziekte.
De diagnostische work-up van axSpA is een uitdaging; enkele van de argumenten waarom 
dit het geval is zijn de revue al gepasseerd. In het algemeen moet de ziekte worden vermoed 
bij patiënten met chronische rugpijn (chronic back pain: CBP) met een aanvang vóór het 
45e levensjaar en een voorgeschiedenis van CBP die bijna drie maanden of langer continu 
aanwezig is (sub-acuut begin). Dit zou moeten leiden tot verdere evaluatie om vast te stellen 
of andere SpA kenmerken aanwezig zijn. Het gemodificeerde Berlijn algoritme dient als een 
nuttig hulpmiddel om reumatologen te helpen bij de diagnose van axSpA. Het algoritme 
suggereert dat röntgenfoto’s van de sacro-iliacale gewrichten worden aanbevolen bij alle 
verwezen patiënten met rugpijn met de hierboven beschreven kenmerken, ongeacht de 
aanwezigheid van andere SpA kenmerken. Indien negatief worden alle patiënten beoordeeld 
op de aanwezigheid van andere SpA kenmerken en getest voor HLA-B27. In het onderzoek 
beschreven in hoofdstuk 3 hebben we geprobeerd te onderzoeken of HLA-B27 testen en 
beeldvorming van de sacro-iliacale gewrichten (door middel van conventionele röntgenfoto’s 
en MRI) noodzakelijk is in een subgroep van patiënten met een lage voorafkans op axSpA: 
gedefinieerd als patiënten met nul of slechts één SpA kenmerk na klinisch onderzoek en 
meting van acute fase eiwitten in het laboratoriumonderzoek. Verrassend genoeg werd een 
diagnose axSpA gesteld in 18.4% van de patiënten met nul SpA kenmerken en 17.9% van 
de patiënten met één SpA kenmerk. We waren verrast door deze relatief hoge percentages. 
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Zelfs bij patiënten zonder één enkel SpA kenmerk na klinisch onderzoek en meting van 
acute fase eiwitten was het niet mogelijk om axSpA volledig uit te sluiten. Het is belangrijk 
om rekening te houden met de populatie van patiënten waarin de onderzoeksvraag werd 
onderzocht. Patiënten die deel uitmaken van het SPACE cohort worden doorverwezen naar 
een reumatoloog. Bepaalde red flags of andere bevindingen kunnen tot deze verwijzing 
hebben geleid.  En in feite zijn meer waarschijnlijke diagnoses al uitgesloten. Daarom 
moeten de resultaten van deze studie niet worden geëxtrapoleerd of gegeneraliseerd naar 
bijvoorbeeld de huisartsenpraktijk.
Deze nuances terzijde gelegd, is het verrassend dat in deze groepen van patiënten met een 
lage voorafkans op SpA de diagnose niet zo ongewoon is als vooraf werd ingeschat. Het 
kan worden betwijfeld hoe realistisch de meerderheid van deze diagnoses is. Beeldvorming 
speelt een cruciale rol en is vaak doorslaggevend bij het al dan niet stellen van een diagnose. 
Dit is goed te begrijpen, aangezien radiologische afwijkingen aanvoelen als een objectief 
teken van ziekte. Maar ter illustratie voelt het onjuist dat bij een vrouwelijke patiënt met 
rugpijn zonder enig ander SpA kenmerk de diagnose wordt gesteld op basis van de solitaire 
vaststelling van sacroiliitis op röntgenfoto’s. Aan de andere kant kan een diagnose nog 
steeds te rechtvaardigen zijn vanwege kenmerken of symptomen die buiten de formele SpA 
kenmerken vallen en dus buiten de kenmerken die we hebben geëvalueerd, bijvoorbeeld 
aanwezigheid van structurele laesies op een MRI van de sacro-iliacale gewrichten (MRI-SI) 
of inflammatoire laesies. Het kan ook zijn dat het gemodificeerde algoritme van Berlijn strikt 
wordt opgevolgd, met name door minder ervaren reumatologen (in opleiding) op het gebied 
van axSpA. Er moet nogmaals worden benadrukt dat het gemodificeerde Berlijn algoritme 
alleen een hulpmiddel is bij het stellen van een diagnose en dat het differentiaal diagnostisch 
denken hier niet door vervangen mag worden. Ook staat de dominantie van conventionele 
röntgenfoto’s in het gemodificeerde Berlijn algoritme ter discussie. In het algemeen is er debat 
gaande in hoeverre aanvullende onderzoeken moeten worden uitgevoerd om een  diagnose 
goed te keuren ofwel af te wijzen en er zijn zorgen geuit als de huidige diagnostische work-up 
niet al te uitgebreid is, vooral bij patiënten met een lage pre-test probabiliteit. Idealiter zouden 
we een diagnostisch proces op maat willen, waarbij artsen alleen specifieke onderzoeken 
onder bepaalde motivaties moeten uitvoeren. Bovendien zal alleen de langdurige follow-up 
van deze patiënten bevestigen of de diagnose correct is geweest en ook is het interessant 
om progressie van afwijkende bevindingen op de beeldvorming over tijd te vervolgen.
Sequentieel testen wordt ook bepleit in het gemodificeerde Berlijn algoritme. Hoewel we het 
algoritme formeel niet hebben getest in hoofdstuk 3, denken we dat de rol voor een MRI van de 
sacro-iliacale gewrichten (MRI-SI) misschien wat te beperkt is. MRI-SI zou alleen in een zeer 
specifieke situatie moeten worden uitgevoerd. Dit in scherp contrast met de conventionele 
röntgenfoto, wat de breed erkende eerste stap van het algoritme is. In een groep patiënten 
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met klachten van korte duur zoals het SPACE cohort is het echter zeer waarschijnlijk dat 
radiografische veranderingen nog niet zijn opgetreden wat tot vals-negatieve diagnoses 
zou kunnen leiden als er geen andere tests worden uitgevoerd. De onlangs gepubliceerde 
EULAR-aanbevelingen zijn eveneens minder conservatief en bevelen MRI-SI aan als een 
alternatieve eerste methode bij beeldvorming van bijvoorbeeld jonge patiënten met een 
korte symptoomduur. In het later beschreven hoofdstuk 8 zullen we het verloop van MRI-SI-
activiteit over een jaar en de identificatie van voorspellende factoren voor een positieve MRI 
evalueren.
Toekomstperspectieven 
De vroege diagnose van axSpA door een reumatoloog is belangrijk en een hoofddoelstelling 
van dit proefschrift. Echter de identificatie van patiënten met een verhoogd risico op axSpA 
in de eerste lijn is hiervoor essentieel. Het is evident dat een late verwijzing van patiënten 
naar een reumatoloog bijdraagt  aan de diagnostische vertraging. Chronische rugpijn komt 
veel voor in de algemene populatie maar in de eerste lijn is axSpA in slechts 5% van de 
gevallen de oorzaak. Effectieve verwijsstrategieën zijn hierbij zeer belangrijk. Daarvoor is 
een verhoogd bewustzijn van de ziekte van cruciaal belang, op niveau van dokter en patiënt. 
Onderwijs is belangrijk om het doel van vroege verwijzing en diagnose te bereiken. Dit 
omvat ook bij tweedelijns instellingen het juiste gebruik van beeldvorming en een correcte 
interpretatie hiervan. Vooral dat laatste is zeer relevant, op dit moment vindt nationale 
voorlichting ook plaats. Voorlichting over het niet gebruiken van classificatiecriteria voor het 
stellen van een diagnose is essentieel. Het algoritme van Berlijn moet zorgvuldig worden 
herzien, vooral de dominante plaats van conventionele röntgenfoto’s staat ter discussie. 
Hoewel MRI ook nadelen heeft lijkt het in het traject van vroege diagnose meer geschikt dan 
conventionele röntgenfoto’s. In dit licht zou het ook interessant zijn om de kosteneffectiviteit 
van zowel conventionele röntgenfoto’s als MRI te onderzoeken.
DEEL II: HET GEBRUIK VAN BEELDVORMING (MRI) IN 
VROEGE AXIALE SPONDYLOARTRITIS
In hoofdstuk 4 worden de resultaten van een systematische literatuurstudie (systematic 
literature review, SLR) beschreven die recente vorderingen in het onderzoek naar beide 
beeldvormende modaliteiten van de sacro-iliacale gewrichten (conventionele röntgenfoto’s 
en MRI) op een rij zetten. Geconcludeerd werd dat substantiële verschillen in de beoordeling 
van conventionele röntgenfoto’s de betrouwbaarheid van dit onderzoek sterk beïnvloeden, 
wat ertoe leidt dat sacroiliitis vaak wordt gemist of ten onrechte wordt vastgesteld. Deze 
variabiliteit in beoordeling tussen lezers (zowel reumatologen als radiologen) kon helaas 
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niet worden verbeterd door training van de lezers. De slechte betrouwbaarheid van het 
evalueren van conventionele röntgenfoto’s werd ook gesignaleerd in post-hoc analyses van 
de ABILITY-1 en RAPID axSpA-trials. Meer recente gegevens van het DESIR cohort lieten 
zien dat bij patiënten met inflammatoire rugpijn verdacht voor axSpA zowel getrainde lezers 
als lokale reumatologen en radiologen het gematigd eens waren over de herkenning van 
radiografische sacroiliitis. Een aanzienlijk deel van de lokaal erkende patiënten werd niet 
bevestigd door centrale lezing (41.5% fout-positieven) terwijl slechts een minderheid fout-
negatief was (7.5%).
In de afgelopen jaren zijn veel studies op het gebied van MRI uitgevoerd. ASAS ontwikkelde 
nuttige aanbevelingen voor het uitvoeren van een optimale MRI van de sacro-iliacale 
gewrichten en ontwikkelde ook een definitie voor een positieve MRI. In tegenstelling 
tot de gematigde overeenkomst met betrekking tot radiografische sacroiliitis was de 
overeenstemming over sacroiliitis op MRI aanzienlijk beter: zowel tussen de twee centrale 
lezers in het DESIR cohort als tussen de lokale en centrale lezer in dit cohort. In hoofdstuk 8 
van dit proefschrift was overeenstemming over een positieve MRI tussen de twee lezers zelfs 
nog beter (kappa: 0.84). 
Het effect van discrepantie van de beeldvorming werd onderzocht op basis van de ASAS 
axSpA classificatiecriteria. Van de patiënten met een afwijkende MRI en/of röntgenfoto had 
28% had anders kunnen worden geclassificeerd (sec op beeldvorming), maar slechts 7.9% 
was ook daadwerkelijk anders geclassificeerd. Dit komt voornamelijk door de aanwezigheid 
van de klinische arm. In het algemeen dienen reumatologen zich bewust te zijn van de 
mogelijke discrepanties ten aanzien van beeldvorming. Dit onderstreept in het diagnostische 
proces het belang van het beoordelen van een patiënt als geheel in plaats van volledig te 
vertrouwen op beeldvorming.
Vanwege de expansieve toename in literatuur op dit gebied werd de vraag gesteld of de 
formulering van de ASAS definitie van een positieve MRI nog steeds de juiste was. Een vaak 
gehoorde kritische opmerking in het veld is dat tijdens het lezen van een MRI men in de 
verleiding komt om gewoon de zichtbare witte vlekken te tellen op de STIR sequenties, wat 
resulteert in een lage specificiteit (dat wil zeggen: dat veel gezonde proefpersonen wel de 
uitslag krijgen van een afwijkende MRI omdat beenmergoedeem ook een aspecifiek teken 
kan zijn, fout-positiviteit). Een lage specificiteit van de MRI-bevinding van beenmergoedeem 
kenmerkend voor sacroiliitis kan leiden tot misclassificatie, vooral bij patiëntpopulaties met 
een lage axSpA-prevalentie. 
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In hoofdstuk 5 werd een consensusoefening onder deskundigen op dit gebied verricht. 
Er werd besloten dat de duidelijke aanwezigheid van beenmergoedeem (bone marrow 
edema, BME) op MRI in subchondraal bot nog steeds wordt beschouwd als de bepalende 
waarneming die de aanwezigheid van actieve sacroiliitis bepaalt, hoewel de presentatie 
van de definitie opnieuw werd geformatteerd. Er werd benadrukt dat de definitie primair is 
voor de classificatie van patiënten met SpA. Verder werd toegevoegd dat voorzichtigheid 
is geboden bij de interpretatie van kleine laesies. Hoewel detectie van ontsteking op een 
enkele slice voldoende kan zijn voor het criterium ‘zeer suggestief voor SpA’ moet worden 
gerealiseerd dat het zeldzaam is voor een MRI-SI met duidelijk bewijs van actieve sacroiliitis 
om slechts laesies aan te tonen op één enkele afbeelding. MRI-sequenties (STIR, T1) moeten 
tegelijkertijd worden beoordeeld. Als er een inflammatoire beenmerglaesie lijkt te bestaan, 
maar het is moeilijk om te bepalen of de laesie voldoet aan het criterium ‘zeer suggestief 
voor SpA’, werd gesteld dat de beslissing kan worden beïnvloed door de aanwezigheid van 
bijkomende structurele schade. Structurele schade is het best zichtbaar op de T1-sequentie 
(tezamen te beoordelen met de STIR-sequentie) en omvat bijvoorbeeld erosies, die op 
zichzelf niet voldoende zijn om aan het criterium te voldoen maar wél een ondersteunende 
bijdrage kunnen hebben. Dat structurele laesies op zich niet voldoende zijn voor een 
positieve MRI heeft niet zozeer te maken met de mogelijk beperkte aanvullende waarde van 
deze laesies (dit wordt juist wel zo verondersteld) maar op dit moment is er nog te weinig 
evidence om deze laesies formeel bij de definitie te betrekken.  Dit wordt echter wel binnen 
afzienbare termijn verwacht. Al met al hebben de huidige wijzigingen al wel geleid tot een 
belangrijke specificatie van een positieve MRI voor sacroiliitis. 
Het voorkomen en de evolutie van structurele laesies in patiënten met axSpA is een hot topic. 
Naast erosies kunnen ook vervetting, sclerose en ankylose worden waargenomen. Daarom 
heeft MRI een groot potentieel voor de beoordeling van zowel actieve inflammatoire laesies 
als structurele schade door middel van één enkele beeldvormende techniek. De ASAS-
groep die de ASAS axSpA-criteria ontwikkelde, onthield zich van het opnemen van andere 
laesies dan beenmergoedeem vanwege een gebrek aan bewijs over het nut van structurele 
laesies in de classificatie van axSpA. Een belangrijke eerste stap was het onderzoeken van 
de omvang en prestaties van structurele laesies op MRI-SI bij patiënten met vermoedelijk 
axSpA. Er zijn verschillende studies uitgevoerd, maar aangezien een controlegroep ontbrak, 
was het onmogelijk om de specificiteit van deze laesies te bepalen. 
De studie van de Hooge et al. heeft wel een controlegroep van CBP-patiënten opgenomen 
aangezien deze patiënten zijn opgenomen in het SPACE cohort. Dit maakte het mogelijk om 
MRI-laesies te kwantificeren bij patiënten met en zonder axSpA. Met opzet werd een hoge 
specificiteit (>95%) geselecteerd om misclassificatie van patiënten te voorkómen, aangezien 
wordt voldaan aan de imaging arm bij positieve beeldvorming plus slechts één extra SpA 
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kenmerk. Deze studie toonde aan dat de aanwezigheid van minstens vijf (≥5) vettige laesies 
en/of erosies evenals ≥3 vettige laesies en ≥3 erosies een aanvaardbare discriminatie van 
axSpA en geen SpA mogelijk maakte terwijl een> 95% specificiteit werd gegarandeerd.
Deze afkappunten hebben wij toegepast in twee studies beschreven in dit proefschrift: 
hoofdstuk 6 en hoofdstuk 7. In deze studies wilden we de rol van deze structurele laesies 
verder verduidelijken en hun bruikbaarheid met betrekking tot de ASAS axSpA classificatie 
van patiënten onderzoeken. Twee scenario’s werden getest: het toevoegen van structurele 
laesies op MRI aan de definitie van ‘sacroiliitis op de beeldvorming’ (1) en het vervangen 
van radiografische sacroiliitis door structurele laesies op MRI (2). Voor beide scenario’s 
werd de impact op de ASAS axSpA classificatie van patiënten geïnventariseerd. Gevonden 
werd dat bij het toepassen van beide scenario’s slechts kleine wijzigingen in de ASAS 
axSpA-classificatie optraden. De meeste patiënten veranderden van de ene subcategorie 
naar de andere, in plaats van dat de classificatie an sich veranderde (van ASAS axSpA 
positief naar negatief of vice versa). Het belang van de aanwezigheid van de klinische arm 
wordt hier nogmaals onderschreven. Er werd geconcludeerd dat structurele laesies op 
MRI betrouwbaar kunnen worden gebruikt als een toevoeging aan of als vervanging voor 
röntgenfoto’s in de ASAS axSpA-classificatie. Dit draagt  bij aan de robuustheid van de ASAS 
axSpA-criteria als geheel. Ondanks het feit dat zowel vervanging als toevoeging min of meer 
hetzelfde effect hadden (vervanging leidde tot verlies van een klein aantal patiënten met 
een lage waarschijnlijkheid van axiale SpA) geven we de voorkeur aan het scenario van 
toevoeging. Dit om redenen van praktische uitvoerbaarheid.
We hebben het gebruik van structurele laesies met betrekking tot de ASAS axSpA classificatie 
onderzocht. Echter, als voor diagnostische doeleinden een T1-sequentie beschikbaar is in 
afwezigheid van een conventionele röntgenfoto én er zijn duidelijke afwijkingen is er in dat 
geval geen reden om alsnog extra röntgenfoto’s te laten maken. In de onlangs gepubliceerde 
aanbevelingen van de EUropean League Against Rheumatism (EULAR) voor het gebruik van 
beeldvorming bij de diagnose en het beleid van axSpA in de klinische praktijk, werd ook 
gepleit om te kijken naar de aanwezigheid van structurele laesies (zoals erosies, vetinfiltratie, 
sclerose en nieuwe botvorming) naast actieve inflammatoire laesies. Onze gegevens komen 
daarmee overeen. 
Zoals eerder beschreven, is de herkenning van radiografische sacroiliitis een uitdaging. 
Helaas was de overeenstemming over structurele laesies op MRI nog steeds slechts matig 
tot redelijk. Het is echter geruststellend om te zien dat dezelfde conclusies (effecten op 
ASAS axSpA classificatie) kunnen worden getrokken door de gegevens van de individuele 
lezers te vergelijken. Dit versterkt onze bevindingen en draagt bij aan de validiteit van de 
criteria zelf, omdat de resultaten niet te veel worden beïnvloed voor de variatie tussen de 
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lezers op dit punt. Dit in tegenstelling tot de modified New York-criteria die onmiddellijk 
veranderen in het geval van discrepante metingen en met ook een veranderende ASAS 
axSpA classificatie tot gevolg.
Omdat axiale SpA gewoonlijk begint in de sacro-iliacale gewrichten, zijn actieve inflammatoire 
(of structurele) laesies van de wervelkolom niet opgenomen in de ASAS axSpA classificatie 
criteria. We weten echter dat inflammatoire laesies in de wervelkolom optreden in axiale SpA: 
soms zelfs bij afwezigheid van sacroiliitis in MRI, zoals aangetoond in de eerder beschreven 
ABILITY-1 trial. Deze studies hebben belangstelling gewekt voor het onderzoeken van 
de opbrengst van een positieve MRI-wervelkolom als beeldvormingscriterium in de ASAS 
axSpA-classificatie van patiënten. Op basis van een literatuurstudie en consensus van 
deskundigen, heeft de ASAS-OMERACT werkgroep een positieve MRI-wervelkolom in 
axSpA gedefinieerd als de aanwezigheid van ≥ 3 inflammatoire laesies in de wervels; en de 
aanwezigheid van elke laesie op ≥2 opeenvolgende slices. De Canadese groep van Weber 
et al. pleitte ervoor dat de aanwezigheid van ≥5 inflammatoire laesies nog beter zou kunnen 
discrimineren tussen axSpA-patiënten en controlegroepen. Ook de eerder beschreven 
studie van de Hooge et al. toonde aan dat een afkapwaarde van ≥5 inflammatoire laesies 
een positieve MRI-wervelkolom definieerde met een hoge specificiteit van ≥95% (d.w.z. <5% 
patiënten zonder axSpA met een positieve MRI van de wervelkolom).
In SPACE en DESIR werd de aanwezigheid van een positieve MRI-wervelkolom (met behulp 
van de cut-off van ≥ 5 inflammatoire laesies) onderzocht door onze onderzoeksgroep (Ez-
Zaitouni et al.). Hieruit is gebleken dat een positieve MRI-wervelkolom zelden werd gezien 
bij patiënten zonder sacroiliitis op MRI-SI en conventionele röntgenfoto’s in zowel SPACE 
(1%) als DESIR (2%). Het toevoegen van een positieve MRI-wervelkolom aan de imaging 
arm van de ASAS axSpA-criteria, leidde tot een andere classificatie in slechts één patiënt per 
cohort, o.a. gezien deze patiënten vaak ook aan de klinische arm voldeden. Daarom werd 
geconcludeerd dat toevoeging van MRI-wervelkolom als beeldvormingscriterium aan de 
ASAS axSpA-criteria niet wordt aanbevolen. De betrokkenheid van de wervelkolom zonder 
sacro-iliacale gewrichten kan echter bij een klein percentage van de patiënten optreden en 
kan tijdens het diagnostisch proces zorgvuldig worden mee genomen, vooral bij patiënten 
met een langere symptoomduur.
In termen van diagnose kan bij sommige patiënten een langere periode van follow-up en 
monitoring nodig zijn, inclusief aanvullend beeldonderzoek. Hoewel inflammatie op MRI nu 
wordt beschouwd als een belangrijke manifestatie in vroege axSpA, was er niet veel bewijs 
beschikbaar over hoe inflammatoire laesies zich ontwikkelen over de tijd. In hoofdstuk 8 
hebben we onderzocht of het in het kader van het diagnostische proces zinvol is om na 
drie maanden of een jaar een MRI van de sacro-iliacale gewrichten te herhalen bij patiënten 
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met chronische rugpijn met verdenking op axSpA.  Geconcludeerd werd dat veranderingen 
in de MRI-SI-status werden waargenomen bij slechts een minderheid van de patiënten in 
het SPACE cohort. Hoewel veranderingen in beide richtingen zichtbaar waren, werden 
meer patiënten negatief dan positief over de tijd. En een deel van dit negatief worden was 
geassocieerd met het begin van de behandeling met TNF-blokkade. Het herhalen van MRI 
na drie maanden of een jaar in het diagnostisch onderzoek bij vroege ziekte bleek niet zinvol. 
Gevonden werd dat zowel het mannelijke geslacht als de HLA-B27-positiviteit onafhankelijk 
van elkaar de waarschijnlijkheid op een positieve MRI beïnvloeden (op elk moment). Niet 
onverwacht leek de MRI-status bij baseline de kans op positieve MRI van de sacro-iliacale 
gewrichten bij de follow-up sterk te beïnvloeden. Als de baseline MRI positief is, is de kans 
dat de MRI opnieuw positief zal zijn na drie maanden of een jaar erg hoog (84%).  
Toekomstperspectieven   
Een belangrijke onopgeloste uitdaging in beeldvormingsstudies in axSpA is de selectie 
van de externe standaard waarmee de MRI kan worden vergeleken. Vergelijkingen tussen 
verschillende beeldvormingsmodaliteiten; bijvoorbeeld het koppelen van structurele laesies 
op MRI aan een low-dose CT zal ons meer inzicht verschaffen. De beschikbaarheid van 
low-dose CT kan de gevoeligheid van de beeldvormingsmethoden verhogen door de 
aanwezigheid en progressie van structurele schade te detecteren en deze gegevens te 
koppelen. Interessante toekomstige vragen zijn hoe MRI kan worden opgenomen in 
toekomstige klinische onderzoeken en of nieuwe geneesmiddelen zoals het aangrijpen op 
de IL-23/IL-17-as verschillende effecten zullen hebben op ontsteking en het ontwikkelen van 
structurele laesies. Methodologie is hier belangrijk, omdat vanzelfsprekend -als we geen 
effect van bijvoorbeeld een biologisch agens op radiografische progressie waarnemen- dit 
kan worden veroorzaakt door afwezigheid van effect; maar ook vanwege het feit dat we 
niet de juiste meetmethode hebben gebruikt. In het algemeen is prospectieve evaluatie 
van zowel inflammatoire als structurele laesies gedurende een voldoende lange tijd nodig 
om de ontwikkeling van axSpA-laesies verder te begrijpen. Longitudinale gegevens van 
het SPACE- en DESIR cohort worden verwacht, maar replicatie van onze bevindingen in 
cohorten van meer geavanceerde ziekte zijn ook zeer gewenst. Idealiter kan een clinicus 
in de nabije toekomst het risico van progressie bij een individuele patiënt bepalen, met 
behulp van baseline parameters zoals HLA-B27-positiviteit, radiografische structurele 
schade, inflammatie op MRI-SI, verhoogd CRP en kan de behandeling dienovereenkomstig 
worden verfijnd. Ten aanzien van beeldvorming in axSpA is een optimale samenwerking 
tussen reumatologen en radiologen van groot belang. De radioloog is de ervaren expert 
op het gebied van beeldvorming en de reumatoloog die betrokken is bij de zorg van een 
bepaalde patiënt kan de bevindingen plaatsen in een klinische context. Idealiter is in de 
klinische praktijk sprake van een synergie tussen deze twee medisch specialismen. Een 
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andere interessante ontwikkeling is dat op dit moment veel onderzoek wordt gedaan naar 
geautomatiseerde technieken voor de evaluatie van het volume, de signaalintensiteit en de 
omvang van de relevante laesies. Hoewel deze benaderingen hun vermogen nog moeten 
aantonen om onderscheid te maken tussen pathologische laesies en lokale anatomische 
weefselafwijkingen of artefacten (om vals-positieve of fout-negatieve scoringsresultaten te 
voorkómen) wordt van deze technieken veel verwacht.
DEEL III: GENETICA IN VROEGE AXIALE 
SPONDYLOARTRITIS  
Sinds de jaren zestig is bekend dat genetische factoren een grote rol spelen bij AS. Het 
eerder genoemde HLA-B27 (een major histocompatibility class (MHC) I molecuul) staat 
bekend als de belangrijkste genetische risicofactor. De sterke associatie met HLA-B27 werd 
meer dan 40 jaar geleden erkend en is sindsdien de sterkste bekende risicofactor gebleven. 
Slechts 5-6% van de HLA-B27-positieve mensen in de algemene bevolking zal de ziekte 
ontwikkelen en de totale bijdrage van HLA-B27 aan de erfelijkheid van AS wordt geschat 
op 23.3%. Dit suggereert dat HLA-B27 alléén niet voldoende is voor de ontwikkeling van 
de ziekte en dit ondersteunt de bijdrage van andere genen. Met andere woorden, ondanks 
de sterke associatie is HLA-B27 slechts verantwoordelijk voor een klein deel van het totale 
genetische risico van AS.
Binnen het MHC-complex is HLA-B*4001 (een allel dat overeenkomt met HLA-B60 op 
serologisch of eiwit-niveau) geïdentificeerd als een tweede genetische risicofactor voor 
AS. In 1989 is in vijf onafhankelijke cohorten aangetoond dat HLA-B60 toegenomen was 
in HLA-B27 positieve AS-patiënten. Recent werd deze associatie bevestigd in een drietal 
cohorten in het Verenigd Koninkrijk, Nederland en Taiwan, respectievelijk. In 2013 werd 
gevonden dat epistasie (de interactie tussen genen op verschillende loci) tussen HLA-B27 
en HLA-B*4001 verband houdt met een verhoogd risico op AS bij Kaukasiërs, met een zeer 
hoog overmatig risico. De epistatische interactie is niet in alle onderzoeken gereproduceerd, 
maar de hoge specificiteit van het gecombineerde genotype werd wél gevonden in alle drie 
eerder genoemde studies (sensitiviteit: 10.1%, 18.2%, 18.7%, specificiteit: 99.7%, 99.6%, 
98.7%). In het onderzoek van van Gaalen et al. bleek de combinatie van zowel HLA-B27 als 
HLA-B60-positiviteit zeer zeldzaam bij controles met een prevalentie van slechts 0.4%, terwijl 
deze werd gevonden bij 18.2% van de patiënten met AS.
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Het gecombineerde HLA-B27+/HLA-B*4001+ genotype is alleen bestudeerd in patiënten met 
ankyloserende spondylitis (AS) in een vergevorderd ziekte stadium. Het doel van studie in dit 
proefschrift was om de toegevoegde waarde van HLA-B27/HLA-B*4001 in de detectie van 
vroege axSpA te beoordelen. Voor zover wij weten, zijn er geen eerdere genetische studies 
uitgevoerd bij vroege axSpA-patiënten. Voor een ziekte waarbij de genetische achtergrond 
belangrijk is, zouden genetische testen een prominentere rol kunnen spelen in de opsporing 
van de ziekte. In hoofdstuk 9 hebben we de prevalentie van het HLA-B27+/HLA-B*4001+ 
genotype bekeken in twee cohorten van patiënten (SPACE en DESIR) met chronische of 
inflammatoire rugpijn verdacht van axSpA en controles gerangschikt per land voor beide 
cohorten. Dit laatste is relevant omdat de prevalentie van HLA-B27 en HLA-B*4001 per 
geografische locatie kan verschillen. Er werd gevonden dat het AS-type met hoog risico 
(HLA-B27+/HLA-B*4001+) significant vaker voorkwam in beide cohorten vergeleken met de 
controles (DESIR: 3.3%, SPACE: 4.8%, versus 0.4% in controles). Vervolgens stratificeerden 
we de patiënten door HLA-B-typering (1. HLA-B27+/HLA-B*4001+; 2. HLA-B27+/
HLA-B*4001-; 3. HLA-B27-/HLA-B*4001+; 4. HLA-B27-/HLA-B*4001-) en vergeleken we 
de ziektekenmerken tussen de verschillende strata. HLA-B27+/HLA-B*4001+ patiënten 
vertoonden een hoog percentage radiografische sacroiliitis (DESIR 42% en SPACE 15%) 
maar waren relatief vergelijkbaar met HLA-B27+/HLA-B*4001- rugpijnpatiënten ( DESIR 
27.6% en 16.5%) en in mindere mate sacroiliitis op MRI. Wanneer het gemiddeld aanwezige 
aantal SpA kenmerken (surrogaat voor een verhoogde kans op axiale SpA) werd vergeleken 
werden geen verschillen waargenomen tussen HLA-B27+/HLA-B*4001+ (DESIR: 2.6, SPACE: 
3) en HLA-B27+/HLA-B*4001- (DESIR: 2.7, SPACE: 3.2) patiënten. We concludeerden 
derhalve dat het HLA-B27+/HLA-B*4001 hoogrisico genotype weliswaar vaker voorkwam 
bij patiënten met vroege rugpijn verdacht van axSpA, maar dat gecombineerd testen voor 
HLA-B27 en HLA-B*4001 geen toegevoegde waarde heeft in de vroege detectie van axSpA.
In de afgelopen decennia is de genetische technologie op het gebied van AS snel 
geëvolueerd. Verschillende grote genoom-brede associatiestudies (genome-wide 
association studies, GWAS) zijn uitgevoerd, wat heeft geleid tot de ontdekking van vele 
ándere genetische risicofactoren dan HLA-B27 en HLA-B*4001. Met GWAS wordt een 
veelheid aan gegevens gegenereerd die veelbelovend lijken. Echter, veel gevonden 
associaties zijn slechts verantwoordelijk voor een klein deel van het risico op AS. De 
grootte van de steekproef (omvang) is absoluut cruciaal voor het vermogen van GWAS om 
koppelingen betrouwbaar te detecteren. Een ander probleem is de moeilijkheid om het effect 
op expressie of functie van een specifiek gen te identificeren. Onlangs zijn twee genetische 
loci in verband gebracht met AS, die van functionele relevantie kunnen zijn: endoplasmatisch 
reticulum-aminopeptidase (ERAP) en de interleukine (IL) 23-receptor. ERAP codeert een 
aminopeptidase wat tot expressie wordt gebracht in het endoplasmatisch reticulum en is 
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betrokken bij het voorbereiden van peptiden voor presentatie van MHC klasse 1 aan immuun-
effectorcellen. De IL-23-receptor activeert T-helpercellen die het cytokine-interleukine (IL) 17 
en andere pro-inflammatoire cellen uitscheiden. De ERAP-1-associatie (niet -2) is beperkt 
tot HLA-B27-positieve gevallen, wat tot uitdrukking brengt dat peptiden die door HLA-B27 
gepresenteerd worden van belang kunnen zijn. 
Zoals eerder in dit proefschrift beschreven is axSpA bij een deel van de patiënten klinisch 
geassocieerd met inflammatoire darmaandoeningen (IBD), psoriasis of reactieve artritis. 
Het is aangetoond dat deze ziekten niet altijd tot klinisch evidente verschijnselen leiden: 
daarom kan de associatie met extra-articulaire manifestaties worden onderschat. Een 
beschadigde barrière van de mucosale oppervlakken van de huid (psoriasis) en darm (IBD) 
en de daaropvolgende blootstelling van het immuunsysteem aan micro-organismen lijkt 
een belangrijke rol te spelen in de pathofysiologie. In diermodellen is aangetoond dat het 
veranderde microbioom van de darm belangrijk is in AS. Echter, dit is grotendeels nog een 
onontgonnen onderzoeksveld. 
Toekomstperspectieven 
Ondanks de vooruitgang die is geboekt, is er nog steeds een duidelijk gebrek aan begrip van 
pathogenese in axSpA. De functionele mechanismen van HLA-B27 en andere genetische 
associaties moeten grondiger worden bestudeerd. Een ander onderwerp voor toekomstig 
onderzoek is de relatie tussen pro-inflammatoire cytokines, ontsteking en botvorming. 
De mechanismen waardoor botontsteking en erosies kunnen optreden bij patiënten met 
axSpA samen met nieuwe botvorming zijn nog niet volledig opgehelderd. In relatie tot 
andere reumatologische aandoeningen is dit een uniek en nog grotendeels onbegrepen 
fenomeen. Idealiter zouden we weefselmonsters koppelen aan beeldvorming om de 
pathogene processen beter te begrijpen die gevisualiseerd worden door verschillende 
beeldvormingstechnieken. Zoals eerder beschreven, breidt de belangstelling voor de rol 
van het microbioom zich uit. Dit kan nuttig zijn om de interactie tussen genetische aanleg en 
omgeving (blootstelling aan microben, bacteriële triggers) beter te begrijpen. Ook interessant 
is de mogelijke invloed van HLA-B27 op het microbioom. Verder zijn we geïnteresseerd in 
de follow-up van axSpA-patiënten van SPACE en DESIR om te beoordelen of HLA-B*4001 
en ERAP-1 mogelijke risicofactoren zijn voor ziekteprogressie (bijvoorbeeld radiografische 




We onderschrijven nogmaals het belang dat de pathogenese van axSpA nader wordt 
opgehelderd. Meer van de genen die betrokken zijn bij de pathogenese dienen te worden 
geïdentificeerd, maar vooral moeten de functionele mechanismes van de bekende 
genetische associaties duidelijker worden. Idealiter vinden we hiermee aangrijpingspunten 
om met behandeling nog gerichter te interveniëren (deel III). Evenzo moet het debat worden 
voortgezet over de vraag of en hoe classificatie en diagnose kunnen worden verbeterd bij de 
vroege identificatie van axSpA patiënten (deel I). MRI zal hierbij een belangrijke rol spelen 
(deel II) en  het verloop van zowel actieve als structurele laesies over langere tijd zal ons 
zinvolle informatie verschaffen. Ook de overeenstemming met andere modaliteiten (zoals 
de low-dose CT) is relevant. De studies in dit proefschrift zijn allen gecentreerd rondom de 
vroege herkenning van axSpA, maar wanneer de diagnose eenmaal is gesteld zijn optimale 
behandelstrategieën essentieel. Treat-to-target door het meten van ziekte activiteit en het zo 
nodig aanpassen van de behandeling resulteert in een verbetering van uitkomsten waarbij het 
doel is om klinische remissie te bereiken. Een belangrijke onbeantwoorde onderzoeksvraag 
is of behandeling ook daadwerkelijk leidt tot preventie of vertraging van de ontwikkeling van 
structurele schade. Idealiter is het binnen niet afzienbare tijd mogelijk om botproliferatie en 
radiografische progressie te stoppen. Hopelijk wordt dit bereikt in het onderzoeksveld indien 
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2016 is zij werkzaam als arts-assistent in opleiding tot radiotherapeut-oncoloog in het LUMC 
(opleiders: prof. dr. C.A.M.  Marijnen, prof. dr. C.L Creutzberg). Onderdeel hiervan was een 
stage Interne Geneeskunde in het Groene Hart Ziekenhuis in Gouda (opleider: dr. T. Koster). 
Per oktober 2018 zal een deel van de opleiding worden gevolgd in het Haaglanden Medisch 





Onderzoek is teamwork, en misschien daarom wel zo leuk. Dit proefschrift is dan ook tot 
stand gekomen met hulp van velen. Met het gevaar iemand te vergeten, zou ik toch graag 
een persoonlijk woord van dank willen uitspreken. 
Om te beginnen alle patiënten die hebben deel genomen aan het SPACE- en COMOSPA 
cohort en de klinische trials op het gebied van axiale spondyloartritis. Hartelijk dank voor 
jullie tijd en moeite om steeds maar weer naar het LUMC te komen, alle vragenlijsten in te 
vullen etcetera. De vele persoonlijke gesprekken met jullie vormden een grote stimulans en 
motivatie en de angst om tijdens een promotietraject het contact met de kliniek te verliezen 
bleek ongegrond. Prof. Huizinga, beste Tom, dank voor de mogelijkheid om te mogen leren 
op een afdeling waar wetenschap pur sang bedreven wordt. Prof. van der Heijde, beste 
Désirée, als ik ook maar een vleugje van jouw kritische blik, doortastendheid, finesse en 
gevoel voor wetenschap heb mee gekregen mag ik mezelf al heel gelukkig prijzen. Groot 
respect heb ik voor de manier waarop jij wetenschap bedrijft. De enorme productiviteit, maar 
vooral dat dit telkens weer met zoveel scherpte en oog voor detail gepaard blijft gaan: een 
unieke combinatie! Veel dank voor je begeleiding en oprechte interesse, ook op persoonlijk 
vlak. Dr. van Gaalen, beste Floris, jij bent het bewijs dat humor en wetenschap een uitstekende 
combinatie zijn. Je niet aflatende optimisme en enthousiasme zijn aanstekelijk en ik heb 
veel geleerd van je directe en pragmatische aanpak. Dr. Reijnierse, beste Monique, dank 
voor je input van radiologische zijde. De samenwerking tussen de afdelingen Reumatologie 
en Radiologie maakt SPACE uniek. De treinreis na de ASAS meeting in Düsseldorf blijft in 
mijn herinnering! All international collaborators in the SPACE-project: thank you for including 
patients across Europe which adds to the credibility of our findings and for your attendance 
during our yearly SPACE meetings. Prof. Landewé, prof. van den Bosch, prof. Dougados and 
all other co-authors: het was een voorrecht om met jullie te mogen samenwerken. It has been 
a real privilege to collaborate with you all! Veel dank, thank you, merci beaucoup! 
Victoria, muchos grazias for our collaborations during the SLR for the EULAR recommendations, 
the DESIR training and calibration process and for the fun we had in San Francisco. Lieve 
Sofia, ik heb grote bewondering voor hoe jij als Portugese je leven in Nederland hebt vorm 
gegeven en je grote doorzettingsvermogen daarbij. Daarnaast ben ik je zeer erkentelijk voor 
alle hulp en betrokkenheid bij het tot stand komen van dit proefschrift en voor je vriendschap. 
SPACE meiden, een groot internationaal cohort draaiende houden is niet niks en wat was het 
plezierig om dit samen met jullie te doen.  Van de inclusie van patiënten, tot het managen van 
de databases, eindeloze dagen, avonden en soms weekenden scoren in het donkere doolhof 
van de afdeling Radiologie, het leren scoren van onze Europese collega’s, het promoten van 
SPACE op de nationale en internationale congressen en wat al niet meer. Rosaline, een artikel 
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schrijven met klassieke muziek en goede koffie werkt toch het beste. Dank voor je hulp en 
adviezen. Manouk, dank voor je vrolijkheid en enthousiasme. Zineb, dank voor je grappen, 
je relativeringsvermogen en je oprechte betrokkenheid bij de laatste loodjes! Miranda, lieve 
meid, nooit te beroerd om als STATA-helpdesk te fungeren, dank daarvoor. Ook mijn overige 
collega’s en mede-promovendi wil ik bedanken voor de gezelligheid op C1, C5, de borrels, 
de congressen en daarbuiten. Een aantal mensen in het bijzonder. In de eerste plaats Iris, 
mijn onbetwiste maatje op C1! Wat was ik blij om op dag één als arts-onderzoeker een warm 
welkom te krijgen van jou en het bleek slechts het begin van onze huidige vriendschap. 
Dank voor alles en wat ben ik blij dat jij en Sofia bij de verdediging naast me staan! Wendy, 
we leerden elkaar kennen in de werkgroep van het eerste jaar Geneeskunde, later volgden 
de belevenissen in de studententijd en toen werden we ook nog eens collega’s: ik heb het 
allemaal zeer gewaardeerd! Willemien, wat miste ik onze koffie momenten toen jij begon 
met werken bij de Interne in het HMC! Gelukkig is het buiten de muren van het LUMC net zo 
gezellig. Féline, wat ben jij toch altijd lief en attent, aan wie had ik mijn bureau op C1-46 beter 
kunnen overdragen. Lukas en Wouter, dank voor de broodnodige mannelijke nuchterheid in 
het vrouwenbolwerk! Ook de buurman op C5 wil ik zeker niet vergeten: Freek, dank voor de 
goede koffie en ondersteuning via Freek’s compjoetersjop. 
Research nurses, Gerry en Marian, dank voor de organisatie rondom de papierwinkel die 
komt kijken bij klinische trials, aanvragen bij de METC etc. Gerrie Stoeken en Linda Herb-
van Toorn, wat fijn dat jullie ons hielpen om de lab- en serum-samples van alle internationale 
partners veilig opgeborgen te krijgen. Hettie, dank voor het plannen van de MRIs en de 
creatieve oplossingen in tijden van krapte. Marjolijn Hameetman, dank voor al je inspanningen 
en het uitvoeren van de PCRs ten behoeve van het genetica project! Jan Schoones, met 
jouw expertise wordt een review gegarandeerd een succes. Je nauwkeurigheid en stiptheid 
zijn onnavolgbaar, ik kom nog eens bij je langs voor een CAT! Joyce, Hughine, Nancy, 
Jozé en Cedric, veel dank voor jullie ondersteuning op het gebied van secretariële zaken, 
datamanagement en het feit dat de deur altijd open stond. Hughine, jij in het bijzonder dank 
voor je warme woorden, je levenswijsheden en natuurlijk alle hulp bij de laatste fase van dit 
proefschrift. Poli secretaresses, dank voor jullie hulp bij de logistieke wirwar. Marie-Jozé in 
het bijzonder, jouw stralende  persoonlijkheid en humeur zorgde ervoor dat ik altijd met een 
glimlach naar beneden kwam om patiënten te zien of formulieren te tekenen! 
Prof. Marijnen en prof. Creutzberg, beste Corrie en Carien, na een leerzame tijd op de 
Reumatologie ben ik heel blij de keus te hebben gemaakt voor de Oncologie en in het 
bijzonder de Radiotherapie. Jullie hebben een afdeling gecreëerd waar de patiënt terecht 
centraal staat, maar waar tegelijkertijd genoeg ruimte is voor andere academische kerntaken 
zoals onderzoek, onderwijs en management. En dat alles met veel persoonlijke aandacht 
voor eenieder die er werkzaam is! Ik waardeer het dat jullie in de volle breedte kijken naar ons 
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als AIOS en als mens, in plaats van alleen naar de puur medisch-inhoudelijke competenties 
van een jonge dokter. Starten in de kliniek en het afmaken van een proefschrift blijkt maar 
weer eens niet de ideale combinatie. Dank voor het vertrouwen en jullie adviezen. Veel dank 
ook aan alle andere medewerkers van de afdeling Radiotherapie voor de goede werksfeer 
en collegialiteit. In het bijzonder natuurlijk aan mijn immer stralende mede-AIOS op wie ik 
zo gesteld ben! Maar ook veel dank aan alle stafartsen, klinisch fysici, radiotherapeutisch 
laboranten, onderzoekers, klinisch fysisch medewerkers, versnellertechnici, heren van de 
ICT, dames van de Voorbereiding, secretaresses, Ronald en natuurlijk de lieve dames van 
de Zorgpost! Door jullie allemaal ga ik iedere dag met zoveel plezier naar mijn werk! 
Een goede professionele omgeving is belangrijk om te promoveren, maar gelukkig is er 
zoveel meer dan werk alleen en prijs ik me gelukkig omringd te zijn door zoveel goede 
vrienden en familie. Mijn middelbare school vriendinnen, meiden van de Eetclub, cordial 
Cayenne, gezelschap Formula, M.F.L.S.-bestuursgenootjes, oud-huisgenootjes, ex-
hockeyteam, leden van de masterclass Zorg van de Jonge Democraten/D66 en iedereen die 
ik nu vergeet: dank voor jullie vriendschap en tijden van ontspanning. Een aantal vriendinnen 
wil ik in het bijzonder bedanken: Tessa, Nina en Juliette. Bij jullie kan alles en met jullie is 
bovendien alles leuk! Ik koester onze  vriendschap, of we nu al dan niet tijdelijk wonen in 
Ethiopië, Stockholm, Amsterdam of Den Haag. 
Familie Bakker, Terschelling is en blijft de basis van onze prachtige familie: gelukkig is het 
weer bijna tijd! Familie Woudenberg, dank voor jullie oprechte interesse. Familie Niens, de 
weekenden in Dalfsen zijn en blijven een rustpunt ten opzichte van het soms hectische leven 
in Den Haag. Dank daarvoor. Lieve papa en mama, dit proefschrift was er niet gekomen 
zonder jullie grote steun en betrokkenheid. Ik ben jullie dankbaar voor de kansen en 
mogelijkheden die jullie ons hebben gegeven, maar vooral ben ik jullie dankbaar voor de 
liefdevolle omgeving waarin Manon en ik zijn op gegroeid. Jullie eigen ambities en carrières 
hebben een warme thuisbasis nooit in de weg gestaan en jullie hebben ons de perfecte 
basis gegeven om ons te ontwikkelen tot waar we nu zijn. Lieve Manon, wat ben ik blij met 
een geweldig zusje zoals jij! We voelen elkaar aan en hebben aan een half woord genoeg. 
Jouw adviezen op allerlei vlakken zijn me zoveel waard. Wahing, dank voor alles! En dus niet 
alleen voor de culinaire hoogstandjes in Wateringen. Kleine Nora, zoals jouw naam al deed 
vermoeden, ben jij het stralende licht binnen onze familie. Als ‘tante Pien’ geniet ik van alle 
kleine en grote stappen die jij maakt. Tot slot, lieve Daan, dank aan jou voor wie je bent en 
dat je bij mij bent! Jij kent de ideale balans tussen aanmoedigen en relativeren en dat met 
zoveel liefde. Ik kijk uit naar onze toekomst samen. 
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